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Zusammenfassung 
Virale Oberflächenproteine spielen eine entscheidende Rolle in der Infektionsforschung, da sie an 
vielen wichtigen Funktionen in der Wechselwirkung zwischen dem Virus und dem Wirt beteiligt sind. 
Ihre rekombinante Expression für strukturelle und funktionelle Analysen ist daher sowohl in der 
Impfstoffentwicklung als auch in der strukturbasierten Wirkstoffforschung ein wichtiger Prozess. Für 
die rekombinante Expression solch anspruchsvoller Glykoproteine ist die Wahl eines geeigneten 
Expressionssystems besonders wichtig, da dieses in der Lage sein muss post-translationale Modifi-
kationen und komplexe Faltungen vorzunehmen. Diese Doktorarbeit widmet sich daher der 
Expression von biologisch aktiven Oberflächenproteinen des Influenza A (IAV) und Hepatitis C Virus 
(HCV), da beide Viren Krankheiten auslösen, die ein globales Gesundheitsproblem darstellen. Ihre 
Oberflächenproteine Hämagglutinin (HA) und E2 sind wichtige Angriffspunkte für die Herstellung 
neuer Antigene in der Impfstoffentwicklung. Darüber hinaus ist die Untersuchung ihrer Struktur- und 
Funktionsbeziehungen wichtiger Bestandteil der strukturbasierten Wirkstoffforschung. Für diesen 
Zweck wurde im Rahmen dieser Doktorarbeit ein Verfahren für die effiziente rekombinante 
Expression und Reinigung der Oberflächenproteine HA und E2 entwickelt.  
Der erste Teil der Arbeit befasst sich mit der sekretorischen Expression der Ektodomäne der human-
pathogenen HA Subtypen H1 und H3 in ihrer ungespaltenen, inaktiven Form für strukturelle Analysen 
der HA Aktivierung. Hierbei hat sich herausgestellt, dass eine Expression in Hi5 Insektenzellen am 
besten für die Kristallisierungsanalysen geeignet ist. Außerdem wurde ein Protokoll für ein Scale-Up 
der HA Produktion entwickelt, das bis zur Produktion im Bioreaktormaßstab geeignet ist. Insgesamt 
wurde sowohl der HA Produktionsprozess als auch dessen Weiterverarbeitung („Downstream 
processing“) in der Art optimiert, dass sehr reines Protein von hoher Qualität gewonnen werden 
konnte.  
Der zweite Teil dieser Arbeit beschäftigt sich mit der Entwicklung einer effizienten Strategie zur 
sekretorischen Expression von rekombinanten Varianten der E2 Ektododomäne. Die Methode der 
transienten Genexpression (TGE) in Hi5 Insektenzellen hat sich hierfür als besonders geeignet 
herausgestellt. Zudem wurde ein geeignetes Verfahren für das Downstream Processing etabliert. 
Anschließende Optimierungen des Produktionsprozesses konnten die Ausbeute der rekombinanten 
E2 Proteine auf 6 – 11 mg/L erhöhen. Des Weiteren wurden biochemische Analysen, in vitro Assays 
und Vakzinierungsversuche durchgeführt, die erste Hinweise auf ihre Funktionalität geben. 
Alles in allem hat sich die TGE in Hi5 Insektenzellen über den gesamten Verlauf der Doktorarbeit als 
vorteilhaft für die rekombinante Expression der gewünschten Oberflächenproteine gezeigt, da diese 
Methode nicht nur eine schnelle Expressionsanalyse verschiedener Konstrukte ermöglicht, sondern 
auch sehr effizient im Rahmen eines Scale-Ups eingesetzt werden kann. 
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Synopsis 
Viral surface proteins are the key players in virus – host interactions. Hence, their recombinant 
production for structural and functional analyses is an important step for vaccination and structure-
based drug design. Recombinant expression of such sophisticated glycoproteins requires an 
expression system that is capable of posttranslational modifications and proper folding mechanisms. 
This PhD thesis addresses the expression and purification of Influenza A (IAV) and Hepatitis C virus 
(HCV) surface proteins, which both constitute a significant global health problem. Their surface 
proteins hemagglutinin (HA) and E2 are important targets for the generation of new antigens for 
vaccination. Besides, the investigation of their structure and function relations are a major task in 
structure-based drug design. Thus, a method was developed for the recombinant expression and 
purification of HA and E2 variants for their functional and structural analysis. For both parts of this 
project the viral surface proteins were successfully expressed and a purification strategy was 
developed that enables efficient purification of biological active recombinant proteins.  
In the first part of this thesis, a method was developed for the secretory expression of the full-length 
ectodomain of the two IAV HA subtypes circulating in human, H1 and H3, in its uncleaved pre-fusion 
state for structural investigation of HA activation. Hi5 insect cells were discovered to be the most 
suitable expression host for the production of these HA precursors with an intact, non-modified 
cleavage loop for crystallization studies. Moreover, a protocol was established for HA expression up-
scaling that was reliable, economic, easy to handle, comparatively fast and accessible for a scale-up 
in bioreactor dimensions. All in all, the production process and its optimized downstream processing 
resulted in very pure protein of high-quality.  
In the second part of this thesis, a strategy for effective expression of recombinant secreted E2 
ectodomain variants via transient gene expression (TGE) in Hi5 insect cells was established. First, the 
most suitable protein constructs and the most qualified expression host was evaluated. 
Subsequently, an efficient downstream processing was established and the whole production 
process was optimized resulting in marvelous protein titers of 6 – 11 mg/L. The different soluble E2 
variants were subsequently applied to biochemical analysis, in vitro assays and vaccination studies 
for further analysis of their structure and function. The recombinant sE2 variants were found to 
inhibit HCV infection in an in vitro inhibition assay and to induce the production of E2-specific 
antibodies in mice, indicating proper folding and functionality.  
Among the different expression systems evaluated in the course of this thesis the method of TGE in 
Hi5 insect cells pointed out to be advantageous for the expression of the desired viral surface 
proteins. This recently established method not only allows the fast expression analysis of different 
constructs, but is also very successful for process up-scaling.  
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1 Introduction 
1.1 Infection research  
Health research in general refers to research that is done to learn more about human health. It is 
mainly about new methods and better ways for efficient diagnosis, prevention and treatment of 
diseases. Its overall guiding principle is to translate research findings quickly and effectively into 
medical care. The main subjects are research in cancer, cardiovascular and metabolic diseases, 
infections, disorders of the nervous system and genetic and environmental influences on common 
diseases (Federal Ministry of Education and Research, 2018). Within this field of health research, 
infection research is a major topic contributing to about one-fifth of all deaths worldwide (Krämer, 
Kretzschmar and Krickeberg, 2010). It concentrates on the molecular mechanisms responsible for the 
development and course of bacterial and viral infectious diseases. For many of these diseases neither 
protective vaccination nor effective treatments exist. Precise knowledge of interactions between 
hosts and pathogens provides the foundation for the development of new strategies for the entire 
spectrum of diagnosis, prevention and treatment. Thus, one important aim in the field of infection 
research is to understand pathogen - host interactions.   
1.2 Viral surface proteins  
Viral surface proteins are the key players in virus – host interactions. They play important roles in 
their virus life cycle and are necessary for viral infectivity. It is therefore important to gain insights 
into their structure and to understand the mechanisms involved in order to fulfil their function. Viral 
surface proteins bind to host cell surface glycans that act as general attachment factors, co-receptors 
or primary receptors that mediate viral infection and entry (Raman et al., 2016). Thus, it is important 
to understand the underlying mechanisms in order to interfere with viral entry or to inhibit fusion. 
However, they not only bind to host cell factors to initiate infection. Besides, they are the major 
targets for immune response and are thus important players in viral strategies for evading the host 
immune system. These strategies include several mechanisms that differ between viral species, but 
also some of them are species independent (Alcami and Koszinowski, 2000). The most widely 
reported viral strategy is mutational escape. In case of influenza the term “antigenic drift” was 
coined for these small genetic changes in order to distinguish it from the reassortment of genome 
segments from different host species that is called “antigenic shift” (Zambon, 1999). Those changes 
often occur in regions that are located next to conserved sequences as receptor- and neutralizing 
antibody-binding regions (Brown et al., 2005, 2007). Besides, a common strategy for viral escape is 
the shielding of antigenic regions by glycosylation. These “evolving glycan shields” have been 
reported manifold to limit sensitivity of different viruses to antibody neutralization (Wei et al., 2003; 
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Abe et al., 2004; Drummer, 2014). Therefore, an important goal in vaccine development is to 
generate antigens that target antibody response towards more conserved regions in order to 
generate broadly neutralizing antibodies that are able to clear infection. Moreover, understanding 
the structural basis for neutralization can guide selection of vaccine targets.  
Hence, this PhD thesis deals with the expression and purification of biological active surface proteins 
of influenza A virus and hepatitis C virus for both structural and functional aspects as well as for the 
generation of antigens for vaccination. More detailed information about these viruses and their 
surface proteins that are relevant in the scope of this project are given in the chapters 1.3 for 
influenza A and 1.4 for hepatitis C virus, respectively. Collectively, this information will pave the way 
to new strategic approaches for selecting vaccine antigens and demonstrates the potential for 
rational vaccine design.  
1.3 Influenza A virus 
Influenza viruses are human respiratory pathogens that cause both seasonal infections and 
pandemics, frequently called “flu”. Seasonal influenza epidemics turn up every year within the winter 
months in temperate climates, whereas pandemic outbreaks caused by a new influenza substrain 
occur at unpredictable intervals (Taubenberger and Morens, 2008; Taubenberger and Kash, 2010). 
Infections with seasonal human influenza display an illness range from mild to severe and even 
death. Based upon the frequency of hospitalization and death, certain high risk groups were defined. 
Among them are pregnant women, young children aged 6 - 59 months, elderly, individuals with 
specific chronic medical conditions such as HIV/AIDS, asthma, and chronic heart or lung diseases, as 
well as health-care employees. For all adult groups a yearly vaccination is recommended. Worldwide, 
these annual epidemics are estimated to result yearly in about 3 to 5 million cases of severe illness, 
and about 250000 to 500000 deaths (World Health Organization, 2016). These seasonal epidemics 
are caused by viruses with modifications within circulating strains. In addition to those epidemics, 
pandemic infections emerge as global outbreaks due to viruses with novel antigenic subtypes. Within 
these pandemics up to 50 % of the population can be infected in one single pandemic year. 
Moreover, those pandemics are associated with a dramatic increase in number of deaths. In the last 
500 years, there have been at least thirteen influenza pandemics. Confirmed pandemics occurred in 
the past 120 years in 1889, 1918, 1957, 1968, 1977 and 2009 (Taubenberger and Morens, 2009). The 
worst pandemic in recorded history was the so-called “Spanish flu” in 1918 with up to 50 million 
deaths worldwide (Taubenberger and Morens, 2009).  
Influenza viruses are RNA-viruses belonging to the Orthomyxoviridae family and were commonly 
known to consist of three genera: Influenza A, B and C. They differ in their pathogenicity and host 
tropism and are likely to have diverged evolutionarily at least several thousand years ago 
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(Taubenberger and Kash, 2010). Whereas influenza A viruses (IAV) have been isolated from many 
species, IBV and ICV have only been isolated from human and seals or pigs and dogs, respectively 
(Wright, Neumann and Kawaoka, 2007). Seasonal epidemics are caused by IAV and IBV with IAV 
evolving more rapidly than IBV and thus escapes more easily from the immune system (Nobusawa 
and Sato, 2006). Only recently, in September 2016, a new genus called influenza D (IDV) was 
determined by the International Committee of Taxonomy of Viruses (South Dakota State University, 
2016). This virus was first discovered in 2011 in swine in Oklahoma, when it was provisionally 
designated as ICV, because of their genetic similarities (Hause et al., 2013). Subsequently, it was 
found in cattle across North America, Europe and Asia arising the proposal of a new genus of 
influenza virus, IDV (Collin et al., 2015; Foni et al., 2017). To date they are not known to infect or 
cause illness in human.  
Based on the two surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) embedded in 
the viral envelope, IAVs are further classified into subtypes. So far, 18 different HA (H1 – H18) and 11 
different NA subtypes (N1 – N11) have been discovered. The latest ones, H17 and H18 as well as N10 
and N11, were found in 2013 in bats (Tong et al., 2013). However, these bat IAV subtypes are 
remarkably different from other IAV subtypes leading to the suggestion that these bat viruses should 
rather be labeled as influenza-like viruses (Wu et al., 2014). Further characterization of influenza 
virus strains includes information on the geographic origin, strain number, year of isolation and virus 
subtype (Hay et al., 2001). For example, influenza virus A/Puerto Rico/8/34 (H1N1) is the 8th strain of 
H1N1 subtype, isolated in Puerto Rico in 1934.  
1.3.1 IAV structure and replication cycle 
Influenza virus particles, called virions, are roughly spherically or pleomorphically shaped with a 
diameter of about 80 – 120 nm. Figure 1.1 depicts an influenza virion that contains the surface 
glycoproteins HA and NA and the ion channel M2 within the envelope. The HA is a homotrimeric 
integral membrane protein responsible for virus attachment to sialic acids (SA) on the host cell 
surface, thereby initiating infection. Whereas the homotetrameric surface protein NA releases new 
virions from infected host cells due to cleaving SAs from glycolipids or glycoproteins. The matrix 2 
(M2) protein forms a proton-specific transmembrane (TM) ion channel required for viral uncoating 
(Kelly et al., 2003), while M1 builds the inner surface of the virion surrounding the viral 
ribonucleoprotein (vRNP) complex. This complex is constituted of viral RNA and the viral RNA-
dependent polymerase consisting of the three subunits polymerase acidic protein (PA), polymerase 
basic protein 1 (PB1) and PB2. Each of its eight negative-sense, single-stranded genomic RNA 
segments is associated with these three proteins and encodes one to two of the viral proteins. 
Furthermore the vRNP complex is coated with multiple nucleoproteins (NPs) which mediate the 
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transport of RNPs to the nucleus and controls viral genome replication (Nayak, Hui and Barman, 
2004; Nayak et al., 2009). The last two proteins are designated as non-structural proteins (NS1 and 
NS2). NS1 was found to be responsible for virus replication in the host cell and NS2 is essential for 
vRNP export and thus is also referred to as nuclear export protein (NEP). Additionally, the NS1 
protein represses the host cell antiviral response by multiple mechanisms (Geiss et al., 2002).  
 
Figure 1.1: Schematic overview of IAV virions 
The virus particle contains eight ribonucleoprotein complexes (vRNPs), which harbor negative sense single-stranded RNA 
segments, associated with the nucleoprotein (NP) and three polymerase proteins (PA, PB1, PB2). The vRNPs are connected 
via matrix protein (M1) with the viral envelope, which is spiked with the surface glycoproteins hemagglutinin (HA) and 
neuraminidase (NA). In addition, the M2-ion channel protein is inserted into the envelope (Nelson and Holmes, 2007).  
The processes involved in the Influenza replication cycle are depicted as schematic diagram in Figure 
1.2. The initial step is mediated by HA binding to SA-containing cell surface receptors followed by 
virus entry via endocytosis. In the next step acidification of endosomes triggers conformational 
changes in proteolytic activated HA resulting in fusion of the viral and endosomal membrane. 
Moreover, proton import via the M2 ion channel abrogates the interaction between vRNPs and the 
M1 matrix protein and thus results in the release of vRNPs into the host cell cytoplasm. After 
transport to the nucleus, the polymerase complex starts to synthesize viral mRNA segments that are 
subsequently exported followed by protein expression. The nascent polypeptides of the viral surface 
proteins HA and NA are imported and N-glycosylated in the endoplasmic reticulum together with the 
M2 matrix protein. In the Golgi apparatus the envelope proteins are post-translationally modified 
and subsequently directed to the cell surface for viral assembly via Golgi vesicles. The other viral 
proteins (PB1, PB2, PA, NP, NS1, NS2 and M1) are transported back into the nucleus where new 
vRNPs are produced. Subsequently, vRNPs are coated with M1 proteins and transported to the 
plasma membrane. At the cellular surface, vRNPS are incorporated into budding viruses via 
interactions between M1 and the cytoplasmic tails of viral surface proteins, while PB1-F2 induces 
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apoptosis by interaction with mitochondria. Finally, the NA protein abrogates the interaction of HA 
with SA receptors and the viral particle can be released from the host cell.  
 
Figure 1.2: Replication cycle of IAV 
Receptor-mediated endocytosis is followed by the release of viral ribonucleoprotein (vRNP) complexes into the cytoplasm 
that is subsequently transported to the nucleus, where replication and transcription take place. While messenger RNAs are 
exported to the cytoplasm for translation. Early viral proteins required for replication and transcription are transported 
back to the nucleus. Late in the infection cycle, the M1 and NS2 proteins facilitate the nuclear export of newly synthesized 
vRNPs while PB1-F2 associates with mitochondria. Finally the assembly and budding of progeny virions occurs at the plasma 
membrane (Neumann, Noda and Kawaoka, 2009). 
1.3.1 Structure and function of IAV glycoprotein hemagglutinin   
The major viral surface protein HA is a prime determinant of the pathogenicity of IAV. It initiates 
infection by binding to cell surface receptors resulting in membrane fusion. Besides, it is the primary 
target for the humoral immune response (Munk et al., 1992; Tate et al., 2014). HA is a homotrimeric 
type I transmembrane glycoprotein with a cylindrical shape (about 135 Å long and 35-70 Å wide) and 
forms spikes on the virion surface (Isin, Doruker and Bahar, 2002). It is synthesized as an inactive 
precursor (HA0) that depends on proteolytic processing by host cell proteases to become active 
(Bertram et al. 2010; Böttcher-Friebertshäuser et al. 2013). The cleavage of HA0 into its subunits HA1 
and HA2, linked by a single disulfide bond, is necessary to become activated and gain its capacity to 
fuse to the membrane. It enables HA to undergo conformational changes at low pH thereby exposing 
the N-terminal hydrophobic fusion peptide of HA2 and trigger membrane fusion (Isin, Doruker and 
Bahar, 2002).  
With the first HA crystal structure already obtained back in 1990 (Weis et al., 1990), today many 
different HA isolates from diverse subtypes have been crystallized (Reid et al., 1999; Ha et al., 2002; 
Russell et al., 2004, 2008, Stevens et al., 2004, 2006; Lu et al., 2012; Zhu et al., 2013; Sun et al., 2013; 
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Yang et al., 2015; Ni, Kondrashkina and Wang, 2015; Song et al., 2017). With this amount of distinct 
structures, comprising nearly 400 entries in the protein data bank (PDB) for HA (total amount of 
entries for “hemagglutinin”, status February 2018), detailed structural information is available. This 
further indicates the vivid interest in structural knowledge about HA. Two major domains in the HA 
ectodomain have been identified: the globular head and a stalk-like stem domain (depictured in 
Figure 1.3). 
 
 
 
 
 
 
 
 
Figure 1.3: Structure of IAV hemagglutinin 
A: The ectodomain of the IAV HA trimer is depicted in cartoon rendering. B: For clarity one monomer is depicted alone in 
different colors for its main structural features: HA1 regions are shown in blue and HA2 regions in red, the fusion peptide is 
colored in yellow and the receptor binding site is indicated as green spheres. The figure was derived from the X-ray 
structure of HA from the (H1N1) isolate A/California/04/2009 (PDB ID 3LZG) and was drawn with the program PyMOL. 
The HA1 subunit of each HA monomer forms the membrane-distal globular head that contains the 
receptor-binding site (RBS) and highly variable immunodominant regions. The conserved stem on the 
contrary is formed by the N- and C-terminal regions of HA1 together with the HA2 subunit (Wiley and 
Skehel, 1987). The main part of HA1 builds the globular head domain, while the remaining part of 
HA1 contributes to the stem (Isin, Doruker and Bahar, 2002). The HA2 subunit is mostly folded into a 
helical coiled-coil structure that constitutes an 80 Å-long helix forming the stem backbone. Besides, 
HA2 contains both the hydrophobic peptide required for membrane fusion (fusion peptide) and the 
hydrophobic anchor (not depicted in Fig. 1.3) (Wiley and Skehel, 1987). The surface loop structure at 
the HA stem contains the proteolytic cleavage site for host cell proteases required for HA-driven 
fusion of viral and cellular membranes and thus for viral infectivity (Chen et al., 1998). Cleavage site 
sequences determine which type of cellular host protease can cleave different types of HA (Horimoto 
and Kawaoka, 2005), as discussed later in detail (see 1.3.2). The major structural consequence of HA 
cleavage is the generation of a new C-terminus of the HA1 subunit and a new N-terminus of HA2, 
Globular head 
domain 
Stalk-like 
stem domain 
Receptor binding 
site (RBS) 
Fusion peptide 
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schematically depicted in Figure 1.4, as well as the relocation of the N-terminal fusion peptide (Cross 
et al., 2009). The newly-generated HA2 N-terminal fusion peptide positions itself into the trimer 
interior where it makes contacts with ionizable residues in order to generate a fusion competent 
neutral pH structure. Subsequent acidification of the endosomal environment can then induce the 
irreversible conformational changes that result in membrane fusion (Worch, 2014).  
 
 
 
Figure 1.4: Schematic representation of proteolytic HA0 activation  
Schematic illustration of the domain organization of HA0 precursor and the cleaved form consisting of the disulfide-linked 
subunits HA1 and HA2. The cleavage site is indicated by an arrow. FP = Fusion peptide. TM = transmembrane domain. 
Both receptor-binding and fusion activation are partly modulated by HA glycosylation. Further, 
glycosylation is essential for correct folding of HA (Gallagher et al., 1992; Roberts, Garten and Klenk, 
1993). It was investigated that some of the HA glycosylation sites are involved in biological functions 
like receptor-binding, HA cleavage and membrane fusion (Klenk et al., 2002; de Vries et al., 2010). 
The presence of glycans in close proximity to the RBS was shown to modulate receptor binding 
affinity and specificity by masking the RBS (Ohuchi et al., 1997; Cherry et al., 2009). Additionally, the 
N-linked glycosylated elements can interact with cellular lectins and therefore affect the host innate 
immune system recognition and thus the ability of HA to induce adaptive immune response (Vigerust 
and Shepherd, 2007; Geijtenbeek and Gringhuis, 2009). Moreover, glycosylation of an antigenic 
epitope prevents antibody binding (Munk et al., 1992; Tate et al., 2014). It therefore contributes to 
immune escape and is an important mechanism underlying antigenic drift. The total number and the 
positions of glycosylation sites vary between HA subtypes and different strains (Cherry et al., 2009). 
Generally the globular head possesses larger variations regarding glycosylation, while the stem is 
highly conserved (Ohuchi et al., 1997; Chen, Sun and Li, 2012; Ni, Kondrashkina and Wang, 2015). 
Sequence analysis of human H1N1 virus isolates from 1918 to 2010 clearly indicated the contribution 
of HA glycosylation to viral antigenic drift. Thereby a gradual increase in glycosylation sites was 
observed, especially in the HA head domain, that ranges from one back in 1918 to four glycosylation 
sites in the seasonal H1N1 strain A/Puerto Rico/8/34 (Igarashi et al., 2010).  
1.3.2 IAV HA activation by proteolytic cleavage 
HA cleavage represents an essential step for influenza infectivity (Klenk and Rott, 1973; Lazarowitz, 
Compans and Choppin, 1973; Klenk et al., 1975; Chen et al., 1998). Cleavage of HA0 of most avian 
            N 
             N C C 
C 
N 
S-S 
HA0 
HA1 
FP 
FP HA2 
TM 
TM 
INTRODUCTION 
 
 
 10 
and mammalian IAVs occurs at a single arginine or lysine at its cleavage site. These monobasic 
cleavage sites are only cleaved by host trypsin-like proteases (TLPs) that are mainly expressed in the 
respiratory and gastrointestinal tract (Klenk and Garten, 1994; Garten and Klenk, 1999). Highly 
pathogenic avian IAVs instead contain a polybasic cleavage site with the consensus motif R-X-R/K-R 
(Bosch et al., 1981; Webster and Rott, 1987; Perdue et al., 1997). These polybasic motives can be 
recognized by ubiquitously expressed eukaryotic subtilisin-like proteases allowing systemic viral 
spread (Stieneke-Gröber et al., 1992).  
The necessity of cleavage by a host protease for fusion activity, infection, and pathogenicity has first 
been described in studies analyzing HA cleavage by trypsin (Klenk et al., 1975). Subsequently, other 
TLPs were identified to activate monobasic HA (e.g. clotting factor Xa (Gotoh et al., 1990) and the 
arginine-specific serine protease “tryptase Clara” (Kido et al., 1992; Klenk and Garten, 1994; 
Steinhauer, 1999)). To date several TLPs were identified to cleave HA in vitro and also to activate IAV 
in cell culture (for overview see Laporte & Naesens 2017). Their role in the airways of influenza-
infected individuals, however, remains to be proven for some of them. A study by Böttcher and 
colleagues discovered that influenza viruses of all subtypes pandemic in humans (H1N1, H2N2 and 
H3N2) can be activated by the type II transmembrane serine proteases (TTSPs), TMPRSS2 (trans-
membrane serine protease 2) and HAT (human airway trypsin-like protease; also designated as 
TMPRSS11D) upon cell line derived expression (Böttcher et al., 2006). Subsequent studies confirmed 
the activation of HA by TMPRSS2 and HAT and besides showed that another TTSP, TMPRSS4, can also 
activate HA (Chaipan et al., 2009; Bertram et al., 2010; Sawoo et al., 2014).  
Moreover, a series of studies identified that TMPRSS2 contributes to viral spread in the infected host. 
First, it was demonstrated that endogenous expression of TMPRSS2 is responsible for trypsin-
independent spread of influenza A in the human cell lines Caco-2 (Bertram et al., 2010) and Calu-3 
(Böttcher-Friebertshäuser et al., 2011). Furthermore, it was shown that TMPRSS2 is co-expressed 
with α-2,6-linked SA, the major HA receptor determinant, in human respiratory epithelia (Bertram et 
al., 2012). Finally, Hatesuer and co-workers demonstrated for the first time that TMPRSS2 is essential 
for viral spread and pathogenesis of influenza virus H1N1 in mice. With TMPRSS2 knock-out mice 
they were able to show that these mice were protected from both viral spread and pathogenesis 
upon H1N1 infection, due to the lack of HA proteolytic processing (Hatesuer et al., 2013). These 
results were confirmed by two subsequent studies (Sakai et al., 2014; Tarnow et al., 2014). Besides, 
TMPRSS2 deficient mice were found to survive not only infection with H1N1, but also with an H7N9 
virus that was lethal in wt mice (Hatesuer et al., 2013; Sakai et al., 2014; Tarnow et al., 2014). This 
human H7N9 isolate with avian-origin contains a monobasic cleavage site (Gao et al., 2013) that is 
mainly cleaved by TMPRSS2 (Sakai et al., 2016). 
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However, for another in human circulating Influenza A subtype, H3N2, the research groups obtained 
different results. Hatesuer and co-workers observed that the H3N2 virus was able to replicate in 
TMPRSS2 deficient mice, but also that those mice showed significantly reduced body weight loss and 
mortality (Hatesuer et al., 2013). While Tarnow and co-workers detected only marginally effects in 
TMPRSS2 knock-out mice upon H3N2 infection (Tarnow et al., 2014). Contrary to these findings Sakai 
and co-workers identified TMPRSS2 to be essential also for infection with H3N2 influenza virus (Sakai 
et al., 2014). Thus, the proteolytic activation of H3 was thought to be dose and strain-dependent. 
This is further supported by the observation that the same H3N2 strain used by Sakai and colleagues 
that was first described to be avirulent in TMPRSS2 knock-out mice, became lethal after ten passages 
in mice (Sakai et al., 2015). This passaged virus lost one N-glycosylation site at the bottom of the HA 
stalk region that is thought to alter the accessibility of the cleavage loop and thus provide access to 
alternative host proteases.  
A study by Kühn and co-workers showed for the first time that H3 HA can recruit different host 
proteases for cleavage activation in vivo (Kühn et al., 2016). In this study they used double-knockout 
mice with deletions for TMPRSS2 and TMPRSS4, which is another TTSP that was previously shown to 
cleave and therefore activate HA in vitro. This double knock-out significantly reduced morbidity after 
H3N2 virus infection, but the mice still showed limited body weight loss, indicating residual viral 
activity and viral spread. Consequently, besides TMPRSS2 and TMPRSS4, additional proteases are 
able to cleave and activate the HA of H3N2 viruses. This might also allow for more efficient 
replication of the H3N2 virus. Thus, it could be a reason why seasonal influenza viruses of the H3 
subtype cause more severe symptoms in humans than H1 viruses, since increased accessibility could 
be associated with higher pathology (Kühn et al., 2016). This hypothesis is further supported by a 
genome wide association study, which showed that increased TMPRSS2 expression levels lead to 
more severe infections caused by the 2009 pandemic H1N1 virus and increased susceptibility to 
influenza H7N9 (Cheng et al., 2015).  
A possible explanation for the differences in protease specificity lies in the structural differences that 
were observed in the available crystal structures of uncleaved HA0 variants of H1 and H3 (H1: PDB ID: 
1RD8 (Stevens et al., 2004), H3: PDB ID: 1HA0 (Chen et al., 1998)). In the H3 HA0 crystal structure, 
the cleavage loop extends from the protein surface, whereas the cleavage site in H1 HA0 is less 
exposed, but instead extends toward the trimer interface. Thus, it is conceivable that this protrusion 
of the H3 cleavage loop provides an easier access for diverse proteolytic enzymes (Kühn et al., 2016). 
The H3 protein used for structural analysis of the uncleaved H3 HA0, however, possesses a mutated 
cleavage site (R329Q) in which the arginine (R) 329 was replaced by a glutamine (Q) in order to 
prevent proteolytic cleavage upon crystallization. Yet, it is assumed that this amino acid exchange 
might have destroyed non-covalent interactions between the cleavage site and other HA domains 
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that might have led to the protrusion of the loop (Kühn, 2015). Crystallization of a non-modified H3 
protein could therefore help to clarify the loop structure.  
 
 
Figure 1.5: Illustration of different HA0 cleavage sites 
Structures of noncleaved HA0 that have been solved for the subtypes H1 and H3. Structural analysis of the H3 precursor 
(R329Q cleavage site mutant) exhibits the HA cleavage site located in a prominent loop that protrudes from the surface 
(Chen et al., 1998). The non-modified cleavage site loop of HA0 of the 1918 pandemic H1N1 virus (“Spanish flu”) on the 
contrary is less exposed (Stevens et al., 2004); (adapted from Lu et al. 2012).   
Recent studies suggested that there are also other factors that could play a role in HA activation, 
because the amino acid sequence of the cleavage site is identical for most of the HAs (Hamilton, 
Gludish and Whittaker, 2012). Besides, protease accessibility can be enhanced by insertion of amino 
acids upstream of the cleavage site (Khatchikian, Orlich and Rott, 1989; Ohuchi et al., 1991), while 
carbohydrate residues due to neighboring glycosylation sites may limit its access for proteases 
(Kawaoka and Webster, 1989; Ohuchi et al., 1989).  
1.3.3 Prevention and Treatment of Influenza Virus Infection  
Vaccination provides the most effective protection against influenza viruses and is already available 
since the 1930s (Shope, 1936). Albeit, for ensuring an effective protection the vaccination has to be 
repeated annually with new vaccine strains due to continuous antigenic drift. Those annual vaccines 
contain antigens from IAV (subtypes H1 and H3) and IBV of the most widespread strains. Until 2007 
all commercial available influenza vaccines were produced in chicken eggs, making it a restricted and 
time consuming  process and in case of a pandemic this process might be too slow (Bommakanti et 
al., 2010; Milián and Kamen, 2015). In 2013, however, the first recombinant influenza vaccine based 
on recombinant HA expressed in insect cells manufactured by Protein Science was licensed by the US 
Food and Drug Administration (FDA) (Cox, Patriarca and Treanor, 2008; Yang, 2013). This was one of 
Human H3                                     Human H1                                
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the most relevant milestones in the development of cell culture-based vaccines, because of its more 
efficient and scalable production system. However, the traditional egg-based vaccine production is 
still state-of-the-art and further development of cell culture-based vaccines is needed, especially in 
terms of effectiveness and speed in order to respond quickly to pandemic outbreaks (Milián and 
Kamen, 2015).  
In case of a pandemic development of a vaccine might take too long and treatment of an influenza 
virus infection is necessary. At present anti-influenza therapy is limited and should be reserved for 
high-risk patients or individuals with a more severe outcome. Other patients should be given a 
symptomatic treatment and are advised to stay at home in order to minimize the risk of spreading 
the infection (World Health Organization, 2018). The therapies are built on only two classes of 
antiviral compounds. The first class of antivirals comprises M2 ion channel blockers like amantadine 
and rimantadine. By blocking the M2 ion channel they inhibit proton influx into the virus particle and 
thus uncoating of the virion (Hay et al., 1985). Thereby, they prevent the release of genetic material 
of the virus into the cytoplasm and thus suppress viral replication (Król, Rychłowska and Szewczyk, 
2014). However, they are only effective against IAV (Pinto and Lamb, 2007) and are often associated 
with severe side effects. Moreover, viruses may rapidly acquire resistance mutations against these 
antivirals. In fact, all currently circulating influenza viruses have developed resistance to adamantane 
antiviral drugs such as amantadine and rimantadine, and are thus not recommended for therapy by 
the WHO (World Health Organization, 2018). The second class of anti-influenza drugs comprises the 
NA inhibitors zanamivir, oseltamivir and peramivir that inhibit the release of progeny virions from 
infected cells. These compounds prevent IAV transmission by blocking the catalytic center of NA 
(Król, Rychłowska and Szewczyk, 2014). However, rapid emergence of resistant viral strains has also 
been reported for NA inhibitors, limiting their use (Hussain et al., 2017). This demonstrates the need 
for new influenza therapeutics directed against new targets in order to combat the persistent threat 
of influenza viruses. New strategies that target highly conserved functional regions of influenza 
proteins, which are important for early stages of viral infection are thought to be highly effective, 
while reducing the probability of resistance mutations (Kadam and Wilson, 2017).  
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1.4 Hepatitis C virus  
Hepatitis C virus (HCV) infections constitute a major global health problem with an estimated 130 –
170 million people infected with HCV worldwide. It is transmitted exclusively through direct blood-
to-blood contacts between humans (Chevaliez and Pawlotsky, 2006). While acute HCV infection is 
usually asymptomatic, 60 – 80 % of infected individuals will develop chronic infection. Chronic 
infection is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and liver-related death (World 
Health Organization, 2017). HCV is a highly variable, blood-born, positive-stranded RNA virus of the 
family Flaviviridae within the genus Hepacivirus. The HCV particle (virion) is spherical with a diameter 
of between 40 and 80 nm (Bradley et al., 1985), composed of an envelope derived from host cell 
membranes in which the glycoproteins envelope 1 (E1) and E2 are embedded, encasing the viral 
genome. Due to the large degree of sequence variability, HCV is further categorized into different 
genotypes and subtypes. Now, up to seven genotypes further divided into 86 subtypes have been 
described (Smith et al., 2017), regarding to the updated genotype and subtype assignments by the 
International Committee for the Taxonomy of Viruses (ICTV) in 2014 (Smith et al., 2014). The 
variability of HCV permits immune evasion and thus facilitates viral persistence.  
The HCV RNA genome, depicted in Figure 1.6 A, is 9.6 kb in length (Choo et al., 1991), it is flanked by 
5’ and 3’ non-translated regions (NTRs) and contains two open reading frames (ORF). The polyprotein 
of HCV is encoded by the large ORF while an alternative ORF produces a single so-called F protein (Xu 
et al., 2001). Although the role of the F protein is not well understood, it is suggested that it could be 
implicated in immune evasion (Komurian-Pradel et al., 2004). The polyprotein of about 3000 amino 
acids (AA) is cleaved by viral and cellular proteases into 10 distinct proteins (Suzuki et al., 1999). 
These include the structural proteins: core and the two glycoproteins E1 and E2 that constitute the 
virus particle, the p7 ion channel protein and the nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A 
and NS5B (Figure 1.1 A). Those non-structural proteins are involved in viral RNA replication and 
contribute to virion assembly but are not incorporated into virions (Moradpour et al. 2007). Before 
moving to their final destination, the proteins are integrated or anchored in the endoplasmic 
reticulum (ER) membrane, where posttranslational modifications take place in order to enhance their 
stability and to modify their activity and antigenicity (Dubuisson et al., 2000). The membrane 
topology and major functions of each cleaved viral protein is illustrated in Figure 1.6 B.  
The organization of the HCV envelope is subject to discussion as it incorporates or associates with 
host-derived lipoproteins, leading to a much lower buoyant density for HCV than of any other virus 
known so far (Thomssen et al., 1992; Thomssen, Bonk and Thiele, 1993; Vieyres, Dubuisson and 
Pietschmann, 2014). Besides, it has been documented that HCV-associated lipoproteins may partially 
mask the virion from the action of neutralizing antibodies (Meunier et al., 2005; Dreux et al., 2006; 
Voisset et al., 2006).  
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Figure 1.6: Hepatitis C virus genome organization and the membrane topology of cleaved viral proteins  
A: The large HCV ORF encoding the polyprotein is flanked by 5′ and 3′ NTRs. Start and stop codons are indicated 
(AUG/Stop). The 5′ NTR contains an internal ribosome entry site (IRES), followed by the structural core (C) protein and the 
two envelope glycoproteins E1 and E2. Together with p7 and NS2 they build the so-called assembly module. The other non-
structural proteins are required for RNA replication (replication module). Polyprotein cleavage by cellular signal peptidases 
is indicated by scissors at the corresponding ORF position, while arrows refer to cleavage by viral proteases. B: Membrane 
topologies and major functions of cleaved HCV proteins. Conveniently only NS5A is depicted as dimer, however, most, if not 
all, HCV proteins form homo- or heterodimers or oligomeric complexes (Bartenschlager, Lohmann and Penin, 2013).  
1.4.1 HCV envelope glycoproteins E1 and E2 
The E1 and E2 glycoproteins form a heterodimer that mediates fusion of the viral lipid envelope with 
the host cell endosomal membrane in a pH-dependent process (Lindenbach and Rice, 2013). 
However, the molecular details of this HCV fusion mechanism have not yet been elucidated 
(Freedman et al., 2016). It is quite possible that the oligomeric status of the global HCV protein 
complex fluctuates during HCV replication cycle (Meertens, Bertaux and Dragic, 2006; Falson et al., 
2015). Indeed, a hierarchical organization of E1E2 was suggested, starting with E1E2 heterodimers, 
bound into E1-driven trimers, which are finally clustered with disulfides (Vieyres, Dubuisson and 
Pietschmann, 2014; Falson et al., 2015). Nevertheless, the E1E2 heterodimer seems to be a stable 
basic entity, in particular at the envelopment and fusion stages (Dubuisson et al., 1994; Duvet et al., 
1998; Meertens, Bertaux and Dragic, 2006; Rouillé et al., 2006). Overall, the folding and maturation 
of E1 and E2 glycoproteins as well as the heterodimer formation are slow, interdependent and 
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complex processes that involve the ER chaperone machinery and disulfide bond formation as well as 
glycosylation (reviewed in Lavie, Goffard and Dubuisson, 2006; Vieyres, Dubuisson and Pietschmann, 
2014). 
A schematic representation of HCV glycoproteins with their individual features is depicted in Figure 
1.7. Both E1 and E2 are type I transmembrane proteins with a large highly glycosylated ectodomain 
and a short C-terminal transmembrane domain (TMD). These TMDs have numerous functions, 
ranging from membrane anchoring, ER localization and heterodimer assembly (Cocquerel et al. 1998; 
De Beeck et al. 2000). The heterodimer formation is essential for interaction with receptors and 
neutralizing antibodies (Drummer and Poumbourios, 2004; Lavie, Goffard and Dubuisson, 2006). 
Both proteins are highly modified by intramolecular disulfide bonds (Dubuisson and Rice, 1996; Krey 
et al., 2010; McCaffrey et al., 2012) and N-linked glycans with their carbohydrate moieties making up 
approximately half of the mass of each protein (Goffard et al., 2005; Falson et al., 2015). 
Glycosylation depends on the viral genotype, is highly conserved between different strains and has 
an important role in protein folding and correct expression (Dubuisson et al., 1999; Goffard et al., 
2005; Brown et al., 2010). E1 contains up to five and E2 eleven N-glycosylation sites, depending on 
the viral genotype (Goffard and Dubuisson, 2003; Goffard et al., 2005). Among them sequence 
analysis indicated four potential N-glycosylation sites to be strongly conserved for E1 among HCV 
genotypes, whereas nine of the eleven sites are strongly conserved in E2 (Goffard and Dubuisson, 
2003; Zhang et al., 2004). Relevant protein features like glycosylation sites, cysteines and domains of 
each protein are indicated in Figure 1.7.  
 
 
 
 
 
 
 
Figure 1.7: Schematic representation of HCV glycoprotein E1 and E2 features 
Location of N-linked glycosylation sites (Y) are indicated for each protein at corresponding positions. The N-linked 
glycosylation site colored in grey is observed only in genotype 1b and 6, while the black ones can be found among different 
genotypes. The hypervariable regions of E2 are highlighted in light red, stem and transmembrane domain (TMD) are labeled 
accordingly. The PDB ID and the related construct design for the different crystal structures are given. 
Despite these conservations, the E1 and E2 coding regions represent one of the most divergent parts 
of the HCV genome. Especially the E2 ectodomain (AA 384 – 661) has a high degree of genetic 
E1 
E2 
Stem     TMD 
TMD 4UOI 
4MWF gssg 
4WEB 
384 - 410 459 - 486 569 - 581 
INTRODUCTION 
 
 
 17 
diversity, mostly within its three hypervariable regions: hypervariable region 1 (HVR1, AA 384 – 411), 
hypervariable region 2 (HVR2, AA 460 – 485) and the so called intergenotypic variable region (igVR or 
HVR3, AA 570 – 580). Those HVRs differ up to 80 % between HCV genotypes and even between 
subtypes of the same genotype (Weiner et al., 1991; Simmonds, 2004). Within these variable regions 
HVR1 displays the greatest genetic diversity between functional isolates and contain dominant 
neutralizing epitopes (Shimizu et al., 1994; Zibert, Schreier and Roggendorf, 1995; Keck et al., 2016). 
In part this diversity is driven by immune evasion (Brown et al., 2007). Some functions of HVR1 have 
been proposed due to diverse studies. These include its involvement in binding to key HCV cell entry 
receptors and acting as an immune decoy to prevent effective antibody neutralization (von Hahn et 
al., 2007; Bankwitz et al., 2010, 2014).  
1.4.1.1 Structural elucidation of E1 and E2 glycoproteins 
An important step towards understanding the structure and function of HCV glycoproteins was 
achieved with the publication of the first crystal structures available for these proteins. In 2013 and 
2014 two research groups independently determined the structure of the so called E2 ectodomain 
core. In the approach by Kong and co-workers a truncated version of the E2 protein from genotype 
1a (strain H77) was expressed in mammalian HEK293F cells. This protein comprised the central core 
region (AA 384 – 645) in complex with the neutralizing antibody AR3C (Boivin, Kozak and Meijers, 
2013). Since flexible regions and glycans can deter protein crystallization, various glycosylation sites 
and flexible parts like HVR1 were deleted within this construct. Besides, HVR2 was replaced by a 
flexible linker leading to crystals diffracting to 2.64 Å (PDB ID 4MWF; Kong et al. 2013). The second 
structure was solved by Khan and co-workers. They used enzymatically deglycosylated E2 from 
genotype 2a (strain J6) produced in HEK293T GnTI- cells by a lentiviral expression system. This shorter 
fragment, also named E2 core, lacking the first 72 AA from the N-terminus (AA 456-656) crystallized 
in complex with the non-neutralizing Fab 2A12 with diffractions to 2.4 Å (PDB ID 4WEB; Khan et al. 
2014). Moreover, both groups truncated their E2 core (E2c) variants at the C-terminus thereby 
removing the stem and TMD. Since such hydrophobic, membrane-associated sequences can cause 
problems during crystallization, they have been removed in essentially all viral membrane envelope 
protein structural determinations (Sabahi et al., 2014). Both E2c structures are depicted in Figure 1.8 
as cartoon diagrams of the individual structures (B) and as topology diagrams (C). Besides, a 
superposition of both structures is shown in Figure 1.8 A.  
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Figure 1.8: E2 core structures 4WEB and 4MWF 
A: Superposition of E2 core from PDB ID 4WMF and 4WEB. B: Cartoon diagram of individual core structures. C: Topology 
diagram of the core domain, highlighting secondary structure and disulfide bonds (yellow) (Khan, Miller and Marcotrigiano, 
2015). 
The core domains of both structures are highly similar with a root mean square deviation (rmsd) of 
less than 0.8 Å for similar carbon α atoms (Khan et al., 2014). They comprise a compact, globular 
architecture with a more basic front layer and a more hydrophobic back layer, but also many regions 
with no regular secondary structure. The front layer contains an immunoglobulin (Ig)-like β-sandwich 
stabilized by two disulfide cross-links. Such a motif consisting of a central β-sandwich is typically 
found in domains I, II and III of class II viral fusion proteins (Kielian 2006; Kielian and Rey 2006). While 
the back layer contains a second β-sheet with a novel fold roughly perpendicular to the plane of the 
central β-sandwich. The CD81 binding site is located at the interface of these two layers.  
A rough outline of the positions of HVR1 and HVR2 and of the C-terminal region of the E2 
ectodomain, that were missing in the crystal structures, were obtained by negative stain cryo-EM by 
Kong and co-workers (Kong et al., 2013). Besides, it was used to further analyze CD81 binding. 
Combined with previous mutational studies it could be demonstrated that binding to CD81 is 
mediated by the loop connecting the inner and outer sheets of the β-sandwich. This exposed loop 
constitutes the composite CD81 binding site together with two segments that were distant to each 
other in the primary structure (Owsianka et al., 2006; Rothwangl et al., 2008; Kong et al., 2013). The 
CD81 binding loop is stabilized by the co-crystallized Fab fragment in 4MWF, but disordered and 
solvent exposed in 4WEB. Combined with the observation that the disulfide connectivity in the two 
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reported structures is the same except for one disulfide bond, this highlights the conformational 
flexibility of HCV E2.  
Further insights into the structural organization of neutralizing epitopes within E2 have been derived 
from co-crystallization experiments of Fab fragments originating from neutralizing antibodies in 
complex with peptides of their respective epitopes (Pantua et al. 2013; Kong et al. 2012; Potter et al. 
2012; Krey et al. 2013; Deng et al. 2013). Furthermore, more recent studies with different antibodies 
in complex with similar epitope peptides indicate that these epitopes are either conformational 
flexible or at least adopt two distinct conformations (Kong et al. 2016; Deng et al. 2014; Keck et al. 
2016; Li et al. 2015; Meola et al. 2015). Just recently those distinct conformations were also revealed 
at the surface of HCV pseudoparticles (HCVpp) and infectious cell culture-derived HCV particles 
(HCVcc) with antibodies that share contact residues but recognize distinct conformations of the Ig-
like domain (Vasiliauskaite et al., 2017). With this it was demonstrated that the structural flexibility 
within E2 extends beyond the composite CD81 binding site and that also the Ig-like domain 
undergoes conformational rearrangement.  
The N-terminal domain of the HCV E1 ectodomain (nE1; AA 192 – 270) lacking the flexible region 
from 245 - 259 was determined with 3.5 Å resolution by El Omari and co-workers (PDB ID 4UOI; El 
Omari et al., 2014). The crystal structure reveals a complex network of covalently linked intertwined 
homodimers that do not harbor the expected truncated class II fusion protein fold, depicted in Figure 
1.9 A. The N-terminus of nE1 instead consists of a β-hairpin followed by a long α-helix flanking a 
three-strand antiparallel β-sheet. The two N-terminal β-hairpins from two monomers are arranged 
into a non-covalently linked antiparallel β-sheet in what is most likely a domain-swapped formation 
(Liu and Eisenberg, 2002; Khan, Miller and Marcotrigiano, 2015). It was suggested that the two types 
of interfaces formed in the dimer may be replaced by an inter domain interface in the monomer, in 
which the β-hairpin folds back. As a result, E1 may be more compact as observed in the crystal 
structure (Freedman et al., 2016).  
It was discovered that the closest structural homologue to nE1 is a phosphatidylcholine transfer 
protein (PDB code 1LN2), which binds to hydrophobic ligands such as sterol and lipid like molecules. 
The superposition of HCV nE1 covalent dimer on its structural homologue by El Omari is depicted in 
Figure 1.9 B. It reveals that the extended β-sheet matches in part the steroidogenic acute regulatory 
protein-related transfer domain responsible for binding hydrophobic ligands. This finding is quite 
interesting as the N-terminal domain of E1 is hypothesized to be responsible for its binding to 
apolipoproteins (Khan, Miller and Marcotrigiano, 2015; Wang et al., 2017). However, there are some 
doubts that the nE1 structure determines the native fold of the E1 protein. In fact, it is suggested 
that the current structure may represent a post-fusion form, as nE1 crystals were obtained at low pH 
(Khan, Miller and Marcotrigiano, 2015). Besides, the construct used for crystallization was not 
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validated functionally or immunologically. Aside from that it was shown that E1 on virions is in a 
homotrimeric state leading to the suggestion that E1E2 heterodimers form trimers with a hetero-
hexamer core constituted by E1 (Falson et al., 2015). Moreover, it is thought to be more likely that 
the native E1 monomer adopts a structure similar to that of the structural homologue. In fact, using 
Rosetta “ab initio” modeling for extending the structure in presence of E2, Freedman and co-workers 
observed structural similarity between both proteins that prolongs even further than observed with 
the crystal structure. Furthermore the structural homology persists even beyond the sequence 
homology between those two (Freedman et al., 2017).  
 
Figure 1.9: Structure of nE1 4UOI 
A: Cartoon diagram of nE1 as a dimer of dimers with each monomer colored differently. Sulphur atoms forming disulfide 
bridges are shown as green spheres and sugar moieties as sticks. The box underneath shows the twofold axis at covalent 
and non-covalent dimer interfaces in cyan and magenta, respectively. B: Superposition of nE1 covalent dimer (red and blue) 
on human phosphatidylcholine transfer protein (grey). Structures are presented in cartoon rendering (El Omari et al., 2014).  
Based on these partial crystal structures for both envelope glycoproteins, combined with additional 
experimental data, two independent in silico models of the E1E2 heterodimer structure were 
recently proposed. Castelli and co-workers made predictions for the fully glycosylated ectodomain of 
the E1E2 heterodimer (Castelli et al., 2017), whereas the model of Freedman and co-workers 
comprise the full-length E1E2 heterodimer and its higher-order structure (Freedman et al., 2017), 
depictured in Figure 1.10. These models combine diverse available data in a valuable way and can 
therefore further increase our understanding of the nature of the HCV glycoproteins. However, they 
cannot surrogate structural investigations of the heterodimer for instance by x-ray crystallography. 
Hence, a complete picture of the E1E2 protein complex is still missing.   
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Figure 1.10: Full-length E1E2 heterodimer model with E1 and E2 structures used for model building 
A: nE1 model with residues modeled after the structure reported under PDB ID 4UOI shown in dark blue and those based 
on homology to the structure reported under PDB ID 1LN2 in gray. B: The part of the nE2 model taken from the crystal 
structure reported under PDB ID 4MWF. C - D: Full-length model of the E1E2 heterodimer in back (C) and front view (D) 
with the same color scheme used for the regions in A and B; additional parts of E1 are colored in cyan and in green for E2 
(Freedman et al., 2017).  
1.4.2 HCV Treatment and vaccine development  
Until 2011 the available treatment options for HCV infection were limited to interferon (IFN)-based 
therapies in combination with ribavirin, which are associated with side effects and suboptimal 
response rates (Haid et al., 2012). Through a combination of compound screening and rational drug 
design, small molecules with potent activity against various HCV enzymes were discovered that 
paved the way for a cascade of new direct-acting antivirals (DAAs). The first generation DAAs licensed 
for use in HCV genotype 1 infection, telaprevir and boceprevir, target the viral protease NS3-4A and 
thereby prevent polyprotein cleavage and virus replication (Ghany et al., 2011; Pawlotsky et al., 
2015). However, they must be administered combined with pegylated interferon alpha (PegIFN-α) 
and ribavirin. This combination was associated with severe side effects that often led to early 
termination of therapy (European Association for Study of Liver, 2014; Gogela et al., 2015). Hence 
the development of additional HCV DAAs that address one of the three viral targets, the NS3-4A 
protease, the viral phosphoprotein NS5A, and the RNA-dependent RNA polymerase NS5B, has 
occurred rapidly. These second generation DAAs can eliminate the virus and cure infection, because 
HCV does not stably integrate into the host cell genome. By this development there are currently 
highly efficacious and well-tolerated treatments for the entire spectrum of HCV genotypes available 
(Gogela et al., 2015; Pietschmann, 2017).  
Despite these enormous achievements some challenges remain. First of all, these drugs are quite 
expensive, especially for most countries with moderate to high HCV prevalence. Besides, they do not 
D 
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protect against reinfection after successful therapy. This is especially of relevance for high risk 
groups. Last but not least the majority of infected patients are not diagnosed. As a result, less than 
5 % of the world’s HCV-infected population is aware that they are infected (Gravitz, 2011; Holmberg 
et al., 2013). Those people will not receive any treatment and the risk for transmitting the infection 
to others remains. These challenges highlight the need for a prophylactic vaccine against HCV. 
However, this approach remains elusive despite extensive research in this area. The major challenges 
for vaccine development are the genetic diversity of the virus and its numerous mechanisms for 
evading immune response, facilitating viral persistence (Houghton and Abrignani, 2005). 
Furthermore, the narrow host tropism of HCV for humans hampers vaccine development with 
chimpanzees being the only fully immunocompetent animal model experimentally susceptible to 
HCV infection (Pfaender et al., 2017).  
1.5 Recombinant expression of glycoproteins  
The beginning of heterologous protein expression started in the early 1970s with the development of 
recombinant DNA technology (Cohen et al., 1973). Since then, many improvements led to rapid 
progress in this field. Today proteins can be modified in various ways via recombinant expression 
making it a very powerful tool in the field of biotechnology. It is not only possible to create mutated 
and truncated proteins, but also to fuse them with markers for identification, purification or 
improved solubility (Arnau et al., 2006; Malhotra, 2009). Moreover, it enables expression of novel 
engineered protein species like single chain variable fragment (scFv) antibody variants or chimeric 
proteins (Carter, 2006; Kontermann, 2010). Next to those diverse genetic modifications, recombinant 
protein expression also enables overexpression of the target proteins. Combined, this allows the 
production of high-quality protein with high yields compared to its isolation out of natural sources.  
Bacteria are the simplest and most often used expression hosts. Among them Escherichia coli (E. coli) 
has evolved to be the first choice in many cases, because of its wide-ranging advantages (Rosano and 
Ceccarelli, 2014). Firstly, it is very well genetically characterized and easy to manipulate. Secondly, 
E. coli grows in high cell density in low cost media and often leads to high protein yields (Baneyx, 
1999). However, as being a gram-negative bacterium E. coli lacks an ER and thus the machinery 
necessary for posttranslational modifications (PTMs) like N-glycosylation. This often results in 
incorrectly folded non-functional proteins that accumulate in inclusion bodies (Gray and 
Subramanian, 2001). Therefore, E. coli is often not capable to produce higher eukaryotic proteins, 
especially glycoproteins, leading to the requirement of eukaryotic expression hosts. Heterologous 
expression in yeasts as Saccharomyces cerevisiae and Pichia pastoris represents a compromise 
between prokaryotic and eukaryotic expression. However, one of its major drawbacks for their use 
for glycoproteins as therapeutics is their lack of human-like glycosylation. Instead yeasts tend to 
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hyper glycosylate heterologous proteins even at positions that are not glycosylated in the native host 
(Frenzel, Hust and Schirrmann, 2013). This heterologous glycosylation can influence the activity of 
recombinant proteins. Besides it can hinder crystallization of glycoproteins thereby limiting the use 
of X-ray crystallography for protein structure solution (Nettleship, 2012). Human-like glycosylation is 
often required for full functionality and plays an important role for therapeutic glycoproteins and 
vaccines. Whereas heterologous glycosylation is a potential source of immunogenicity and thus can 
cause allergic reactions (Frenzel, Hust and Schirrmann, 2013). Furthermore, many protein inter-
actions like receptor-binding are mediated by their glycans (Cohen, 2015). In fact, 50 % of all human 
proteins are thought to be glycosylated (Apweiler, Hermjakob and Sharon, 1999), indicating the 
importance of glycosylation for recombinant protein expression. Human or human-like glycosylation 
can be achieved in mammalian expression hosts, which will be considered in more detail in the next 
section.  
1.6 Mammalian expression systems  
Two of the most common mammalian cell lines used for recombinant expression are Human 
Embryonic Kidney (HEK) and Chinese Hamster Ovary (CHO) cells. Both cell lines are used for different 
strategies for the production of recombinant proteins in mammalian cells. While transient expression 
is frequently used for construct screening in small scale formats in HEK cells, CHO cells are generally 
used for generation of stable producer cell lines (Almo and Love, 2014). Stable expression enables 
rapid scale-up in bioreactors and reproducible protein production that is especially needed when it 
comes to protein production at industrial scale (Bandaranayake and Almo, 2014). However, 
generation of stable CHO producer cell lines is a significantly more time-consuming task in 
comparison to plasmid based transient expression (Edros, McDonnell and Al-Rubeai, 2013).  
The CHO cell line was first isolated by Theodore Puck in the late 1950`s (Puck, Cieciura and Robinson, 
1958) and soon became the predominant mammalian host cell line for stable expression, because of 
its ability to integrate exogenous DNA with high efficiency (Hoeijmakers, Odijk and Westerveld, 
1987). After approval of the first recombinant biopharmaceutical produced in CHO in 1985 (Kaufman 
et al., 1985), stable CHO cells are nowadays the workhorse for the production of therapeutic 
antibodies (Kunert and Reinhart, 2016; Voronina et al., 2016). Numerous cellular processes in CHO 
cells were genetically engineered over the years in order to achieve various desired properties. These 
include improved glycosylation patterns, proper gene amplification and adaptation to suspension 
culture, to name just a few.  
The cell line HEK293 originates from a primary HEK epithelia cell culture that were transformed with 
sheared adenovirus type 5 DNA (Russell et al., 1977). Since its development, it has become one of 
the most commonly used human cell lines for protein production (Bandaranayake and Almo, 2014). 
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To further improve recombinant protein expression, genetically engineered variants of this cell line 
have been developed. One of these strains is HEK293-6E that enables episomal replication of 
expression plasmids by genomic integration of the Epstein-Barr virus EBNA1 protein (Van Craenen-
broeck et al. 2000; Durocher et al. 2002). Accordingly, the expression vector is retained in the 
nucleus of the host cells leading to semi-stable expression and consequently higher expression yields. 
Thus, this qualifies this cell line particularly for transient protein production. HEK293-6E cells were 
used in this work for the transient expression and screening of protein targets by using an optimized 
protocol published by Jäger and co-workers (Jäger et al., 2013) that is based on the established 
method by Durocher and co-workers (Durocher, Perret and Kamen, 2002).  
Whereas human- or human-like glycosylation is favored for therapeutic proteins, the heterogeneity 
introduced by glycosylation can hinder crystallization. Therefore, glycosylation deficient mammalian 
cell lines such as CHO Lec3.2.8.1 or HEK293-GNTI- cells that only express truncated glycan patterns 
are employed (Stanley, 1989; Reeves et al., 2002). The glycosylation deficient cell lines 
SMT_dneo(2)_24 and TE3-B4-H1 (Baser et al., 2015) based on CHO Lec3.2.8.1 cells were used in this 
thesis to generate cell lines for stable expression of protein targets. An alternative option to mutant 
cell lines is to inhibit N-glycosylation by glycosylation inhibitors like kifunensine (Elbein et al., 1990), 
swainsonine (Elbein et al., 1981) or N-butyl-deoxynojirimycin (NB-DNJ). Otherwise expression hosts 
that exhibit simpler glycosylation patterns like insect cells can be applied for the expression of 
recombinant proteins.  
The Multi-Host expression system was developed for protein expression screening and production in 
the diverse expression systems routinely used in our facility (Meyer, 2012; Meyer et al., 2013). An 
overview of the underlying vector and its applications is depicted in Figure 1.11. Next to the already 
mentioned transient expression in HEK293-6E cells and stable expression in CHO cells, it also in-
corporates baculoviral-driven expression in insect cells that will be covered in the next section. It is 
based on the multi-host vector pFlp-Bac-to-Mam (pFlpBtM) that offers all the elements needed for 
the three mentioned expression systems.  
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Figure 1.11: Multi-host expression system  
The multi-host expression system can be used for construct screening in several expression systems. It is based on pFlp-Bac-
to-Mam vectors that contain all necessary elements needed for fast transient expression on HEK293-6E cells (I), fast 
generation of stable CHO  cells via RMCE (II) and is applicable to Tn7 based Baculovirus Expression Vector Systems (III) 
(Meyer et al., 2013). 
1.7 Insect cell expression systems  
The first insect cell lines have already been isolated and established more than five decades ago by 
Grace in 1962 (Grace, 1962). Since then, over hundreds of different insect cell lines have been 
developed from over hundred different insect species (van Oers et al., 1999; Kumar et al., 2009). The 
most frequently applied cell lines for recombinant protein expression are the Lepidoptera moths 
Spodoptera frugiperda (S. frugiperda) and Trichoplusia ni (T. ni). The Sf21 cell line (IPLB-Sf21-AE) was 
isolated from pupal ovarian tissue of the fall armyworm S. frugiperda in 1977 (Vaughn et al. 1977) 
and was later adapted to serum-free suspension cultivation. Five years later the Sf9 cell line was 
described as a subclone thereof at Texas A&M University (Summers, Station and Smith, 1987). In 
addition to the S. frugiperda cell lines, the cell line Hi5 was developed from embryonic tissue of T. ni. 
It was first described in 1984 by Granados and co-workers at the Boyce Thomson institute and was 
named BTI-Tn5B1-4 (Granados, Derksen and Dwyer, 1986). Since Lepidoptera are the natural hosts 
for baculoviridae (Blissard and Rohrmann, 1990) the described insect cell lines Sf21, Sf9 and Hi5 are 
widely used in the Baculovirus Expression Vector System (BEVS) (Summers, 2006). Within BEVS T. ni 
based cell lines are often favored for protein production, because they have a low capacity to 
produce infective baculovirus particles, whereas S. frugiperda cell lines are mostly preferred for 
amplification of baculovirus (Wilde et al., 2014). Glycoproteins produced in insect cells typically 
contain paucimannosidic N-glycans that are advantageous for crystallization, since this type of 
glycosylation is more homogenous, quite simple and thus less flexible (Tomiya et al., 2004; 
Nettleship, 2012).  
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1.7.1 Baculovirus expression vector system 
BEVS has a broad range of applications. Predominantly it is used for heterologous protein expression 
in basic and applied research (Jarvis, 2009; Trowitzsch et al., 2010; Scholz and Suppmann, 2017). 
Lepidoptera cell lines, for instance, are favorable for the production of proteins for crystallization due 
to their simple glycosylation pattern (Tomiya et al., 2004) and the scalability of virus-dependent 
expression in suspension culture. Hence, BEVS is predominantly used for protein expression for 
structural analyses with a share of almost 50 % among all eukaryotic systems based on total number 
of protein chains deposited in the PDB in 2012 (Meyer et al., 2013). Besides, it is well-suited for 
producing antigens and virus-like particles (VLPs) for the development of vaccines (Metz and Pijlman, 
2011; Vicente et al., 2011) such as the influenza vaccine Flublok™ (Treanor et al., 2011) and vaccines 
against hepatitis E (Shrestha et al., 2007; Zhang et al., 2015).  
The power of BEVS for heterologous protein expression particularly lies in its ability of extreme 
overexpression driven by very strong late viral promoters (polH, p10) (Sriram, Palhan and 
Gopinathan, 1997). Those promoters are designated as late promoters because of their onset of 
transcription in the late phase of infection. Since the corresponding genes are not essential for viral 
replication they can be replaced by the genes of target proteins (Kuzio et al., 1984; Williams et al., 
1989; Summers, 2006). Today there are two different strategies for the generation of recombinant 
baculovirus that have been developed and commercialized. The Bac-to-Bac (DH10Bac Invitrogen, 
Multibac and EMBacY (Trowitzsch et al., 2010)) uses Tn7 transposition of the target gene from a 
donor vector into the baculovirus genome within E. coli cells that already carry the virus genome, the 
so-called bacmid. Recombinant baculovirus is subsequently selected by blue-white screening and the 
bacmid DNA can easily be isolated and further analyzed for correct gene integration. The BagMagic™ 
(Novagen) and flashBAC™ (Oxford Expression Technologies) systems generate recombinant baculo-
virus directly in insect cells by homologous recombination after co-transfection of transfer vector and 
bacmid DNA (Possee et al., 2008; Hitchman, Possee and King, 2012). With this the flashBAC system is 
faster compared to Bac-to-Bac and also leads to higher viral stability due to the absence of a putative 
instable transposon element (Pijlman, 2003). However, the costs of these systems limit their use 
(Stolt-Bergner et al., 2018), so that baculoviruses produced in the scope of this work were generated 
by the use of Tn7 transposition.  
The major disadvantage is that baculovirus generation is rather time- and work-intensive compared 
to plasmid-based transient systems. Furthermore, recombinant baculovirus might not remain stable 
over several rounds of viral amplification. Thus, it can cause problems during scale-up when a large 
amount of amplified virus is needed that could result in instable virus (Kool et al., 1991; van Lier et 
al., 1992; Krell, 1996; Pijlman, van Schinjndel and Vlak, 2003). Hence there are recently published 
approaches that address these problems by using transient plasmid-based gene expression (TGE) 
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(Shen et al., 2014, 2015; Bleckmann et al., 2015) or the combination of TGE with baculoviral 
coinfection, the so-called transactivation method (Radner et al., 2012; Bleckmann et al., 2016) that 
are both predominantly used in terms of construct screening.  
1.7.2 Transient plasmid-based gene expression in insect cells  
Aside from BEVS, TGE is a promising method for recombinant protein expression in insect cells. It is 
based on recombinant expression of a suitable transient transfected expression vector. The vector is 
transported into the cells by the help of the cationic polymer, polyethylenimine (PEI) that is capable 
of delivering DNA molecules into mammalian and insect cells as charged complexes (Boussif et al., 
1995; Meunier-Durmort et al., 1997; Ringenbach et al., 1998; Ogay et al., 2006; Shen et al., 2014). In 
contrast to BEVS, where the expression is based on strong very late promoters, these promoters 
cannot be applied in TGE, because they require the viral transcription machinery. In this case 
baculoviral promoters, which are not dependent on the viral transcription machinery, can be used. 
Among them, the immediate early and early promoters can be used in insect cells in the absence of 
baculovirus. The most common used early viral promoter is the Autographa californica (Ac) 
immediate early 1 (IE1) promoter, with or without its enhancer homologous region 5 (hr5) (Guarino 
and Summers, 1987). While the use of the Orgyia pseudotsugata (Op) OpIE1 (Theilmann and Stewart, 
1991) and OpIE2 promoters (Theilmann and Stewart, 1992) is more rare. Plasmid-based expression 
driven by the immediate early OpIE2 promoter in Hi5 cells was recently discovered as a valuable 
alternative to BEVS (Bleckmann, 2016). An important step in TGE development was the establishing 
of PEI usage for transfection of insect cells by Ogay and co-workers (Ogay et al., 2006). This protocol 
was further optimized for Sf9 cells by Shen and co-workers (Shen et al., 2014) and later also for 
transfection of Hi5 cells (Shen et al., 2015) leading to transfection efficiencies of about 70 % to over 
90 %, respectively. With this strategy yields for recombinant protein expression were achieved that 
lie in the range of expression via BEVS, while expression was much faster, thus representing a valid 
alternative to BEVS. Based on these strategies a protocol was established in our laboratory that was 
recently described in Methods in Molecular Biology (Karste, Bleckmann and van den Heuvel, 2017). 
This method was used for the expression of different viral surface proteins described in this thesis.  
1.8 Crystallization of proteins for structure elucidation 
The molecular function of a protein is closely linked to its structure. Thus, the determination of 
protein structures can help to reveal and understand their biological functions. In order for an object 
to diffract light and hence become visible under magnification, it must be in the size range of the 
wavelength of the used light. Since visible light has a wavelength of 400 – 700 nm, light microscopy is 
not sufficient to resolve atomic details of a protein structure in which the typical bond-lengths 
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between atoms are about 0.15 nm (1.5 Å). The electromagnetic radiation corresponding to the 
required wavelength falls into the range of X-rays (Egli, 2016). Single molecules in a protein, 
however, interact only weakly with an X-ray beam. To overcome this problem, a protein crystal with 
molecules arranged in a repetitive pattern in a defined crystal lattice is needed. The scattering of the 
X-rays by the electrons of every single molecule in this ordered crystal causes interference effects 
having two major beneficial consequences: In the case of destructive interference, the diffracted 
waves cancel each other out and only in the case of constructive interference signals are recorded, 
leading to discrete spots ("reflections") on the X-ray film or detector. The constructive interference 
also causes amplification of the diffracted waves by many times and thus makes the reflections 
technically detectable. 
To put it in a nutshell, for structure elucidation by X-ray crystallography, high-quality crystals of the 
purified protein are needed that can be used to measure the directions and intensities of X-ray 
beams diffracted by those crystals. This data set is then used to compute the three-dimensional 
distribution of electrons within the crystal. In the final step this electron density map is interpreted 
by the crystallographer, which comprises the building of a molecular model explaining the 
experimentally determined electron density distribution (Rhodes, 2006a).  
1.8.1 Protein crystallization 
Protein crystallization is in general an unpredictable process that depends on many variables in 
addition to quality and concentration of the protein sample. External parameters like temperature, 
pH and composition of the precipitant solution are crucial factors for crystallization so that it often 
requires extensive screening and optimization to obtain crystals of sufficient X-ray diffraction quality 
(D’Arcy et al., 2014; Gorrec, 2016). The basic principle of crystallization is the stepwise reduction of 
protein solubility in a closed system. For this purpose, a protein solution is mixed with precipitants to 
lower the solubility limit of the protein leading to formation of a supersaturated, metastable 
solution. Considering a phase diagram, like the one depicted in Figure 1.12, crystallization of proteins 
in solution follows a two-step process.  
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Figure 1.12: Scheme of a protein crystallization phase diagram  
In the phase diagram, the different zones for precipitation, nucleation and crystal growth (metastable zone) are shown, 
assuming the adjustable parameter is precipitant concentration. The solubility is defined as the concentration of protein in 
the solute in equilibrium with crystals. The supersolubility curve is defined as the line separating conditions where 
spontaneous nucleation occurs from conditions where the crystallization solution remains clear if left undisturbed (adapted 
from Chayen 2004). 
 
The first step, called nucleation, is the initial formation of molecular clusters from which crystals start 
to grow. This involves a transition at which the protein molecules are present in a concentration 
higher than their solubility level. This supersaturated state comprises the precipitation zone and 
conditions that support both nucleation and growth (nucleation zone) as well as conditions that only 
support crystal growth (metastable zone). Due to the attachment of molecules in all dimensions to 
the very first para-crystalline nuclei, three-dimensional nucleation takes place (McPherson, Malkin 
and Kuznetsov, 1995, 2000). This results in a reduced local protein concentration so that it drops 
back into the metastable phase where further crystal growth takes place.  
In theory the supersaturated state can be reached by changing various parameters like temperature, 
salt concentration and addition of polymers or precipitant concentration. In practice, however, 
usually these conditions are predefined by the use of initial crystallization conditions of commercial 
screens. Instead, the protein concentration is elevated towards supersaturation via vapor diffusion 
by using either the hanging drop or the sitting drop experimental set-up, depicted in Figure 1.13. 
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Figure 1.13: Vapor diffusion by hanging and sitting drop methods 
The schematic representation of the hanging drop (A) and sitting drop (B) vapor diffusion methods used for crystallization is 
illustrated.  
In both cases the protein drop contains less concentration of the precipitant compared to the 
reservoir solution. This results in a net transfer of water by vapor diffusion from the protein drop to 
the reservoir. Thus, the protein concentration in the drop steadily increases until the equilibrium is 
established. Added polymers further induce molecular crowding by the volume-exclusion effect that 
leads to the separation of protein molecules and solution (McPherson, 1976; Ingham, 1990). After 
identifying initial crystallization conditions, a systematic optimization of the conditions that resulted 
in those hits is usually carried out until high diffraction quality crystals are obtained.  
1.8.2 Structure determination by X-ray crystallography 
The underlying principle of X-ray diffraction is the interaction of an electromagnetic wave with a 
crystalline substance. The diffraction is thus dependent on the internal order of the crystal: the more 
uniform the molecules are arranged within the crystal lattice the higher is the resolution of its 
diffraction. Lawrence Bragg and his father William Henry Bragg proposed a simple model in which X-
rays can be treated as reflections by planes of molecules or atoms instead of considering diffraction 
by each molecule (Bragg, 1913). This theory provides the basis for Bragg’s law:  
𝑛𝜆 = 2𝑑 sin 𝜃                                                                     eq 1.1 
With n = integer, λ = wavelength of the incident wave, d = spacing between the planes and θ = diffraction angle 
between the incident beam and the plane. 
The Figure 1.14 depicts the constructive diffraction when the equation of Bragg’s law is fulfilled. This 
rule constitutes that interference can only be constructive when the path difference is equal to 
integer number of the wavelength (nλ). When this constructive interference occurs, a diffracted 
beam of X-rays will leave the crystal at an angle equivalent to that of the incident photon beam that 
foil                                            glass plate 
A B 
protein drop                                        
Silicon oil 
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will be visible as a reflection. From the X-ray diffraction pattern that is generated by these planes 
crystal parameters can be calculated.  
 
Figure 1.14: Schematic representation of Bragg's law 
Two X-ray beams A and D that are in phase strike the planes with an angle θ. The diffracted X-rays can only be constructive 
when the distance between the paths ABC and DEF is an integer number of the wavelength (figure adapted from 
www.sciencetopia.net).  
The goal of every diffraction experiment is to determine the electron density for all atoms within the 
crystal. In order to calculate this electron density distribution, information on the intensity and the 
phases of the reflections are required. The intensities are directly measured by the detector, but 
there is no technical way to also measure the phase angle, resulting in the so-called phase problem, 
considered later. The first step of data processing aims at determining the unit cell parameters and 
the space group of the crystal. The space group defines the internal symmetry of the crystals lattice 
and thereby describes the reconstruction of the unit cell from its smallest element, the asymmetric 
unit, by symmetry operations as translation, rotation and reflection. The relative positions of the 
reflections are used to obtain the unit cell parameters, the orientation of the crystal and to propose 
the possible space group (Rhodes, 2006b). This allows the attribution of the Miller indices hkl for 
each reflection and furthermore to predict the position of every reflection in the dataset. With this 
knowledge the data processing software will integrate the data and finally reduce it to obtain one 
intensity value for each reflection.  
The reflections can be described by a structure-factor equation Fhkl that contains the amplitude and 
phase of the beam diffracted by the different planes in the crystal. The amplitude is proportional to 
the measured intensities and can be calculated from the obtained data. Fhkl is the sum of contribu-
tions from each volume element of electron density in the unit cell. Its Fourier transformation is the 
representation of the crystal content that precisely describes the mathematical relationship between 
the object and its diffraction pattern (Rhodes, 2006c). It allows the conversion of a Fourier-sum 
description of the reflections to a Fourier-sum description of the electron density resulting in 
equation 2: 
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𝜌(𝑥𝑦𝑧) =  
1
𝑉 
∑ ∑ ∑ 𝐹ℎ𝑘𝑙𝑙𝑘ℎ ∗  𝑒
𝑖𝛼ℎ𝑘𝑙 ∗  𝑒−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)                            eq 1.2 
With ρ(xyz) = electron density at grid point xyz, V = volume of the unit cell, Fhkl = amplitude term of complex 
structure factor Fhkl, αhkl = phase angle term of complex structure factor Fhkl.  
1.8.3 Molecular replacement 
The phase information that is lost during data collection can be obtained from an existing similar 
structure, if available, in a procedure called molecular replacement. It is based on the assumption 
that the phases of a homologous protein model will provide the estimation of the real phases. For 
this purpose, it uses the phase from an existing model and combines this with the experimentally 
obtained structure factor amplitudes of the target protein structure. This method is very efficient, 
but it can only be employed if the target protein reveals sufficient similarity to an already existing 
model. After determination of the phases by molecular replacement the initial electron density map 
is calculated that will be used for model building.  
1.8.4 Model building and refinement 
After the determination of the phases by molecular replacement, the calculated electron density 
map is interpreted and a first model is build. The obtained phases are likely to be partially incorrect, 
which is reflected by errors in the electron density that can be corrected by structure refinement 
using manual adjustments in real space and by computer software in reciprocal space.  
First, the initial model is refined against the experimental data by algorithms implemented in typical 
refinement programs like phenix.refine. This model is then used as starting point for iterative rounds 
of manual adjustments and refinement software runs for further phase improvement. The refine-
ment process is monitored among other things through the development of so-called R-factors: Rwork 
and Rfree. These factors represent the correlation between the current model and the experimental 
data. In order to avoid overfitting of the data 10 % of the reflections are excluded from the 
refinement and are used in the calculation of the Rfree value that hence is an unbiased indicator for 
refinement (Brünger, 1992).  
After solving the three dimensional structure of a protein, this structural information can be linked 
with biological data in order to understand and explain the functioning of the protein.  
1.9 Aim of this work 
Viral surface proteins are the key players in virus – host interactions. Hence, their recombinant 
production for structural and functional analyses is an important step for vaccination and structure-
based drug design. This PhD thesis deals with the expression and purification of biological active 
INTRODUCTION 
 
 
 33 
surface proteins of IAV and HCV for the investigation of their structure and function relations as well 
as for the generation of new antigens for vaccination.  
As described in section 1.3 millions of people suffer IAV infections of the respiratory tract every year 
in seasonal epidemics since its high genetic variability hinders efficient vaccination strategies. This is 
why a major emphasis of recent research is focusing on the identification of host cell factors essential 
for the viral life cycle and on targeting conserved regions of the HA antigen. This thesis therefore 
aims at the production and purification of different variants of the influenza A surface protein HA in 
its inactivated pre-fusion state. This paves the way for precise structural investigation of HA 
activation and provides a first step for novel approaches against IAV by interfering with HA 
activation.  
In order to get deeper insights into HA activation by proteolytic cleavage, structural analysis of the 
uncleaved, non-modified cleavage loop of HA subtypes with substantial differences in their protease 
specificity was intended. For this purpose, the most suitable expression host for recombinant 
expression of three HA subtypes H1, H3 and H7 in their unprocessed non-cleaved form has been 
evaluated. In the next step the downstream processing for recombinant HA production has been 
optimized, followed by HA0 crystallization. Besides, a protocol for large scale expression and 
purification of HA subtype H1 has been developed for application in transfollicular vaccination 
strategies. For this approach it is not only desired to produce very pure material in large quantities, 
but the process should also be economic, easy to handle and accessible for a scale-up in bioreactor 
dimensions.  
As described in section 1.4 HCV infections constitute a major global health problem and the need for 
a prophylactic vaccine against HCV remains. One of the major challenges for vaccine development is 
the genetic diversity of the virus and its numerous mechanisms for evading host immune response, 
facilitating viral persistence. Its surface proteins E1 and E2 mediate virus receptor interactions and 
virus uptake into human liver cells. Besides, they are the targets of neutralizing antibodies that 
inactivate circulating viruses in vivo. Still, so far no effective vaccine against HCV is available due to 
the limited broadly-neutralizing activities of these antigens. Therefore, the second part of the project 
deals with the recombinant expression and efficient purification of new HCV protein variants. First, 
the most suitable protein constructs and the most qualified expression host was evaluated. 
Subsequently, the downstream processing was established and the whole production process was 
optimized resulting in protein yields suitable for biochemical analysis and vaccination studies. 
Subsequent to secondary structure and glycosylation analysis, the purified E2 variants are applied to 
further investigation by functional in vitro assays and in vivo vaccination studies by collaboration 
partners.  
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2 Materials and methods 
2.1 Chemicals, kits and reagents 
If not stated otherwise, all chemicals were obtained from the companies Amersham Biosciences, 
Bayer, Becton Dickinson (BD), GE Healthcare, Gibco, Invitrogen, Life Technologies, Lonza, Macherey-
Nagel, Merck, Millipore, New England Biolabs (NEB), Qiagen, Riedel de Haen, Roche, Roth, Sigma-
Aldrich, Stratagene and Thermo Fisher Scientific.  
2.1.1 Enzymes and molecular weight standards 
Enzymes and molecular weight standards used in this work are listed in Table 2-1, Table 2-2 and 
Table 2-3. 
Table 2-1: Restriction Endonucleases 
Restriction Endonucleases Supplier 
AvrII (5.000 U/mL) NEB 
BamHI‐HF (20.000 U/mL) NEB 
BbsI (5.000 U/mL) NEB 
EcoRI‐HF (20.000 U/mL) NEB 
DpnI (20.000 U/mL) NEB 
HindIII‐HF (20.000 U/mL) NEB 
KpnI‐HF (20.000 U/mL) NEB 
NcoI (10.000 U/mL)  NEB 
NcoI‐HF (20.000 U/mL) NEB 
Not-I-HF(20.000 U/mL) NEB 
MfeI (10.000 U/mL) NEB 
PacI (10.000 U/mL) NEB 
XhoI (20.000 U/mL) NEB 
 
Table 2-2: Enzymes 
Name Supplier 
Antarctic Phosphatase NEB 
DNAse SFPR, HZI 
EndoH NEB 
Fusion enzyme Biotool 
KOD Hot Start DNA Polymerase Merck 
Phusion® Hot Start II DNA Polymerase Finnzymes 
PNGaseF NEB 
RNase A Qiagen 
SAP (Shrimp Alkaline Phosphatase) Roche 
Taq DNA Polymerase NEB 
Thrombin SERVA/ GE Healthcare 
T4 DNA Ligase  Roche 
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Table 2-3: Molecular weight standards 
Name Usage Supplier 
Smart Ladder  agarose gel electrophoresis  Eurogentech  
PageRuler Plus prestained SDS-PAGE Fermentas 
PageRuler prestained SDS-PAGE Fermentas 
Precision Plus AllBlue SDS-PAGE BioRad 
 
2.1.2 Antibodies 
Antibodies that were used in western blot analysis in this work are listed below in Table 2-4. 
Table 2-4: Antibodies used in this work 
Antibody Supplier/source 
Mouse IgG1 α-His-Tag Merck 
Mouse α-E2 AP33  prepared by Tanvi Khera at Twincore 
Goat α-mouse IgG (H+L)-AP Promega 
 
2.1.3 Culture media & supplements 
Bacterial cultures were grown in Lysogeny-Broth (LB) media (Table 2-5) supplemented with the 
respective antibiotics or reagents required for selective growth and screening (Table 2-6). For LB agar 
plates, the LB medium was supplemented with 16 g/L of Bacto-Agar (BD) prior to sterilization. 
Subsequent to transformation super optimal broth for catabolite repression (SOC) media was used 
(Table 2-7). All media were heat-sterilized at 121 °C for 20 min. Heat unstable components were 
sterilized by filtration through a 0.2 μm filter and added after cooling down the autoclaved media.  
Table 2-5: LB medium 
Composition Final concentration 
Bacto-Tryptone  10 g/L 
Yeast extract 5 g/L 
NaCl 5 g/L 
In H2O  
 
Table 2-6: Antibiotics and supplements for bacterial cultures 
Name Final concentration 
Ampicillin (Amp) 100 µg/mL 
Gentamicin (Gm) 7 μg/mL 
Kanamycin (Kan) 50 μg/mL 
Tetracyclin (Tet) 10 μg/mL 
Bluo-Gal 100 μg/mL 
IPTG 40 μg/mL 
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Table 2-7: SOC medium 
Composition Final concentration 
Bacto-Tryptone  20 g/L 
Yeast extract 5 g/L 
KCl 0,186 g/L 
MgCl2 10 mM 
NaCl 50 mg/L 
Glucose 10 mM 
In H2O  
 
Cell culture media for insect and mammalian cell lines (Table 2-8) were purchased as ready-to-use 
solutions. Supplements were added according to Table 2-9 after filtration (0.2 µm).  
Table 2-8: Cell culture media 
Cell culture medium Cell lines Supplier 
EX-CELL™ 405 Hi5 SAFC 
EX-CELL™ 420 Sf21 SAFC 
F17 HEK293-6E Invitrogen 
ProCHO5 CHO Lec3.2.8.1 Lonza 
CD Hybridoma CHO Lec3.2.8.1 Invitrogen 
 
  
Table 2-9: Supplements 
Supplements Supplier 
Fetal Calf Serum (FCS) Gibco 
Fungizon (250 µg/mL) Gibco 
Gentamicin (10 mg/mL) Gibco 
Geneticin G418 (50 µg/mL) Gibco 
Pluronic F68 (100 g/L) Invitrogen 
L-Glutamine (200 mM) Invitrogen   
Phenol red Sigma   
Tryptone N1 Organotechnie S.A.S.   
Valproic acid (80 mM) Sigma-Aldrich   
  
2.1.4 Transfection reagents 
The delivery of recombinant DNA to mammalian and insect cells was performed by cationic 
lipofection techniques. Reagents used for transfection of each cell line are listed below in Table 2-10.   
Table 2-10: Transfection reagents 
Reagent Usage Supplier 
Superfect Bacmid Transfection QIAGEN 
Polyethylenimine (linear, MW ~25 kDa) Transfection of HEK293-6E and Hi5 Polysciences 
Nucleofection solution I Transfection of CHO Lonza 
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2.1.5 Kits 
All applied kits were used according to the manufacturer’s instructions and are listed in Table 2-11.  
Table 2-11: Commercial kits used in this work 
Kit Usage Supplier 
NucleoSpin® Plasmid Plasmid preparation small scale Machery-Nagel 
PureYield™ Plasmid 
Midiprep System 
Plasmid preparation mid-scale Promega 
QIAGEN Plasmid Giga Kit Plasmid preparation preparative scale QIAGEN 
NucleoSpin® Gel and PCR 
Clean-up 
Purification of PCR products and extraction of DNA 
from agarose gels 
Machery-Nagel 
2.1.6 Columns and Resins for purification 
The following columns and resins were used for purification via affinity chromatography (Table 2-12) 
or size exclusion chromatography (Table 2-13) according to the protocols described in section 2.6.  
Table 2-12: Resins used for affinity chromatography 
Resin  Usage Supplier 
HisTALON™ Superflow Purification of His-tagged proteins Clontech 
HisTrap™ excel Purification of His-tagged proteins GE Healthcare 
Bio-Scale Mini Profinity IMAC 
Cartridge 
Purification of His-tagged proteins Bio-Rad 
His Mag Sepharose™ excel Small scale purification of His-tagged proteins GE Healthcare 
MagStrep "type3" XT beads Small scale purification of Twin-Strep-tagged 
proteins 
iba 
Strep-Tactin Superflow Purification of Twin-Strep-tagged proteins iba 
 
Table 2-13: Columns used for Size exclusion chromatography 
Column Supplier 
Superdex 200 16/60 GE Healthcare 
Superdex 200 10/300 HR GE Healthcare 
Superdex 200 increase 10/300 GE Healthcare 
Superdex 75 10/300 GL GE Healthcare 
2.1.7 Crystallization Screens 
For crystallization setups commercial screens and self-prepared screens were used. A list all used 
screens is summarized in Table 2-14.  
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Table 2-14: List of crystallization screens used 
Screen Supplier 
JCSG+ QIAGEN 
PEGs Suite I QIAGEN 
RI self-prepared  
RII self-prepared  
RIII self-prepared  
H1_Grid self-prepared  
2.2 Oligonucleotides and plasmids 
All oligonucleotides were synthesized at MWG Eurofins Operon in HPLC purified quality and are listed 
in Table 2-15. 
Table 2-15: Oligonucleotides 
Name Sequence 5’-3’ Use 
PCR FAST R  (M13) AGCGGATAACAATTTCACACAGG Bacmid-PCR (KOD) 
PCR FAST F  (M13) CCCAGTCACGACGTTGTAAAACG Bacmid-PCR (KOD) 
NcoI-CoreE1E2_f GGATCCATGGACCTCATGGGGTAC PCR - Insert 
CoreE1E2-XhoI_r AGGAGCTCGAGTGCTTCGGCCTGGCCCAAC PCR - Insert 
IgSSCoreE1E2_f GGATGAATTCATGGACCTCATGGGGTAC PCR - Insert 
IgSSCoreE1E2_r GGATAAGCTTTGCTTCGGCCTGGCCCAAC PCR - Insert 
EcoRI-sE2_f GGATGAATTCCGCACCCATACTGTTGGGGG PCR - Insert 
sE2-HindIII_r GGATAAGCTTGGCGGGCAGGTCCGAGTAAG PCR - Insert 
EcoRI-sE2_dHVR1_f GGATGAATTCATCCAGCTCGTTAACACCAATGG PCR - Insert 
sE2661_f GGATGAATTCACGCACCCATACTGTTGGGGG PCR - Insert 
sE2.698_r GGATAAGCTTGAGGCGGGCAGGTCCGAGTAAGAGC PCR - Insert 
sE2661_r GGATAAGCTTTCTGTCCTCCAAGTTGCAAC PCR - Insert 
sE2dH661_f GGATGAATTCGATCCAGCTCGTTAACACCAATGG PCR - Insert 
sE2_661_r GGATAAGCTTGATCTGTCCTCCAAGTTGCAAC PCR - Insert 
sE2.689_r GGATAAGCTTGAGGCGGGCAGGTCCGAGTAAGAGC PCR - Insert 
SL-OpIE2-IgGSS_f CTGTTCGAGGATCCATGGGCTGGAGCTGCATC  
SL-OpIE2-tstrepHis_r CCTGAGGCCTAGGTTAATGGTGATGGTGATGGTGC  
H1-R326Q-f_CSC CATTCCGTCCATTCAATCCCAAGGTCTATTTGGAGCC
ATTGC 
mutagenesis 
H1-R326Q-r_CSC CAATGGCTCCAAATAGACCTTGGGATTGAATGGACGG
AATGTTC 
mutagenesis 
CoreE1E2_seq_for ACCAATGGCAGCTGGCACATCAA sequencing 
CoreE1E2_seq_rev GAGGATAATGTCACCAATCC sequencing 
pFlpBtM_seq_for CGGATCGGGAGATCAGCTTGAAG sequencing 
pFlpBtM_Seq_rev CAGCCATACCACATTTGTAGAGG sequencing 
CoreE1E2_seq_r GGATTGGTGACATTATCCTC sequencing 
CoreE1_seq_f GTTGTCATCCTTCTGTTGGCCGC sequencing 
pTT5_Seq_for GGCCATACACTTGAGTGACAATGAC sequencing 
pFlpBtM13_seq (for) GGATCCGAAGTTCCTATTCCG sequencing 
 
All plasmids generated in this work, used for cloning and for recombinant protein expression are 
listed in Table 2-16.  
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Table 2-16: Plasmids 
Vectors used for generation of bacmids 
pFlpBtM-II-H1, pFlpBtM-II-H3, pFlpBtM-II-H7 (R. Lambertz, HZI) 
These variants of pFlpBtM-II were used for the generation of recombinant HA(H1/H3/H7)-expressing 
bacmids via Tn7 transposition. The HA constructs are fused to an IgG secretion signal for secretory 
expression and they are fused C-terminally to T4 foldon sequence allowing trimerization (see Figure 
3.1), followed by pFlpBtM-II derived tags for purification and cleavage sites for removing these 
parts. 
Vectors used for TGE in Hi5 cells 
pOpIE2-eGFP-HA (S. Meyer, HZI) 
This vector was used to monitor transfection efficiencies via TGE in Hi5 insect cells due to eGFP 
expression upon OpIE2 derived transient expression. 
pOpIE2-H1 and pOpIE2-H3 
These vectors were used for TGE of HA (H1 and H3) in Hi5 insect cells upon OpIE2 derived transient 
expression. 
pOpIE2-tpa-sE2(1a)wt, pOpIE2-sE2(2a)wt, pOpIE2-sE2(2a)ΔHVR1, pOpIE2-sE2(2a)ΔHVR1-N534A 
(M. Sommer, HZI) 
These vectors were used for TGE of the E2 variants sE2(1a)wt, sE2(2a)wt, sE2(2a)ΔHVR1 and 
sE2(2a)ΔHVR1-N534A, ending at AA position 661 of the E2 protein (numbering refers to HCV 
polyprotein) in Hi5 insect cells upon OpIE2 derived transient expression. The constructs are fused N-
terminally to an IgG secretion signal for secretory expression and C-terminally to pFlpBtM-III derived 
tags for purification and cleavage sites for removing these parts. 
Vectors used for TGE in HEK293-6E cells 
pTTo/GFPq (NRC, BRI, Montreal, Canada) 
This vector was used to monitor transfection efficiencies via TGE in HEK293-6E cells due to eGFP 
expression upon CMV derived transient expression. 
pcDNA3.1_tpa_E2661-6xHIS (W. Li, HZI) 
This vector was provided by Wei Li for recombinant expression of sE2(1a)wt. It contains a CMV 
promoter for transient expression in HEK cells and comprises the sE2(1a)wt variant, ending at AA 
position 661 of the E2 protein (numbering refers to HCV polyprotein) with an N-terminal tpa fusion 
peptide.  
pFlpBtM-III-sE2_661, pFlpBtM-III-sE2ΔHVR1_661 and pFlpBtM-III-sE2ΔHVR1-N534A_661  
These vectors were used for TGE of the E2 variants sE2(2a)wt, sE2(2a)ΔHVR1 and sE2(2a)ΔHVR1-
N534A, ending at AA position 661 of the E2 protein (numbering refers to HCV polyprotein) in 
HEK293-6E cells upon CMV derived transient expression. The constructs are fused N-terminally to an 
IgG secretion signal for secretory expression and C-terminally to pFlpBtM-III derived tags for 
purification and cleavage sites for removing these parts. 
pFlpBtM-III-sE2_688, pFlpBtM-III-sE2ΔHVR1_688 and pFlpBtM-III-sE2ΔHVR1-N534A_688  
These vectors were used for TGE of the E2 variants sE2(2a)wt, sE2(2a)ΔHVR1 and sE2(2a)ΔHVR1-
N534A, ending at AA position 688 of the E2 protein (numbering refers to HCV polyprotein) in 
HEK293-6E cells upon CMV derived transient expression. The constructs are fused N-terminally to an 
IgG secretion signal for secretory expression and C-terminally to pFlpBtM-III derived tags for 
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purification and cleavage sites for removing these parts. 
pFlpBtM-III-cE1E2-J6, pFlpBtM-III-cE1E2ΔHVR1-J6 and pFlpBtM-III-cE1E2ΔHVR1-N534A-J6 
These vectors were used for TGE of the E1E2 variants cE1E2(2a)wt, cE1E2(2a)ΔHVR1 and 
cE1E2(2a)ΔHVR1-N534A in HEK293-6E cells upon CMV derived transient expression. The constructs. 
comprise the last 60 AA of the core protein followed by full-length E1 and E2, fused N-terminally to 
an IgG secretion signal for secretory expression and C-terminally to pFlpBtM-III derived tags for 
purification and cleavage sites for removing these parts. 
Vectors used for generation of stable CHO cell lines 
pFlpBtM-II-H1 and  pFlpBtM-II-H3 (R. Lambertz, HZI) 
These variants of pFlpBtM-II were used for the generation of recombinant HA(H1/H3)-expressing 
CHO Lec3.2.8.1 master cell lines employing FRT F3 and Fwt sites (SMT_dNeo(2)_24) via RMCE. 
pFlpBtM-II-H1 F13 14 and  pFlpBtM-II-H3 F13 14  
These variants of pFlpBtM-II were used for the generation of recombinant HA(H1/H3)-expressing 
binary CHO Lec3.2.8.1 master cell lines employing FRT F13 and F14 sites (TE3-B4-H1) via RMCE. 
Parental vectors  
pFlpBtM-II (S. Meyer, HZI) 
Second version of multi-host expression and donor vector for transient expression in mammalian cell 
lines, Tn7 transposition based generation of recombinant bacmids and it also contains FRT sites for 
RMCE in CHO Lec3.2.8.1 master cell lines employing FRT F3 and Fwt sites. For secretory expression, 
pFlpBtM-II offers an IgG secretion signal and 8xHis- and Twin-Strep-tags for purification.  
pFlpBtM-II F13 14 (B. Baser, HZI) 
Variation of the second version of multi-host expression and donor vector for recombinant protein 
integration into the binary CHO cell line TE3-B4-H1. It contains FRT sites for RMCE in CHO Lec3.2.8.1 
master cell lines employing FRT F13 and F14 sites.  
pFlpBtM-III (S. Meyer, HZI) 
Third version of multi-host expression and donor vector for transient expression in mammalian cell 
lines, Tn7 transposition-based generation of recombinant bacmids and it also contains FRT sites for 
RMCE in CHO Lec3.2.8.1 master cell lines employing FRT F3 and Fwt sites. Besides it can be used in the 
Acembl system (Trowitzsch et al., 2010) for co-expression through cre/LoxP assembly. For secretory 
expression, pFlpBtM-III offers an IgG secretion signal and a 8xHis-tag for purification and a BirA ligase 
for in vitro biotinylation. 
pOpIE2-eGFP-HA (S. Meyer, HZI) 
This vector was used for recombinant HA and E2 expression via TGE in Hi5 insect cells by replacing 
the eGFP-HA with the respective constructs. 
pcDNA3_DcE1E2-J6 GKp, pcDNA3_DcE1E2/dHVR1 and pcDNA3_DcE1E2delHVR1534 (T. Khera, 
Twincore, Hannover) 
These vectors were provided by the group of Thomas Pietschmann and contain the last 60 AA of the 
core protein, followed by full-length E1 and E2. They were used for generation of sE2 variants and for 
cloning of cE1E2 variants into the pFlpBtM-III expression vector. 
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2.3 Bacterial strains and cell lines 
The electro competent E. coli strain Top10 was used for plasmid amplification and cloning via 
electroporation. Chemical competent One Shot® OmniMAX™ 2 T1R cells were used for sequence and 
ligation–independent cloning (SLIC) with the Quickfusion Cloning Kit (Bimake). For generation of 
recombinant bacmids E. coli DH10 strains were used, that contain the EmBacY bacmid and a 
transposase expressing helper plasmid (DH10EmBacY). The genotype of each strain is listed together 
with its source in Table 2-17.  
2.3.1 Bacterial strains 
Bacterial strains used in this work are listed below in Table 2-17.  
Table 2-17: Bacterial strains 
E. coli strain Genotype Source 
Top10 F-, mcrA Δ(mrr-hsdRMS-mcrBC) Φ80(lacZ)  
 ΔM15ΔlacX74 recA1 araD139 Δ(ara, leu) 
 7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
One Shot® OmniMAX™ 2 T1R F´ {proAB lacI
q
 lacZΔM15 Tn10(Tet
R
 ) Δ(ccdAB)} 
mcrA Δ(mrr hsdRMS-mcrBC) Φ80(lacZ)ΔM15 
Δ(lacZYA-argF)U169 endA1 recA1 supE44 thi-1 
gyrA96 relA1 tonA panD 
Invitrogen/Thermo 
Fisher Scientific 
DH10EMBacY F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80(lacZ)  ΔM15ΔlacX74 recA1 endA1 araD139 
 Δ(ara, leu)7697 galU galK l- rpsL nupG  
/BacloxP/ pBADZ-His6Cre/pMON7124 
EMBL (Berger) 
  
2.3.2 Cell lines 
The following mammalian and lepidopteran cell lines have been used as host cell lines for virus 
amplification or protein expression in this work.  
CHO Lec3.2.8.1 cell lines SMT_dNeo(2)_24 and TE3-B4-H1 
Derived from the parental Chinese hamster ovary (CHO) clone Por-5 (ATCC no. CRL 1781) the CHO 
Lec3.2.8.1 glycosylation mutant cell line was developed (Stanley, 1989) and adapted to grow in 
suspension. The CHO Lec3.2.8.1 cell lines SMT_dNeo(2)_24 and TE3-B4-H1 were used in the scope of 
this thesis for the generation of stable cell lines expressing recombinant hemagglutinin. The RMCE 
master cell line was generated by stable transfection of CHO Lec3.2.8.1 cells with tagging vector pEF-
FS-eGFP-FRTwt-Δneo (Sarah Tokarski, HZI). The binary cell line TE3-B4-H1 was generated by tagging 
of SMT_dNEo(2)_24 with the linearized pEF-F13F14-tdTomato-dpuro vector in order to create a 
second locus for the integration of recombinant proteins.  
HEK293-6E  
The parental human embryonic kidney (HEK) epithelial cell line HEK293 was established in 1977 by 
transformation of a primary cell culture with an adenovirus (Russell et al., 1977). The subclone 
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HEK93-6E derived from this cell line is adapted to suspension and has a truncated Epstein-Barr 
nuclear antigen 1 (EBNA1) integrated (Durocher, Perret and Kamen, 2002). It was used within this 
project for transient gene expression (TGE) of diverse target proteins.  
IPLB-SF-21AE (Sf21)  
The used insect cell line IPLB-SF-21AE (DSMZ no. ACC 119), short Sf21, was originally isolated form 
ovary cells of the fall armyworm Spodoptera frugiperda (Vaughn et al., 1977). This cell line is adapted 
to suspension and was used in BEVS for transfection with bacmids, virus amplification and protein 
production.  
BTI-Tn-5B1-4 (Hi5) 
The cell line BTI-Tn-5B1-4 is an ovary cell line originating from the cabbage looper Trichoplusia ni 
(Wickham and Nemerow, 1993). It is the subclone of the BTI-Tn-5B-28 cell line commercialised by 
Invitrogen under the brand name High Five™. According to its high expression rates for many target 
proteins it is often used as an alternative host for recombinant protein expression with BEVS. 
Besides, it was used in this thesis for recombinant protein expression via TGE.  
2.4 Molecular biological methods 
Protocols for molecular biological methods have been adapted from standard collections such as 
Sambrook 2001. All DNA plasmids were subjected to validation by restriction digestion (2.4.3) and 
sequencing. Sequencing was performed at the Genome Analytics platform GMAK at the HZI 
Braunschweig. 
2.4.1 Polymerase Chain Reaction (PCR) 
PCR was applied for DNA amplification for both cloning and analysis. For standard cloning reactions 
Phusion® Hot Start II DNA Polymerase (NEB) was used. For analysis of bacmid DNA KOD Hot Start 
DNA Polymerase was preferred. The standard reactions and standard programs are listed in Table 
2-18 to Table 2-19 and Table 2-20 to Table 2-21, respectively.  
Table 2-18: Standard PCR reaction with Phusion Hot Start DNA Polymerase 
Component Volume /50 μl reaction Final conc. 
H2O 33 μL  
5x Phusion HF Buffer 10 μL 1x 
10 mM dNTPs 1 μL 200 μM each 
Forward-Pr (10 µM) 2,5 μL 0.5 μM 
Reverse-Pr (10 µM) 2,5 μL 0.5 μM 
template DNA (10 ng/µL) 0,5 μL  
Phusion Hot Start DNA Polymerase (2 U/μl) 0,5 μL 0.02 /μl 
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Table 2-19: Standard PCR program for Phusion HotStart DNA Polymerase 
Program Steps Temperature Time Cycles 
Initial denaturation 95 °C 1 min  
Denaturation 95 °C 30 sec  
Annealing 
(adjusted in a range 
suitable for the primers Tm) 
50 °C – 72°C 30 sec  
25x 
Extension 72 °C 15-30 s **/1 kb  
Final extension 72 °C 5 min  
Pause 12 °C Pause  
 
 
Table 2-20: Standard PCR reaction with KOD Hot Start DNA Polymerase 
Component Volume /50 μl reaction Final conc. 
H2O 30 μL  
10x PCR Buffer for KOD Hot Start DNA Polymerase 5 μL 1x 
10 mM dNTPs 1 μL 200 μM each 
MgSO4 2 μl 1 mM 
Forward-Pr (10 µM) 3 μL 0.3 μM 
Reverse-Pr (10 µM) 3 μL 0.3 μM 
template DNA  1 μL  
KOD Hot Start DNA Polymerase (1 U/μl) 1 μL  
 
 
Table 2-21: Standard PCR program for KOD Hot Start DNA Polymerase 
Program Steps Temperature Time Cycles 
Initial denaturation 94 °C 2 min  
Denaturation 94 °C 15 sec  
Annealing 60 °C 30 sec 30–40 
Extension 72 °C 20 sec/kbp  
Final extension 72 °C 5 min  
Pause 12 °C   
 
2.4.2 Agarose gel electrophoresis 
DNA agarose gel electrophoresis was performed with gels comprising 0.8 - 1 % (w/v) agarose in 1x 
TAE buffer. Prior to use, the agarose was completely dissolved by heating and was supplemented 
with ethidium bromide (10 mg/ml stock solution) or Roti®-GelStain (Carl Roth; 1.5 μL staining 
substance per 100 mL gel) after cooling and cast on prepared gel trays. DNA samples were mixed 
with 6x DNA loading buffer before loading into the sample pockets. After solidifying the gels were 
run in 1x TAE buffer at 100 V for 30 - 40 min and were subsequently documented under UV 
illumination at 254 nm using Kodak Gel logic 212 Imaging system.  
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2.4.3 Restriction digestion of DNA  
Amplified gene fragments and cloning vectors were digested with appropriate restriction enzymes 
from NEB following standard protocols. Briefly, 1 μg of either purified PCR product or plasmid DNA 
was mixed with 1 μl of both 3’ and 5’ restriction enzymes in 1x reaction buffer and incubated at 37 °C 
for 1 h. For plasmid dephosphorylation 1 µl phosphatase was added to digested vector and the 
reaction was further incubated at 37 °C for 1 h in order to remove the free 5´-phosphate group to 
minimize relegation of the linearized plasmid. Digested products were loaded on agarose gels and 
genetic material was extracted from the gel with Gel Extraction Kit (2.1.5) according to the 
manufacturer’s instructions. The concentration of purified DNA was determined by NanoDrop 
spectrometer.  
2.4.4 Ligation of DNA fragments  
Ligation of target gene inserts into linearized vectors was carried out using the T4 DNA Ligase and 1x 
ligation buffer (Roche). The ligation reaction was prepared with 4-fold molar excess of the insert DNA 
compared to linearized vector together with 1 μl (5 U) T4 DNA ligase. The mixture was incubated at 
room temperature (RT) for 1 – 2 h or overnight at 4 °C followed by heat-inactivation of the ligase at 
65 °C for 10 min prior to transformation. 
2.4.5 Preparation of competent E. coli cells 
Electro competent cells were used in this thesis for plasmid transformation. For preparation of those 
competent cells first glycerol stocks of E. coli Top10 or XL1 blue were stroke out on non-selective LB-
agar plates and incubated overnight at 37 °C. An isolated colony was used to inoculate 40 ml pre-
culture and was incubated overnight at 37 °C and 130 rpm. With this pre-culture the main culture of 
500 mL – 1 L was inoculated in a 1:100 or 1:50 dilution and grown at 37 °C and 130 rpm until an 
optical density (OD)600 between 0.5 – 1.0 was reached. Then, sterile centrifuge tubes were used to 
chill the cell suspension on ice for 30 min with occasionally mixing. Centrifugation of the chilled 
bacterial solution for 10 min at 4 °C and 3000 rpm was followed by a washing step with 500 mL of 
sterile ice-cold HEPES-glycerol washing buffer (1 mM HEPES, 10% (v/v) glycerol, pH 7.0) per pellet. 
The washing step was repeated twice. The supernatant of the final wash was removed and the pellet 
was washed with 20 mL ice-cold sterile 15 % glycerol once, pelleted and then carefully resuspended 
in 10 mL ice-cold sterile 15 % glycerol. It was aliquoted in sterile Eppendorf tubes, shock frozen in 
liquid nitrogen and stored at -80 °C.  
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2.4.6 Transformation of E. coli 
Transformation of E. coli was carried out either via electroporation or by heat shock transformation. 
Electroporation was performed in a 1 mm cuvette using the Gene Pulse™ Controller (BioRad) 
applying an electric pulse at 25 μF, 200 Ω and 1.8 kV for 5 ms. For this purpose, 50 μL electro 
competent cells are thawed on ice and transferred to a chilled cuvette containing 2 μL ligation 
reaction or < 4 ng of purified plasmid DNA. After addition of 1 mL of SOC-medium the cells were 
incubated for 1 h at 37 °C and 300 rpm. Transformed clones were selected on LB-agar plates with 
appropriate antibiotic selection. 
Chemical transformation was accomplished by heat shock treatment of chemically competent cells. 5 
- 10 ng of plasmid DNA was added to thawed cells and incubated for 30 min on ice. A heat shock of 
45 s at 42 °C was applied and the mixture was subsequently cooled down on ice for 2 min. 1 mL SOC-
medium was added and the cells were incubated for 1 h at 37 °C and 300 rpm. Transformed clones 
were selected as described above. 
2.4.7 DNA preparation and purification 
2.4.7.1 DNA gel extraction and purification from reaction mixes 
To extract DNA fragments from agarose gels, the NucleoSpin® Gel and PCR Clean-up Kit (Macherey-
Nagel) was used according to the manufacturer’s protocol. Besides, the kit was used for direct 
purification of DNA from PCR and restriction digestion samples. 
2.4.7.2 DNA plasmid mini and midi preparations 
For plasmid isolation in small scale the NucleoSpin R plasmid kit (Table 2-11) was applied. For plasmid 
in larger scale PureYield Plasmid Midiprep kit (Promega) or Plasmid Giga Kit (Qiagen) was used. Prior 
to plasmid preparation LB-medium with appropriate selection pressure (antibiotic, Amp) was 
inoculated with transformed E. coli Top 10 cells. These cultures were incubated overnight at 37 °C 
and 130 rpm. Purifications were performed according to the manufacturers’ protocol. Finally, yields 
and purity of plasmid DNA were measured by spectrophotometry using NanoDrop (section 2.4.9). 
2.4.8 Generation and preparation of recombinant bacmids  
Isolation of recombinant bacmid DNA was performed according to the MultiBac manual (Bieniossek, 
Richmond and Berger, 2008) based on the Tn7 transposition method by using the EMBacY bacmid 
(Trowitzsch et al., 2010). The EmBacY bacmid is a derivative of the Multibac bacmid with an 
integrated enhanced yellow fluorescence protein-coding gene (YFP) that enables monitoring of virus 
performance using either fluorescence microscopy or spectrophotometry. The donor vectors used in 
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this study for Tn7 transposition are pFlpBtM-II based vectors carrying the constructs for HA-
expression. The vectors were transformed into E. coli DH10 (EmBacY) cells that already carry the 
baculovirus genome. Recombinant baculovirus is subsequently selected by blue-white screening and 
the bacmid DNA can further be analyzed for correct gene integration by PCR. For selection the cells 
were plated on LB agar plates supplemented with tetracycline, gentamicin and kanamycin, bluo gal 
and IPTG. After growth, white colonies were picked and streaked out on fresh agar plates to avoid 
false positives.  
After this selection step recombinant bacmids were prepared by inoculation of 3 - 5 mL LB medium 
supplemented with kanamycin, gentamicin and tetracycline with a single white colony. The culture 
was incubated at 37 °C and 130 rpm for up to 24 h. 1.5 mL of the culture was then transferred to 
reaction tubes and centrifuged for 2 min at 13,000 x g and 4 °C. The supernatant was completely 
removed and the cells were resuspended in 300 μL of the solution P1 (Qiagen), followed by addition 
of 300 μL lysis solution P2 and gently mixing. After about 5 min incubation at RT the mixture 
becomes translucent and 300 μL of the neutralization solution P3 was added. The sample was 
incubated on ice for 5 - 10 min followed by for 10 min at 13,000 x g and 4 °C. The clear supernatant 
was transferred to a fresh reaction tube containing 800 μL of isopropanol to precipitate the bacmid 
DNA. The sample was mixed by inverting the tube a few times and was incubated on ice for 5 - 10 
min and the centrifuged for 15 min at 13,000 x g and 4 °C. The supernatant was removed, the DNA 
pellet was washed with 500 μL of 70 % ethanol and it was again centrifuged for 15 min at 13,000 x g 
and 4 °C. The ethanol was completely removed and the pellet was air dried at RT. Finally, the bacmid 
DNA was resuspended in 40 μL of TE buffer (5 mM TrisHCl, pH 8.5). The buffers P1-P3 are listed in 
Table 2-22.  
Table 2-22: Buffers for bacmid preparation 
Buffer Composition 
Solution P1 (Resuspension, Qiagen) 50 mM TrisHCl (pH 8.0), 10 mM EDTA, 100 µg/mL RNAse A 
Solution P2 (Lysis, Qiagen) 0.2 M NaOH, 1 % (w/v) SDS 
Solution P3 (Neutralization, Qiagen) 3 M Potassium Acetate (pH 5.5) 
2.4.9 Quantification of DNA and protein concentrations 
The concentration of DNA and proteins was determined by spectrophotometry with a NanoDrop ND-
2000c (Thermo Fisher Scientific) as described in the manufacturers’ manual. Nucleic acid concen-
trations were quantified at 260 nm. Besides, the quality of prepared DNA can be determined by 
additional measurement of absorption of 280 nm (A280). A280 is the absorption maximum of 
proteins caused by their aromatic amino acids tyrosine and tryptophane. Hence, the relation 
between A260 and A280 can be used to assess the amount of protein impurities within each sample. 
A highly pure sample has a A260/A280 ratio of 1.8 in case of DNA and 2.0 for RNA. Protein 
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quantifications were carried out with the absorbance of 280 nm accordingly. To relate the 
absorbance to the actual protein concentration, it had been divided by the molar extinction 
coefficient of the measured protein according to the Beer-Lambert law. The molar extinction 
coefficient of each target protein was calculated by Vector NTI.  
2.5 Cell culture techniques 
2.5.1 Maintaining cells in culture 
If not stated otherwise cell lines were maintained as suspension cultures in either TPP Bioreactor 
tubes at 155 rpm and 25 mm orbit for small scale cultivation or shake flasks ranging from 125 mL 
(culture volume of 20 – 50 mL) up to 3 L fernbach shake flasks (with culture volume of 1 L) at 110 - 
130 rpm on 50 mm orbital shakers. Media and supplements for each cell line were used according to 
Table 2-8 and Table 2-9. Sf21 and Hi5 insect cells were cultivated at 27 °C in ExCell420 media (Sf21) 
or ExCell405 (Hi5) media, respectively. Cells were maintained in exponential growth and diluted by 
passaging to a cell density of 3 - 5 x 105 cells/mL every 2 to 3 days. Adherent cultures were grown in 
6-well plates in a humidified incubator to prevent evaporation. 
HEK293-6E and CHO Lec3.2.8.1 derived cell lines were cultivated in suspension at 37 °C and 100 rpm 
in humidified atmosphere (95 %) with 5% CO2. To maintain them in the exponential growth phase, 
they were diluted by passaging to a cell density of 3 - 5 x 105 cells/mL every 2 to 3 days or of 1.5 – 
3 x 105 cells/mL every 3 to 4 days. Adherent cultures were incubated at 8 % CO2 and were expanded 
to larger vessels or transferred to suspension culture when reaching confluency.  
2.5.2 Determination of cell count and viability 
Cell count and viability was assessed either by trypan blue exclusion method in a Neubauer 
hemocytometer or by flow cytometry after staining with propidium iodide. In both methods the dye 
is only able to permeate dead cells so that only dead cells are stained, thus allowing to distinguish 
between dead and alive cells. While trypan blue binds to intracellular proteins, propidium iodide 
intercalates with nucleic acids. For manual determination of the cell count and viability the trypan 
blue exclusion method was applied with 25 μL cell suspension diluted in 75 μL of 0.5 % trypan blue 
staining solution. Both stained and unstained cells were counted within all four large squares of the 
hemocytometer and cell density and viability were subsequently calculated with equation 2.1 and 
2.2. 
                                      𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 [
𝑐
𝑚𝐿
] =
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠∗ 104∗𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑎𝑟𝑔𝑒 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
                                        eq. 2.1 
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                                                                𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 [%] =
𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦∗100
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
                                        eq. 2.2 
The determination of cell count and viability by flow cytometry was performed using a Guava 
EasyCyte™ Mini System (Millipore). Cell suspensions were diluted 10-fold in PBS and stained with a 
final concentration of 50 µg/mL propidium iodide for the identification of dead cells.  
2.5.3 Cell size determination  
The size of cells in suspension is a parameter frequently used in BEVS for identification of successful 
infection with recombinant baculovirus and was monitored with the CASY Cell Counter (Innovatis). 
The CASY Cell Counter enables simultaneous readouts for the cell number, the viability and the size 
of measured cells. The devise uses the principle of electric current exclusion of particles diluted in an 
electrolyte. While the particles flow through a capillary, they pass an electrical field, which induces a 
resistance that is proportional to the size of each particle. Since the intact membrane of living cells 
exhibits a significantly higher resistance compared to dead cells, it can also be used for viability 
determination. The device was used according to the manufacturer’s guidelines after the samples 
were diluted in an isotonic, particle pure buffer.  
2.5.4 Analytic flow cytometry 
The flow cytometry is, in comparison to the electrically-based CASY technology, a laser-based high-
throughput real time measurement technology that allows cell counting, cell sorting and 
fluorescence detection. Within this method cell suspension samples are aspirated into a capillary in a 
liquid stream and the optical response is recognized. The cell size is measured by a detector in line of 
the beam (forward scatter), whereas granularity (side scatter) and fluorescence is simultaneously 
determined by perpendicular detectors. The data is directly analyzed by associated software and 
presented either as histograms or two-dimensional scatter plots. Besides, clusters of cells with 
similar properties can be defined through a gate which enables to mark certain subpopulations for 
evaluation purposes. Thereby, for instance determination of transfection efficiencies or viability is 
possible on the basis of the number of eGFP-positive cells or cells stained by propidium iodide, 
respectively. 
In this work the Guava EasyCyte Mini System (Millipore) was used for flow cytometric analysis. Its 
incorporated 488 nm diode laser allows the excitation of samples and 3 band pass filters can be 
selected for the detection of fluorescence emission signals (525/30 nm (green), 583/26 nm (yellow) 
and 680/30 nm (red)). Flow cytometry was mainly used for the determination of cell count, viability 
(see section 2.5.2) and efficiencies of both transfection and infection with recombinant baculoviruses 
(section 2.5.5 - 2.5.6 and 2.5.7 - 2.5.8).  
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2.5.5 Transient transfection of HEK 293-6E cells with PEI  
Transfection of serum-free cultivated HEK293-6E cells was performed using the optimized protocol 
by Jäger and co-workers (Jäger et al., 2015) based on the protocol of the National Research Council 
of Canada (NRCC). The cells were transfected in their exponential growth phase at a cell density of 
1.5 – 2.0 x 106 cells/mL using linear 25 kDa polyethylenimine (PEI) (Polysciences) with a 1 : 2.5 DNA : 
PEI ratio. The transfected DNA comprised a mix of 95 % expression vector and 5 % of pTTo/GFPq 
allowing monitoring of transfection efficiency. The transfection mix was prepared with 1 μg DNA mix 
and 2.5 μg PEI per mL culture, each diluted in 1.5 mL supplemented F17 medium. The DNA : PEI 
mixture was incubated for 15 min at RT to allow complex formation before it was added to the 
HEK293-6E cells.    
2.5.6 Transient transfection of Hi5 insect cells with PEI 
For transient transfection of Hi5 insect cells with linear 25 kDa PEI a protocol was established in our 
laboratory adapted from the protocol recently described by Shen and co-workers (Shen et al., 2015). 
The cells were kept in exponential growth phase and were adjusted to a cell density of 5 x 
106 cells/mL by centrifugation and media exchange prior to transfection. Transfection was performed 
with a DNA : PEI ratio of 1 : 4 with 1 - 2 µg DNA per 1 x 106 cells. In order to monitor transfection 
efficiency, the used DNA comprised a mix of 95 % expression vector and 5 % of pOpIE2-eGFP. The 
DNA mix was directly added to the suspension culture followed by the addition of PEI. Suspension 
cultures were then incubated for 3 – 4 h at 100 rpm and 27 °C. Afterwards suspension cultures were 
diluted to a cell density of 1 x 106 cells/mL with pre-warmed (27 °C) ExCell 405 medium at 110 – 
130 rpm.  
2.5.7 Transfection of adherent insect cells for baculovirus generation 
To generate recombinant viruses adherent Sf21 cells were transfected with recombinant EMBacY-
bacmids (2.4.8). For transfection Sf21 cells from a culture supplemented with 5 %FCS were seeded on 
6-well plates with a density of 0.75 - 1 × 106 per well. After adhesion the cells were transfected with 
5 μg bacmid DNA in a solution of 100 μL ExCell420 without FCS and 10 μL SuperFect. The solution 
was incubated for 10 min at room temperature and then diluted with 600 μL ExCell420 containing 
5 % FCS before addition onto the cells. After 2 h incubation the transfection mixture was replaced by 
fresh medium containing FCS. The successful transfection was evaluated with a fluorescence 
microscope (Evos, PeqLab). The supernatant containing the first-generation virus was harvested 5 – 
7 days post transfection.   
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2.5.8 Virus amplification  
To amplify first generation virus harvested from transfection supernatants, Sf21 cells were seeded 
with a density of 0.5 × 106 cells/mL in 50 -200 mL serum free ExCell420 and infected with 10 - 20 % 
(v/v) transfection supernatant. The infected suspension culture was incubated at 100 rpm and 27 °C 
up to five days. Cell number, viability and diameter were determined every 24 h. Besides, the 
number of fluorescent cells was measured at the Guava flow cytometer in order to further monitor 
the infection process. The supernatant was harvested at a viability of approximately 80 % and after 
showing a significant increase in diameter through centrifugation for 15 min at 5000 rpm. The 
cleared supernatant was subsequently sterilized by filtration using a Stericup vacuum system 
(Millipore) with a 0.45 μm filter and stored at 4 °C until further use. 
2.5.9 Cryoconservation of baculovirus-infected insect Cells 
To prevent a loss of infectivity during long-term storage, the virus was preserved using the method of 
baculovirus infected insect cells (BIIC) (Wasilko and Lee, 2006). For BIIC preparation 200 – 300 mL of 
a Sf21 suspension culture with a density of 1 x 106 cells/mL with an estimated multiplicity of infection 
(MOI) of 3 and cultivated at 27 °C and 100 rpm. When a significant increase in cell diameter was 
observed at 24 hpi, the cells were harvested by centrifugation for 4 min at 180 × g. The infected cells 
were subsequently resuspended in ExCell420 supplemented with 10 % DMSO and 45 % conditioned 
medium in a concentration of 1 × 107 cells/mL followed by aliquotation in cryo vials (Nunc). The 
aliquots were cooled down to -80 °C with a constant rate of -1 °C per minute in a special freezing 
container (Nalgene). After 24h the cryo vials were transferred into the gas phase of a liquid nitrogen 
tank for long-term storage. 
2.6 Protein Production and Purification 
2.6.1 Plasmid based transient protein expression in HEK 293-6E cells  
Transfection of HEK293-6E cells was carried out according to Section 2.5.5. Transfection efficiency 
was monitored daily using flow cytometry (2.5.4). Besides, cell number and viability were observed 
every 24 h (2.5.2). 48 h post transfection (hpt) the culture volume was doubled by adding fresh F17 
medium. Additionally, the culture was supplemented with tryptone (TN1) to a final concentration of 
0.5 %. At 72 hpt supplementation of glucose (final concentration of 4.5 g/L) was carried out in order 
to avoid nutrient depletion. Finally, if stated, 96 hpt 3.75 mmol/L valproic acid was added at 96 hpt 
to boost expression rates in the stationary phase of the culture (Backliwal et al., 2008). Cultures were 
harvested 72 – 168 hpt at 4.000 rpm in a bench top centrifuge. The culture supernatants were 
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pooled and supplemented with 0.1 % sodium acid for storage at 4 °C. If the cell pellets were needed 
those were washed with 1x PBS pooled in one Falcon tube and stored at -20 °C. 
2.6.2 Plasmid based transient protein expression in Hi5 insect cells  
Transfection of Hi5 insect cells was carried out according to Section 2.5.6. Transfection efficiency, cell 
number and viability were monitored daily using flow cytometry and microscopy (2.5.4, 2.5.2). 48 hpt 
the culture volume was increased according to the cell number to maintain the culture in logarithmic 
growth phase. The supernatants were harvested 72 – 96 hpt by a first centrifugation step at 200 x g 
for 5 min followed by a second centrifugation step at 5000 x g for 10 min. The culture supernatants 
were pooled and supplemented with 0.1 % sodium acid for storage at 4 °C. If the cell pellets were 
needed those were washed with 1x PBS, pooled in one Falcon tube and stored at -20 °C. 
2.6.3 Protein expression in insect cells using BEVS 
The virus amplification prior to protein expression was carried out as described in 2.5.8. For protein 
expression Sf21 or Hi5 insect cells were seeded in suspension cultures with an initial cell density of 1x 
106 cells/mL and were subsequently infected with 10 - 20 % (v/v) of virus stock. Infection kinetics 
were monitored every 24 h by determining cell count, cell diameter and percentage of fluorescent 
cells. Samples of the culture supernatant were taken for analysis and stored at -20 °C until further 
use. The supernatant was harvested 72 – 96 hpi by centrifugation once at 5000 x g or in two steps 
(5 min at 200 x g, followed by 10 min at 5000 x g) depending on further purification strategy. The 
supernatants were pooled and supplemented with 0.1 % sodium acid for storage at 4 °C. If the cell 
pellets were needed those were washed with 1x PBS pooled and stored at -20 °C. 
2.6.4 Protein production in stable CHO cell lines 
For test expressions in CHO producer cell lines cultures were expanded and cultivated for 3 - 5 days 
in shaker flasks. Culture supernatants or cell pellets were typically harvested at 2000 x g for 10 – 
20 min or at 4.000 rpm in a bench top centrifuge using 50 mL Falcon tubes. Cell pellets were further 
washed with 1x PBS transferred to a 50 mL Falcon tube and centrifuged again at 4000 rpm. Culture 
supernatants were supplemented with 0.1 % sodium acid and stored at 4 °C. Cell Pellets were stored 
at -20 °C. 
2.6.5 Cell lysis of HEK 293-6E, Sf21 and Hi5 cells 
Pellets of 1x 106 cells/mL were resuspended by vortexing with ice cold lysis buffer, incubated on ice 
for 15 min. Afterwards the mixture was centrifuged at 16,000 x g for 15 min to separate the soluble 
and insoluble fractions. The samples were stored at -20 °C or directly used for analysis.  
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2.6.6 Trichloroacetic acid (TCA) precipitation of proteins 
To preliminary test protein expression in stable CHO producer cells TCA precipitation was used to 
concentrate the protein for Western blot analysis. 1 mL of culture supernatant or total cell lysate was 
mixed with 100 µL of 100 % TCA, incubated on ice for 30 min and centrifuged at 13000 x g and 4 °C 
for 15 min to pellet the precipitated protein. The protein pellet was washed in 1 mL of ice-cold 70 % 
ethanol followed by 5 min centrifugation at 13000 x g and 4 °C. The protein pellet was dissolved in 
50 µL water and 50 µL 2x Laemmli buffer, heated for 5 min at 95 °C for denaturation and then the 
sample was analyzed by SDS-PAGE (2.7.1).  
2.6.7 Dialysis and diafiltration 
Dialysis was performed for buffer exchange of small volumes (< 50 mL per sample) by using dry 
Spectra/Por® dialysis tubes (Spectrum Laboratories Inc., Rancho Dominguez, California, USA) with a 
MWCO depending on protein size. Prior to use, the tubes were soaked in the desired exchange 
buffer. Dialysis was conducted at 4 °C with slow stirring of the buffer with up to 10-fold volumes of 
exchange buffer compared to the volume of the original sample. Larger samples were buffer 
exchanged by diafiltration with the KrosFlow® research IIi TFF system. Prior to use the 10 % storage 
ethanol was removed from the MidiKros column and the system was cleaned with at least 500 mL 
MilliQ water to remove residual ethanol. Afterwards the complete system was filled with buffer and 
approximately 200 mL of the cell culture supernatant was placed into the concentrate reservoir. The 
remaining cell culture supernatant was connected as feed reservoir. The sample was concentrated 
down to approximately 50 mL - 100 mL by re-circulation through the system. After concentration of 
the sample the exchange buffer was connected to the feed reservoir and the concentrated sample 
was diafiltrated through re-circulation through the system with at least 500 mL exchange buffer. The 
concentrated and diafiltrated sample was recovered, the system cleaned according to the 
manufacturers guidelines and stored in 10 % ethanol.  
2.6.8 Small scale protein purification with magnetic anti-His beads 
His Mag Sepharose™ excel beads (GE Healtchare) were used for small scale protein purification for 
analytics according to the manufacturers’ protocol. 200 µL slurry magnetic beads was equilibrated 
with equilibration buffer and then used for incubation with 10 ml culture supernatant for at least 4 h 
with slow end-over-end mixing. Beads were 3x washed with washing buffer and protein was eluted 
with 200 µL elution buffer after 1 minute of incubation. The eluted protein was then analyzed by 
SDS-PAGE and western blot.  
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2.6.9 Small scale Strep-Tactin purification with magnetic beads 
MagStrep “type3” XT beads (iba) were used for a first test of reverse Strep-Tactin purification after 
cleavage with thrombin in order to remove all tagged contaminants in small scale. Purification was 
performed according to the manufacturers’ protocol. 100 µL slurry (5 % (v/v) beads) magnetic beads 
was washed and equilibrated with buffer W and then used for incubation with samples from 
thrombin-cleavage (1 mg protein in 1 mL) overnight with slow end-over-end mixing. The supernatant 
containing the purified samples was removed and the beads were 3x washed with washing buffer W. 
For elution sample buffer was added to the beads and the mixture was heated for up to 10 min at 
95 °C. The samples were then analyzed by SDS-PAGE (2.7.1).  
2.6.10 Affinity chromatography 
Purifications of cell extracts or cell culture supernatants were performed with self-packed Mobicol 
columns (MoBiTec) or an ÄKTA-FLPC unit (GE Healthcare) using commercially available or self-packed 
columns with the materials and methods listed below. Fractions were collected and analyzed by SDS-
PAGE and Western blot (sections 2.7.1 and 2.7.2). 
IMAC Profinia  
For the purification of His‐tagged proteins with the Profinia protein purification system Bio‐ScaleTM 
Mini ProfinityTM IMAC Cartridges with 1mL bed volume were used. The purification step was followed 
by desalting of the eluate with Bio‐ScaleTM Mini Bio‐Gel® P‐6 Desalting Cartridge with 10 mL bed 
volume. Pre‐programmed methods and the respective buffers were used for the purification and 
desalting of target proteins. 
HisTALON™ Superflow 
For the purification of diafiltered cell culture supernatant or Ni-NTA pre-purified proteins 1 – 5 mL 
HisTALON™ Superflow columns (prepacked or self-prepared) were used. Prior to purification the 
protein sample was dialyzed against 50mM TrisHCl, 150mM NaCl, pH7.4 and imidazole was added to 
a final concentration of 10 mM before the sample was loaded with a flow rate of 1 mL/min. The 
washing step was performed with 10 mM imidazole for 15 CV (ÄKTA-FLPC usage) or until the UV 
monitor (280 nm) signal decreased to zero (Mobicol usage). The target protein was eluted in a series 
of 500 µL to 1 mL fractions with elution buffer containing 150 mM imidazole for up to 10 – 20 CV by 
ÄKTA-FLPC usage or until the UV signal significantly decreased (Mobicol usage).  
HisTrap™ excel  
HisTrap™ excel material was used for the purification of his-tagged proteins directly from the 
supernatant with 1 or 5 mL columns.  Prior to use the columns were equilibrated with buffer 
MATERIAL AND METHODS 
 
 
 54 
containing 20 mM sodium phosphate, 0.5 M NaCl, pH 7.4 before the sample was loaded with a flow 
rate of 1 – 5 mL. This was followed by a washing step of 20 CV with wash buffer containing 30 – 
75 mM imidazole. Elution was performed with 500 mM imidazole for up to 10 – 20 CV.  
Strep-Tactin Superflow 
Strep-Tactin superflow purification was performed in order to remove tagged contaminants after 
thrombin cleavage. The protein sample is loaded to self-packed columns washed with washing buffer 
(100 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, pH 8.0), and eluted with 4 mL elution buffer (100 mM 
TrisHCl, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin, pH 8.0) or by boiling the material with 
loading buffer. 
2.6.11 Thrombin cleavage 
In order to remove the heterologous trimerization domain, elution fractions were pooled and 
dialyzed (2.6.7) before thrombin was added in a concentration of 2.5 U/mg protein. Incubation was 
carried out for 4 - 16 h (overnight). The fusion tag, TEV protease and uncleaved protein were 
removed by SEC (2.6.13) or reverse Strep-Tactin purification (2.6.9/2.6.10). 
2.6.12 Concentration of protein samples with Vivaspin concentrators 
Vivaspin concentrators (Sartorius AG) with polyether sulfone (PES) membranes were used to concen-
trate protein samples and to change buffer in small volumes. For this, protein solutions were 
centrifuged at 15,000 x g (Vivaspin 500), < 5,000 x g (Vivaspin 20) or < 4,000 x g (Vivaspin 2 and 
Vivaspin 6) until the desired volume or concentration was reached. Buffer exchange could be 
performed by refilling the columns with the exchange buffer after concentration. This was done with 
at least 10 volumes (related to the original sample). 
2.6.13 Size exclusion chromatography 
Size exclusion chromatography (SEC) is performed for further polishing the affinity-purified proteins 
and for isolation of distinct oligomeric states with an ÄKTA-FLPC unit. This technique separates 
molecules on the basis of their differences in size that leads to different retention volumes in the 
column packed with SEC medium. The SEC media consists of particles with pores of different sizes 
that allow small molecules to enter the pores thereby retarding them compared to larger molecules. 
Concentrated protein samples are loaded on Superdex 75 or Superdex 200 columns (list of used 
columns can be found in Table 2-13) depending on the size of the purified protein. The separation of 
the protein sample was performed with a flow rate of 0.3 mL/min. Fractions of 0.5 mL were collected 
and analyzed by SDS-PAGE (section 2.7.1).  
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2.7 Protein analytical methods  
2.7.1 SDS-PAGE  
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) was used to analyze protein 
quality and yields under denaturing conditions (Laemmli, 1970). Self-prepared gels were used 
consisting of a lower resolving gel (10 % or 12 % acrylamide) and an upper stacking gel (5 % 
acrylamide) (Table 2-23 and Table 2-24). Usually about 12 µL of protein sample was mixed with an 
appropriate amount of 4 x SDS loading buffer (Table 2-25) and heated for 5 min at 95 °C for 
denaturation. In case of non-reducing SDS gels samples were prepared with loading buffer without 
beta-mercaptoethanol and were not heated. For a better resolution, the samples were collected in 
the stacking gel by an initial run at 120 V for 5 min. Thereafter, the gels were run at 160 V for about 1 
h. The SDS gel was subsequently washed 3 x 5 min in H2O to remove SDS and was then stained with 
InstantBlue (Expedeon). Additionally, Mini-PROTEAN® TGX™ gels and Criterion™ precast gels (Bio-
Rad) were used according to the supplier’s protocols. With these gels the electrophoresis was 
performed at 150 V. The used molecular weight standards are listed in Table 2-3. 
Table 2-23: Compositions of SDS-PAGE gels (for eight gels) 
Component  12 % Resolving Gel 10 % Resolving Gel 5 % Stacking Gel 
Acrylamide/bisacrylamide 30 % (v/v) 12 mL 10 mL 1.5 mL 
4× Upper buffer - - 2.5 mL 
4× Lower buffer 7.5 mL 7.5 mL -  
10 % SDS in H2O 0.3 mL 0.3 mL -  
H2O 10.1 mL 12.4 mL 5.9 mL 
TEMED 40 µL 40 µL 30 µL 
40 % APS 60 µL 60 µL 30 µL 
 
Table 2-24: Buffers for SDS-PAGE 
Buffer Composition 
4× Upper buffer 0.5 M Tris/HCl pH 6.8, 0.4 % SDS (v/v) 
4× Lower buffer 1.08 M Tris-base, 0.42 M Tris-HCl, pH 8.8 
SDS Running Buffer 3 g/L Tris-base, 14.4 g/L Glycine, 1 g/L SDS, pH 8.3 
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Table 2-25: 4x SDS loading buffer 
Component Final concentration 
SDS 7 % (v/v) 
Glycerol p.a.  0.22 % (v/v) 
Tris/HCl pH 6.8 9.6 mM 
Beta-mercaptoethanol 2.4 mM 
Bromphenol blue 0.22 mg/mL 
In H20  
2.7.2 Native PAGE  
Native PAGE allows the separation of protein samples without denaturation of its secondary 
structures. The migration is therefore not only influenced by its mass but also by the net charge of 
the protein surface and its hydrodynamic radius. A slightly negative charge is applied through 
Coomassie G-250 usage in order to ensure migration to the cathode in the absence of SDS. The 
NativePAGETM Novex Bis-Tris Gel System (Thermo Fisher Scientific) was used according to the 
manufacturer’s instructions. The gels had a gradient of 4 to 16 % and the used molecular weight 
markers were HMW Native (66 - 669 kDa) and LMW Native (14.4 - 97 kDa) standards from GE 
Healthcare.  
2.7.3 Western blot  
Western blot analysis was used for the detection of specific proteins or tags with high sensitivity. The 
blotting was performed with a Trans-Blot-SD device or a Trans-Blot Turbo Transfer System (Bio-Rad) 
in a semi dry blotting procedure. The SDS gel was washed with water and was then incubated 
together with two pieces of western blot filter paper in transfer buffer for 10 min. The polyvinylidene 
difluoride (PVDF) membrane (Immobilon-P, Merck) was briefly hydrated with 100 % methanol and 
subsequently equilibrated in transfer buffer for 10 min. The transfer was performed for 30 – 40 min 
at 12 V (Trans-Blot-SD) or for 7 min with the mixed MW program (Trans-Blot Turbo). To prevent 
unspecific binding, the membrane was blocked by incubation at RT for 1 - 2 h in 10 mL blocking 
solution consisting of TBS-T-2.5% SMP (TBS-T supplemented with 2.5% (w/v) skim milk powder). The 
saturated membrane was then washed 3 x for 5 min in TBS-T (20 mM Tris-base, pH 8.0, 150 mM 
NaCl, 0.05 % (v/v) Tween) and incubated at RT for at least 1.5 h over at 4 °C overnight with 10 mL of 
TBS-T supplemented with an appropriate amount of the primary antibody. Again, the membrane was 
washed 3 x with TBS-T before the membrane was incubated with the secondary antibody conjugated 
to AP (alkaline phosphatase) for 2 h. Prior to detection it was again 3 x for 5 min washed with TBS-T 
in order to remove unbound secondary antibodies. For AP staining, the membrane was equilibrated 
for 5 min shaking in AP buffer (100 mM Tris-base pH 9.5, 100 mM NaCl, 5 mM MgCl2). Staining was 
performed by the BCIP/NBT Color Development Substrate (Promega) with 33 µL BCIP (50 mg/mL) 
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and 66 µL NBT (50 mg/mL) in 10 mL AP buffer. Antibodies used in western blot analysis are listed in 
Table 2-4.  
2.7.4 Mass spectrometry 
MALDI-TOF (Matrix Assisted Laser Desorption Ionization – Time-Of-Flight) mass spectrometry (MS) 
was used to identify protein fragments of SDS-PAGE samples by tryptic digestion. The corresponding 
protein bands were cut out of a stained SDS gel and were then transferred into 1 mL H2O. After 
tryptic digestion, proteins were co-crystallized with organic acids and desorption of protein 
fragments was triggered by a UV laser beam. The TOF measurements exposed mass-to-charge ratios 
of the ions. The results were compared with the MASCOT database to identify the analyzed proteins. 
For intact mass analyses by ESI (Electrospray Ionization), the buffer of purified protein samples was 
changed with Vivaspin concentrators (2.6.7) to H2O in order to remove any salts within the sample. 
All MS analyses were conducted by the MS platform of the research group Cellular Proteomics 
(CPRO) at the HZI (Braunschweig, Germany). 
2.7.5 Deglycosylation analysis 
In order to remove N-glycans of glycosylated proteins, deglycosylation experiments were performed 
with two different endoglycosidases. Endoglycosidase H (Endo H) is a glycosidase that cleaves within 
the chitobiose core of high mannose and some hybrid oligosaccharides from N-linked glycoproteins. 
Whereas the glycoamidase Peptide-N-Glycosidase F (PNGase F) cleaves between the innermost 
GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosaccharides from N-
linked glycoproteins. Deglycosylation analysis was performed according to the manufacturers’ 
protocol both with native and denatured protein samples. Deglycosylation of the different 
approaches were analyzed after distinct time points by SDS-PAGE (2.7.1).  
2.7.6 Thermofluor Buffer Screen 
A Thermofluor Buffer Screen was conducted in order to find the optimal buffer conditions for protein 
samples. The buffer of the protein sample influences protein stability by pH, ion strength and several 
additives (Newman, 2004). Thermofluor buffer screen, also called thermal shift assay, allows 
determining the optimal buffer conditions for each protein sample by assessing its melting point (Tm).  
The principle of this assay is the binding of a fluorescence dye as a function of protein unfolding and 
temperature, depicted in Figure 2.1. The added dye shows only weak fluoresce in buffer solutions, 
but its fluorescence increases in a nonpolar environment. A gradual increase of temperature leads to 
protein unfolding resulting in binding of the fluorescent dye to the hydrophobic protein core. The 
more the protein unfolds the more dye binds to the protein thereby increasing the fluorescence 
MATERIAL AND METHODS 
 
 
 58 
(Ericsson et al., 2006; Niesen, Berglund and Vedadi, 2007). Due to this increase in fluorescence by 
rising temperature the melting-curve can be calculated. If certain buffer conditions increase protein 
stability, Tm that corresponds to 50 % unfolded protein and is calculated by the apex of the melting 
curve and the minimum of its first derivative, is elevated.  
 
Figure 2.1: Thermofluor thermal denaturation assay  
A: Exemplary melting curve with a protein solution heated in the presence of the hydrophobic dye SYPRO Orange. The dye 
binds to the internal hydrophobic protein core upon denaturation thereby increasing the fluorescence signal. The maximal 
fluorescence intensity is obtained when the protein is completely unfolded. Subsequently, the SYPRO Orange signal 
decreases because of dissociation of protein and dye. B: Alternative representation of the melting curve using the first 
derivative – (dRFU)/dT of the raw data. The apex of the melting curve and the minimum of its first derivative represent the 
Tm that corresponds to 50 % unfolded protein (adapetd by Boivin et al. 2013b). 
At first a concentration test is performed to analyze the optimal amount of protein and dye. For this 
purpose the dye 10x SYBRO Orange (Invitrogen) was diluted from 5000x to 100x, 50x and 10x and the 
protein sample was diluted to 0.5 mg/ml, 1 mg/ml and 2 mg/ml. A screen was set up on an 
appropriate 96-well PCR plate with the different protein and dye concentrations. Afterwards the 
actual measurement with the buffer screen (tested conditions listed in APPENDIX V) was performed.  
The assay was performed in a real time PCR-system (BIO RAD CFX96 Real-Time System C1000 
Thermal Cycler) and results were evaluated with CFX Manager (BIO-RAD).  
2.7.7 Dynamic light scattering 
Dynamic light scattering (DLS) was used to measure the hydrodynamic radius of the protein sample 
and its size distribution in solution by scattered laser light. This technique is often used to investigate 
the homogeneity of a protein sample and judge its potential to crystallize (Zulauf and D’Arcy, 1992). 
In this thesis it was additionally used as another approach to determine the size and thereby the 
oligomeric state of protein samples. Prior to the measurements protein samples were centrifuged at 
60000x g for 30 min. Then 60 µL of the sample was transferred in a cuvette (UVette® 220-1600 nm; 
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Eppendorf) that is subsequently inserted in the DynaPro Titan DLS (Wyatt technology). Data points 
were accumulated over ten seconds, averaged and analyzed by the DYNAMICS software (version 
6.10.1.2; Wyatt technology). Up to 20 measurements were carried out to obtain redundant data. The 
resulting graph and table indicate the percentage of polydispersity (peak broadening) and the 
average particle size in nm for each determined peak.  
2.7.8 Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy was employed in order to analyze the secondary structure 
composition of protein samples with a Jasco J-815 CD spectrometer (Jasco, Inc). This technique is 
widely used for rapid determination of secondary structure and folding properties of recombinant 
proteins (Greenfield, 2006). The basic principle is the difference in absorption of left-handed and 
right-handed circularly polarized light (CPL) by chiral molecules. The electrons within a chiral 
molecule absorb energy and undergo transition to an excited state when it is hit by a circularly 
polarized wave (Garab and van Amerongen, 2009). The resulting excitation depends on the 
polarization (left or right-handed), on the wavelength and also on the geometry of the chiral 
molecule. In proteins the geometry is determined by specific angles of the peptide backbone which 
allows to analyze the CD spectra between 260 and 180 nm for the different secondary structure 
components (Johnson, 1990). Each sample was measured at 20 °C in a 0.1 cm path-length cuvette. 
Spectra were recorded in the range of 190 – 260 nm and 1 nm bandwidth and 4 s digital integration 
time (D.I.T.). Signal-to-noise correction of each measurement was achieved by recording ten spectra 
per sample. For buffer-signal correction, a spectrum was recorded with buffer only using the same 
experimental setup and the identical quartz cuvette. The buffer spectrum was subtracted from the 
other spectra prior to secondary structure analysis.  
2.8 Protein crystallographic methods 
2.8.1 Initial screening and crystal optimization 
Initial crystal screening was performed by the sitting drop vapor diffusion method using commercially 
available JCSG+ and PEGs Suite I Screens (Qiagen). The purified protein was used at a concentration 
of 10 mg/mL. Drops of 200 nl protein and 200 nl buffer were prepared with HoneyBee pipet robot 
(Digilab Genomic Solutions) on an 96 well Intelli Plate (Art Robinson) with sitting drop method. 
Crystallization plates were sealed with Quick-Combi Sealer plus (HJ-BIOANALYTIK GmbH) and then 
transferred into the Rock Imager 1000 (Formulatrix), which enables automatic documentation during 
storage. All crystallization setups were incubated at 20 °C in the temperature controlled imaging 
system and screened on a regular basis.  
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Initial crystals hits were further optimized during several rounds of random screening optimization 
with the self-prepared screens RI, RII, RIII and H1_Grid. The screens RI, RII and RIII were randomly 
generated with the software Rock Maker (Formulatrix) on the basis of conditions that yielded first 
hits by using the Formulator liquid handling system (Formulatrix). In case of H1_Grid only the 
parameters pH (range of 7.2 – 7.8) and the concentration of the precipitant PEG 550 MME (20 – 
30 %) were varied along X-axis and Y-Axis of the 96 well plate. In order to avoid crystal damage after 
harvesting, the crystals were transferred into a drop containing mother liquor supplied with (2-R, 3-
R)-2,3-Butandiol that functions as cryo-protecting agent prior to freezing in liquid nitrogen. 
2.8.2 Data collection 
X-ray diffraction data of H1 crystal used for structure determination was collected at beamline 14.2 
of BESSY II (Helmholtz center Berlin, Germany). The diffraction data of H3 crystal used for structure 
determination was collected at DESY (Deutsches Elektronen-Synchrotron, Hamburg) beamline P11 at 
PETRA III.  
2.8.3 Model building and refinement 
Molecular replacement of H1 and H3 was performed with HA0 crystal structure PDB ID: 1HA0 (Chen 
et al., 1998). The model building and refinement of H1 was performed by Jörn Krausze (HZI, 
Braunschweig). In case of H3 the initial model was received by the AutoBuild wizard (Terwilliger et 
al., 2008) implemented in phenix software. It was further improved by iterative steps of manual 
building in Coot (Emsley et al., 2010) and refinement in Phenix.refine (Afonine et al., 2012) by help of 
Peer Lukat (HZI, Braunschweig).   
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3 Influenza surface protein Hemagglutinin 
3.1 Recombinant HA expression in the multi host expression system 
Influenza A is a viral infection of the respiratory tract affecting millions of people every year. The 
infection process is initiated through binding and fusion of the viral envelope to the host cell 
membrane via the surface glycoprotein HA. Therefore, the HAs, which are produced as inactive 
homotrimeric precursor proteins, are cleaved by host cell proteases and transferred into their active 
form. Since this cleavage represents an essential process for viral infectivity, the idea is to interfere 
with HA cleavage as a novel approach against IAV. For this purpose three HA subtypes (H1, H3 and 
H7) should be recombinantly expressed in their unprocessed non-cleaved form for structural and 
functional analysis. Besides, a protocol for large scale expression and purification of H1 HA should be 
developed for application in transfollicular vaccination strategies. 
Expression constructs were designed and cloned by Joop van den Heuvel and Ruth Lambertz (HZI). 
They comprise the whole HA ectodomain followed by the T4 foldon sequence allowing recombinant 
trimer expression since it functions as an artificial trimerization domain (Stevens et al., 2004). An N-
terminal IgG secretion signal is implemented to secrete the proteins into the supernatant, while His- 
and Strep-tags can be used for purification and Thrombin and TEV cleavage sites are necessary to 
eliminate heterologous parts after purification.  
 
 
 
 
Figure 3.1: Construct design for recombinant hemagglutinin expression  
The IgG secretion signal (IgG ss) is fused N-terminally to HA ectodomain comprising the subunits HA1 and HA2 to direct it to 
the supernatant. A trimerizing sequence (T4 foldon) was incorporated with a thrombin cleavage site introduced between 
the C-terminus of HA ectodomain and foldon. At the extreme C-terminus of the construct a TEV cleavage site followed by 
Twinstrep and an 8xHis tag are fused to the protein to enable purification and detection. 
Expression was initially tested for the different subtypes in the multi host expression system 
developed in our department for evaluation of the optimal expression host (Meyer et al., 2013). For 
this approach the constructs were cloned into the pFlpBtM-II vector and first expression tests were 
performed. 
HA1 HA2 
IgG ss 
Thrombin cleavage site 
T4 foldon 
TEV cleavage site 
Twinstrep tag 8x His tag 
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3.1.1 Insect cell expression 
Insect cells are very promising as expression host for recombinant HA expression since successful 
expression of HA proteins in insect cells has already been reported (Stevens et al., 2004; Wang et al., 
2006; X. Li et al., 2015). Furthermore, lepidoptera cell lines are widely used to express heterologous 
proteins for crystallization as they offer various advantages due to their safety, ease of use and 
simple glycosylation pattern (Tomiya et al., 2004; Nettleship et al., 2010; Nettleship, 2012).  
First of all, recombinant baculoviruses were produced for protein expression via BEVS that express 
HA of the subtypes H1, H3 or H7, respectively. As described in 2.4.8 the HAs were integrated via Tn7 
transposition into the baculovirus genome maintained as a bacmid in DH10B E. coli cells. 
Recombinant bacmids could be screened by blue-white selection in consequence of lacZ gene 
disruption. Afterwards they were further analyzed by PCR (2.4.1) and subsequently used for 
transfection 2.5.7. The integration of an YFP expression cassette within the backbone of the 
baculovirus EmBacY enables efficient monitoring of virus performance. Upon transfection of 
adherent S. frugiperda (Sf21) cells recombinant YFP expression could be used as indication for 
effective infection confirmed by fluorescence microscopy (shown in Appendix I, Figure 8.1).  
Transfection supernatants were subsequently used for virus amplification to generate viral stocks for 
recombinant protein expression. Throughout virus amplification growth kinetics, fluorescence and 
changes in cell diameter of cells infected with recombinant baculovirus were observed to identify 
successful infection. Growth kinetics, fluorescence and variations in cell diameter during virus ampli-
fication are presented in Appendix I, Figure 8.2.   
After successful generation of recombinant baculoviruses their ability to produce HA variants was 
determined in Sf21 and Hi5 cell lines in 40 mL scale. Suspension cultures with an initial cell density of 
1 * 106 cells/ml (Sf21) and 0.7 * 106 cells/ml (Hi5) were infected with either 5 vol% or 10 vol% of 
external virus stock and cultivated for 96 h. Infection was monitored during cultivation by fluores-
cence measurements with FACS and additionally by determining the mean cell diameter with CASY 
Cell Counter. Supernatants were analyzed every 24 h for recombinant protein expression via western 
blot incubated with His-tag primary monoclonal antibody (mAb) and secondary goat-anti-mouse AP-
conjugated polyclonal antibody (pAb) (2.7.3, Table 2-4). Detection of recombinantly expressed HA 
was successful in Hi5 cells, whereas the expression was too low in Sf21 cells within 96 h of cultivation 
to detect the recombinant proteins (Figure 3.2 A).  
In order to further verify HA-expression additional SDS-PAGE was performed with Hi5 derived 
supernatants (Figure 3.2 B) for mass analysis. The corresponding bands (indicated by an arrow in 
Figure 3.2 B) were cut out of the gel and were subsequently subjected to tryptic digestion for protein 
analysis via MALDI-TOF. MALDI-TOF analyses were conducted by the MS platform of the research 
group Cellular Proteomics (CPRO) at the HZI, Braunschweig (2.7.4). With that up to 95 % of the amino 
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acid sequence was verified for each subtype. The observed variation in size of different HA subtypes 
are thought to depend on differences in their glycosylation.  
 
 
 
 
 
 
Figure 3.2: Small scale HA Expression test in Sf21 and Hi5 cells with BEVS 
Expression of the three HAs (H1, H3 and H7) via BEVS could be detected in crude culture supernatants by SDS-PAGE and 
western blot analyses using a primary mouse α-His mAb and a secondary goat AP-conjugated α-mouse pAb. Infection was 
performed with 5 vol% or 10 vol% virus stock in Sf21 and Hi5 cells as idicated above the gel/blot. A: Western blot of Sf21 
and Hi5 samples. B: SDS gel with Hi5 samples. Colorimetric AP staining of the western blot was done with NBT and BCIP. 
The SDS gel was stained with InstantBlue. M: PageRuler Prestained, all samples were taken at 96 hpi.  
After the success of small scale expression in Hi5 cells, expression was performed in larger scale 
(500 mL) for subsequent purification. Here, suspension cultures with an initial cell density of 0.5 * 
106 cells/ml were infected with 15 vol% (H1) or 10 vol% (H3 and H7) virus stock according to their 
infection performance in small scale. Infection and growth kinetics were monitored during cultivation 
(Figure 3.3). The infection of Hi5 suspension cultures by the recombinant baculoviruses was verified 
via measurements of YFP fluorescence by flow cytometry and through a distinct increase of the mean 
cell diameter of about 3 µm during the first 24 h. While the respective YFP fluorescence indicates 
infection efficiencies of at least ~ 50 %. The culture supernatants were harvested at a viability of 
about 80 % at 75 hpi, except for H1. Due to the higher virus dose that was applied cells infected with 
EMBacY-H1 already had a decrease in viability below 70 % after 48 hpi so that they were harvested at 
48 hpi.  
A B 
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Figure 3.3: Growth kinetics, fluorescence and cell diameter of Hi5 cells infected with indicated baculoviruses 
The graphical data depicts the daily assessed growth and infection parameters. Hi5 suspension cultures with a cell density 
of 0.5 × 10
5
 cells/mL were infected with recombinant baculovirus (EMBacY-HA variants). The cells were counted manually 
with a Neubauer hemocytometer. The vitality was assessed by trypan blue staining. The YFP expression of EmBacY was 
monitored by flow cytometry in the GFP channel (488 nm excitation). The mean cell diameter was analyzed with CASY 
counter. Significant increase in cell diameter and YFP fluorescence indicate successful infection.  
The crude culture supernatants were subsequently diafiltrated and the buffer was exchanged to 
50 mM NaH2PO4, 300 mM NaCl, pH 8.0 with the KrosFlo Research IIi TFF System (2.6.7). Purification 
was performed via Ni-NTA IMAC using the Profinia Protein Purification System (IMAC-catridge 1 mL, 
Desalting catridge 10 mL, according to the protocol described in 2.6.10). IMAC fractions and 
supernatants were further analyzed via SDS-PAGE and western blot, shown in Figure 3.4.  
Recombinant HA accumulated in the supernatants and a first rough purification was achieved. Each 
eluate fraction contained up to 3 mg protein. However, contamination by non-specifically bound 
protein and degradation was observed. The high amount of degraded H1 is probably due to the low 
viability of its expression culture 48 hpi (<70 %) caused by the lytic nature of BEVS. In comparison to 
H1 and H3 that were predominantly purified in its uncleaved form, high amounts of H7 were already 
cleaved by host proteases during insect cell cultivation and purification.  
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Figure 3.4: SDS-PAGE and Western Blot analysis of IMAC purification of HA  
The HA (H1, H3, H7) protein was expressed upon BEVS in Hi5 cells. Diafiltrated cell culture supernatants were applied to a 
BioRad Profinia system equipped with a Profinity IMAC Cartridge (1 mL) and a Bio-Gel P6 Desalting Cartridge (10 mL). Daily 
samples of supernatants and fractions from IMAC purification are presented in each gel and western blot. The SDS gel was 
stained with InstantBlue. The Western blot was performed with primary anti-His mAb together with a secondary goat-anti-
mouse AP-conjugated pAb. Colorimetric AP staining was done with NBT and BCIP. M = PageRuler™ Protein Ladder, 24: 
sample at 24 hpi, 48: sample at 48 hpi, dia: diafiltrated supernatant, Ft = flow through, W1 = wash fraction 1, W2 = wash 
fraction 2, H1/H3/H7: purified HA of indicated subtype.  
Overall, the generation of HA-expressing bacmids resulted in recombinant baculovirus suitable for 
infection of Sf21 and Hi5 insect cells. While the expression via BEVS was too low for a successful 
detection in Sf21 cells, recombinant HA of the subtypes H1, H3 and H7 was successfully expressed 
and purified in Hi5 cells. In comparison to H1 and H3 that were predominantly purified in its 
uncleaved form, high amounts of the subtype H7 were already cleaved by host proteases during 
insect cell cultivation and purification. 
HA0 
HA0 
HA0 
HA2 
HA2 
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3.1.2 Mammalian expression  
In order to find the optimal expression host, both transient gene expression in HEK293-6E cells as 
well as stable expression in engineered CHO cell lines, implemented in the multi-host system for 
expression in mammalian cells, were performed. The transient expression in HEK293-6E was 
analyzed in 25 mL scale as described in 2.6.1. pTTo-GFPq was co-transfected to determine efficiency 
of transfection. Growth kinetics and fluorescence signals are presented in Figure 3.5. Transfection 
rates of about 70 % could be observed for all three HA constructs ensuring efficient transfection. 
 
Figure 3.5: Growth kinetics and fluorescence of HEK 293-6E cells transfected with HA H1, H3 or H7 
HEK293-6E suspension cultures with a cell density of 2 × 10
6
 cells/mL were transfected with pFlpBtM-II-HA variants and the 
cultures were expanded to 50 mL and supplemented with 0.5 % tryptone 48 hpt. The cells were counted manually with a 
Neubauer hemocytometer. The viability was assessed by trypan blue staining. The GFPq expression of co-transfected pTTo-
GFPq was determined at a Guava EasyCyte flow cytometer using a 488 nm laser for extinction and allowed to monitor 
transfection efficiencies.   
Since recombinant HA expression was detected for the three subtypes H1, H3 and H7 by Western 
blot (data not shown), the next step was a large scale expression with subsequent purification for 
subtype H1. For this large scale expression a slightly different approach was used than for small scale 
expression. In this case herring sperm DNA was used as filler DNA to test its effect on enhancing 
transfection as already described for other proteins (Kiseljak et al., 2011). 1 L suspension culture was 
transfected with 25 µg DNA (12.5 µg pFlpBtM-II-H1 + 11.25 µg Herring sperm DNA + 1.25 µg pTTo-
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GFP) and 62.5 µg PEI (DNA PEI ratio 1:2.5). For even further improving recombinant expression 
valproic acid was added 96 hpt to a final concentration of 3.75 mmol/L in order to possibly increase 
recombinant mRNA and protein levels (Wulhfard et al., 2010). With this changed protocol a rather 
scant transfection rate below 20 % was observed (Appendix I, Figure 8.3). The supernatant was 
harvested 168 hpt followed by purification via Ni-NTA IMAC with the Profinia Protein Purification 
System as described above for insect cell derived HA, resulting in ca. 22 mg rather pure protein 
(Appendix I, Figure 8.4). Unfortunately, the protein was not very stable and tended to precipitate 
after purification.  
Besides, stable glycosylation deficient CHO cell lines expressing HA (derived from different CHO Lec 
3.2.8.1 master cell lines) were generated by the Protein Sample Production Facility (PSPF) at the HZI. 
However, the HA expression was so low that it could only be detected in concentrated samples of 
TCA precipitation via western blot so this approach was not pursued further.   
3.1.3 Analysis of quality of the HA expressed in insect and mammalian cells  
Since glycosylation can hinder crystallization of proteins because of the chemical and conformational 
heterogeneity of their carbohydrate moieties (Wulhfard et al., 2010), deglycosylation experiments 
were performed with both HEK and insect cell derived H1 (2.7.5). For this approach the two different 
endoglycosidases Endo H and PNGase F were applied. Herewith PNGase F is the most effective 
enzyme for removing almost all N-linked oligosaccharides from glycoproteins (Freeze and Kranz, 
2010). Yet, most glycoforms produced by insect cells can also be trimmed by treatment with Endo H 
(Nettleship, 2012). Both endoglycosidases, however, are sensitive to some kind of core fucosylation 
frequently occurring in insect cells (Altmann et al., 1999; Walski et al., 2017).  
H1 expressed in Hi5 cells was not susceptible to deglycosylation at all, neither with Endo H nor 
PNGase F, even after prolonged incubation or with denatured protein. While H1 expressed in 
HEK293-6E cells was affected by severe degradation and increased precipitation after treatment with 
PNGaseF (data not shown). For more details on particular glycosylation both glycosylated proteins 
were subjected to mass spectrometry performed by the MS platform of the research group CPRO at 
the HZI. The determination of each protein mass by MALDI-TOF is depicted in Figure 3.6.  
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Figure 3.6: Mass analysis of H1 derived from Hi5 and HEK293-6E cells 
The MALDI analysis of H1 expressed in Hi5 cells showed a major peak at the size of ~62 kDa (left hand site), whereas the 
dominant peak at the size of ~67 kDa was observed for H1 expressed in HEK293-6E cells (right hand site). Peaks with smaller 
molecular weight correspond to multiply charged monomers. Besides, the spectra demonstrate a homogenous glyco-
sylation for H1 expressed in Hi5 cells and a heterogenous glycosylation pattern for H1 expressed in HEK293-6E cells.  
Both proteins differ in their total mass with 62.3 kDa for the H1 monomer expressed in Hi5 cells (H1-
Hi5) and 67.5 kDa for the HEK293-6E derived monomer (H1-HEK). Besides, the observed masses are 
higher than the theoretical mass of 57.4 kDa of the thrombin-cleaved monomer. Increased masses of 
ca. 5 kDa for H1-Hi5 and ca. 10 kDa for H1-HEK can be most likely explained by their different glyco-
sylation with almost 1 kDa for each glycosylation site for H1-Hi5 and 2 kDa for H1-HEK, respectively. 
Besides, the spectra clearly demonstrate a very homogenous glycosylation of H1-Hi5 compared to 
the heterogeneous pattern of H1-HEK indicated by the broad irregular mass peak. Additionally, 
dynamic light scattering (DLS) analysis was performed with both protein batches in order to confirm 
trimeric HA-expression and to further examine the molecular weight of the non-cleaved samples. The 
data derived from DLS measurements clearly indicate higher molecular weights for H1-HEK 
compared to H1-Hi5, confirming the previous results derived from mass analysis by MALDI-TOF 
(Appendix I, Figure 8.5).  
Taken together these results indicate a quite homogenous H1 protein derived from Hi5 insect cell 
expression. Its uniform glycosylation pattern should not hinder crystallization. As opposed to this, H1 
transiently expressed in HEK293-6E cells has a more diverse glycosylation that probably would hinder 
crystallization and could not be removed without protein degradation. All results indicate that the HA 
produced in HEK293-6E cells is not of such a good homogeneity as HA produced in Hi5 cells, even 
though it had a much higher product titer. Further efforts would need to be done in order to try to 
overcome those obstacles, whereas recombinant HA expression in Hi5 already was very promising. 
Hence, Hi5 cells represent a better expression host for recombinant HA. Consequently, expression 
was performed in Hi5 cells thereafter.   
H1 – Hi5 cells H1 – HEK293-6E cells 
RESULTS  
  
 
 69 
3.2 Optimization of downstream processing for recombinant HA production 
3.2.1 Improving protein purity by affinity chromatography  
In order to further improve the HA purity Ni-NTA purified samples were subsequently subjected to 
HisTALON purification. The Co2+–CMA matrix of Talon resin (Clontech) has a lower affinity for the 
polyhistidine affinity tag than the Ni2+–NTA resin, resulting in elution of the tagged proteins under 
milder conditions. Besides, the Co2+–CMA has been reported to exhibit less nonspecific protein 
binding than the Ni2+–NTA resin, resulting in higher elution product purity (Bornhorst and Falke, 
2000). Hence, Talon purification was performed subsequent to previous Ni-NTA purification.  
Ni-NTA purified HA was dialyzed against 50mM Tris/HCl 300 mM NaCl pH 7.4 for ensuing HisTALON™ 
Superflow purification. Following dialysis, purification was performed for each HA, H1, H3 and H7 
according to the manufacturers’ protocol (2.6.10). Eluted fractions were analyzed by SDS-PAGE and 
Western Blot as shown in Figure 3.7. Nice single bands of about 70 kDa corresponding to monomeric 
HA protein could be observed in SDS-PAGE for the subtypes H1 and H3 after this second affinity 
purification. The pooled eluate fractions of H1 and H3 contained 0.6 mg and 1.4 mg of purified 
protein, respectively. For H7, however, the major part of the purified protein was already cleaved 
into its subunits HA1 and HA2 due to host proteases during purification steps. Proteolytic H7 
cleavage even increased after the second purification step, resulting in nearly completely processed 
H7.  Hence, further purification steps and crystallization setups were only performed with H1 and H3.  
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Figure 3.7: SDS-PAGE and Western Blot analysis of HisTALON purified HA subtypes H1, H3 and H7 
The Ni-NTA purified HA proteins (A: H1, B: H3, C: H7) were subjected to HisTALON purification. The samples of different 
fractions are presented in each gel and western blot. The SDS gel was stained with InstantBlue. The Western blot was 
performed with primary anti-His mAb together with a secondary goat-anti-mouse AP-conjugated pAb. Colorimetric AP 
staining was done with NBT and BCIP. M = PageRuler™ Protein Ladder, Ft = Flow through of the HisTALON column, W = 
Wash fraction, E0 – E8 = Elution fractions, Ni-NTA = Ni-NTA purified sample used for HisTALON purification.  
In the next step HisTALON purification of the dialyzed supernatants was examined without prior Ni-
NTA purification. In this way the yield should be improved from only 1.2 (H1) and 2.8 mg/L (H3) after 
two rounds of affinity purification and dialysis. For this approach 1 L suspension culture of Hi5 cells 
with an initial cell density of 0.9 * 106 cells/ml was infected with 10 vol% of virus stock and was 
harvested 48 h after infection. Purification of the HA protein was performed according to the manu-
facturers’ protocol with HisTALON™ Superflow (5 mL HisTALON™ Catridge) and the purification 
achievement was analyzed by SDS-PAGE (Appendix II, Figure 8.6).  
With this adapted purification strategy with HisTALON™ Catridge a total amount of 5.9 mg/L pure 
protein was successfully purified. This represents a five-fold increase to the previous strategy 
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regarding to the protein yield per liter suspension culture. The H1 protein already reached a high 
grade of purity and could be used for further processing by thrombin cleavage (3.2.3) and size 
exclusion chromatography (3.2.4) as well as first crystallization trials (3.4).   
3.2.2 Direct HA capture from the supernatant 
In the previous purification strategies recombinant HA was purified from the culture supernatant in 
two steps: First, the supernatant was concentrated and buffer exchanged during diafiltration and 
afterwards it was purified by affinity chromatography. Especially for HA production in large scale, up 
to 6 L expression cultures, this procedure was cumbersome, time-consuming and lead to varying loss 
of the target proteins. Furthermore, the required time for this two-step purification set up could 
have a severe influence on protein quality. Proteolytic processing and degradation by proteases was 
already observed for the HA subtypes H1 and H7 (Figure 3.4 and Figure 3.7) and was thought of as a 
critical factor for the purification protocol.  
For direct HA capture, the supernatant of infected Hi5 cells was harvested 72 hpi in two steps: First 
suspension cultures were centrifuged for 5 min. at 200 x g in order to carefully remove the cells. 
Afterwards the supernatant was supplementary centrifuged for 10 min. at 5000 x g to thoroughly 
remove remaining particles to avoid clogging of the cartridge. Thereafter the supernatant was 
directly loaded onto a HisTrap excel column (1 mL HisTrap excel IMAC column, GE Healthcare) and 
purification was performed according to the manufacturers’ protocol (2.6.10). Elution fractions of 
1 mL were analyzed by SDS-PAGE and western blot as shown in Appendix II, Figure 3.8. HA capture 
was effective; however, some minor impurities remained within the elution samples. Nevertheless, 
further purification with HisTALON did not increase the level of purity (data not shown). Therefore, 
the imidazole concentration was increased up to 75 mM in the next purification set-ups due to 
stronger binding of the target protein according to the trimeric His tag (see section 3.3.2). 
All in all, the optimization of affinity purification of recombinant HA was very effective. The purity 
and the yield were successfully increased by both HisTALON™ and HisTrap excel purification 
strategies. Furthermore, the implementation of the fast and more gentle HisTrap excel purification 
was able to replace the more cumbersome and time-consuming previous procedure of diafiltration 
prior to affinity purification. With this changed protocol the overall purification process was some 
days up to more than a week faster, depending on the applied expression volume. Moreover, the 
saved time and the gentle process also improved the product quality by minimizing protein 
degradation.  
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Figure 3.8: SDS-PAGE and western blot analysis of HA expression and subsequent purification with HisTrap excel  
The H1 protein was expressed in BEVS using an EMBacY-pFlpBtM-II-H1 virus and was subsequently subjected to HisTrap 
excel purification. The SDS gel was stained with InstantBlue. The Western blot was performed with primary anti-His mAb 
together with a secondary goat-anti-mouse AP-conjugated pAb. Colorimetric AP staining was done with NBT and BCIP. The 
samples of different fractions are presented in each gel and western blot. M = P PageRuler™ Plus Protein Ladder, SN = crude 
supernatant after harvesting, Ft = flow through, W = wash fraction, E1 – E11 = elution fractions 1 – 11.  
3.2.3 Thrombin cleavage 
For both immunization and crystallization further processing of the purified recombinant HA is 
necessary. First, the heterologous part of the protein, consisting of the trimerization domain foldon 
and tags for purification, should be removed by cleavage with thrombin (2.6.11). Therefore cleavage 
analysis of the H1 and H3 trimer was performed using Thrombin from bovine plasma (SERVA). 
Samples were taken at different time points and analyzed by SDS-PAGE and western blot for 
validation of cleavage efficiency (Appendix II, Figure 8.7).  
After initial tests cleavage was routinely performed with Thrombin (SERVA) in a concentration of 
2.5 U/mg for at least 5 h. However, cleavage was not of constant quality. Therefore an additional 
optimization of H3 cleavage using Thrombin of different suppliers was conducted. Analysis was 
performed with Thrombin from SERVA and GE Healthcare. Evaluation was done by SDS-PAGE as 
depicted in Figure 3.9. Successful cleavage was observed due to the reduction in size according to the 
separation of a roughly 10 kDa large fragment from the remaining part of about 60 kDa. For further 
purification, thrombin-cleaved proteins were subsequently applied to either size exclusion chroma-
tography (3.2.4) or reverse Strep-Tactin purification (3.2.5). 
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Figure 3.9: SDS-PAGE analysis of H3 cleavage with Thrombin  
H3 cleavage with Thrombin was performed in order to remove the heterologous trimerization domain including tags for 
purification. Cleavage was performed according to the manufacturers’ protocol with 2.5 U (SERVA) or 10 U (GE Healthcare) 
/ mg protein for 16 h at RT. Successful cleavage can be observed due to reduction in size because of the separation of ~ 
10 kDa fragment, as illustrated in the right hand site. The SDS gel was stained with InstantBlue. M1 = PageRuler™ Plus 
Protein Ladder, 0h = sample prior to cleavage, SE = Thrombin from SERVA, GE = Thrombin from GE Healthcare, M2 = 
PageRuler™ Protein Ladder.  
3.2.4 Size Exclusion Chromatography 
After thrombin cleavage size exclusion chromatography (SEC) was performed using a Superdex 200 
16/60 column. In a first experiment thrombin-cleaved protein samples as well as uncleaved HA 
samples were used to determine their individual retention volumes (Figure 3.10).  
Selected elution fractions were analyzed by SDS-PAGE. Their retention volumes were compared 
among each other and the molecular weight was calculated using the calibration curve provided by 
the manufacturer. Additionally, the isolated peak of monomeric H1 was further analyzed by DLS 
(Lorber et al., 2012) for determining its molecular weight and size distribution (Appendix II, Figure 
8.8).  
 
Figure 3.10: Elution profile of thrombin cleaved H1 (A) and uncleaved H1 (B) during size exclusion chromatography 
A: Superdex 200 16/60 gel filtration was used to separate cleaved H1 from both foldon with tags and thrombin as well as 
uncleaved H1. B: Superdex 200 16/60 gel filtration was used to analyze the molecular weight of uncleaved H1 compared to 
thrombin cleaved H1 shown in A.   
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Table 3-1 summarizes the calculated masses compared to the theoretical ones and those obtained 
with DLS measurements. Notably, the calculated mass of every protein sample, based on its 
retention volume, is below its theoretical mass, based on its amino acid composition. Probably this is 
caused by the fact that the stokes radius of globular proteins is the underlying principle of those 
calculations. Hence, the cylindrical shape of the trimeric HA protein leads to underestimation of its 
size. Nevertheless, the size range of each type of protein observed during SEC provides valuable 
information about its oligomeric state. With this approach it was observed that the major part of the 
thrombin-cleaved protein has been dissociated into HA monomers after the separation of the 
trimerization domain. 
 
Table 3-1: Summarized data of molecular mass of monomeric and trimeric H1 obtained by different approaches 
 Ve Kav Mw_calculated Mw_theoretical  Mw_DLS 
Monomeric cleaved H1  81,0 0,48 43 59  44 
Trimeric uncleaved H1   65,7 0,28 155 205  191 
Trimeric cleaved H1  72,0 0,36 91 178  - 
 
Since high ionic strength can influence the oligomer dissociation into monomers, the ionic strength 
was decreased by reducing the salt concentration to 50 mM NaCl prior to and during SEC. Indeed, 
this led to an increased isolation of trimeric H1 with only little dissociation into monomers as 
depicted in Figure 3.11. The isolated trimeric protein was subsequently pooled, concentrated and 
used for first crystallization trials (3.4).  
 
 
Figure 3.11: Elution profile of thrombin cleaved H1 during SEC using low salt concentrations 
Superdex 200 16/60 gel filtration was used to separate the trimeric thrombin cleaved H1 from monomeric protein and 
foldon with tags and thrombin as well.  
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3.2.5 Reverse Strep-Tactin purification 
In order to ensure the complete removal of uncleaved HA and potentially remaining parts of the 
trimerization domain, another affinity purification step with Strep-Tactin resins was included to 
remove all tagged contaminants. In a first test experiment small scale purification of H3 with 
magnetic beads (MagStrep "type3" XT beads, iba) was performed (2.6.8) prior to SEC and purification 
was analyzed by SDS-PAGE, depicted in Appendix II, Figure 8.9. With this additional purification step 
all tagged contaminants could be removed successfully. Hence, additional large scale Strep-Tactin 
purification was performed by using Strep-Tactin Superflow residue (iba) (2.6.10). The complete 
removing of tagged protein was evaluated by SDS-PAGE, presented in Figure 3.12 A for H3, and 
purified material was then applied to SEC. In case of H1 that was used for reverse Strep-Tactin 
purification after SEC (Figure 3.12 B), the purified protein was afterwards utilized for crystallization 
set-ups.  
 
 
 
 
 
 
 
 
 
Figure 3.12: HA batch purification with Strep-tactin superflow 
For removing tagged contaminants Strep-Tactin purification of H3 (A) and H1 (B) was performed according to the manu-
facturers’ protocol. M1 = PageRuler™ Plus Protein Ladder, 1 = Thrombin-cleaved HA, 2 = flow-through containing purified 
protein, 3 = wash fraction, 4 = elution fraction under native conditions, 5 = elution fraction under denaturing conditions, M2 
= PageRuler™ Protein Ladder.  
3.3 Scale-up of H1 expression for transfollicular vaccination strategies 
One aim of this project was to produce the HA isolate H1 (A/Puerto Rico/8/34) in high amounts and 
with high quality for transfollicular vaccination strategies by our collaboration partners Guzman and 
co-workers. For this approach it was not only necessary to produce lots of very pure material, the 
process was also desired to be both affordable and easy to handle. For this purpose three different 
methods were evaluated to optimize the production process that should lead to high yields while 
being accessible for a scale-up in bioreactor dimensions with a production scale of up to 1 g.  
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3.3.1 Baculoviral Expression using BIICs  
In a first approach for up-scaling of the HA production process it was investigated to use the TIPS 
(Titerless Infected-Cells Preservation and Scale-Up) method described by Wasilko and Lee. This 
method depends on application of cryopreserved Baculovirus Infected Insect Cell (BIIC) stocks for 
infection and recombinant protein expression (Wasilko and Lee, 2006). Those BIICs are harvested and 
frozen after infection with recombinant baculovirus, but prior to cell lysis, when virus would be 
released into the culture supernatant. With this method cell stocks densely packed with recombinant 
baculovirus can be generated. This virus stocks can subsequently be used to infect insect cells for 
large-scale productions since as little as 1 mL of BIICs is needed for a 100 L expression scale (Wasilko 
et al., 2009). Besides, the TIPS method eliminates repeated virus amplification steps and at the same 
time provides a long-term stable storage form of recombinant virus. Thus, it not only enables a stable 
virus stock suitable for scale-up, but also leads to higher reproducibility. By applying BIICs there are 
no differences in infection efficiency depending on the individual virus stocks and no loss of infection 
over time. Furthermore, in large scale expression set-ups the handling is much easier compared to 
external virus stocks generated by virus amplification (Wasilko and Lee, 2006; Wasilko et al., 2009).  
Unfortunately, this method was not very convenient in our hands as we could not achieve infections 
that were comparable to that with the extracellularly virus stock used before (3.1.1). Therefore 
different BIIC-culture ratios were tested for infection efficiency in Sf21 cells in order to test their 
ability to infect the cells. However, only very high amounts of applied BIICs (1:20, 1:50 and 1:100) led 
to successful infection of at least 50 % Sf21 cells within 48 h, whereas lower BIIC volumes of 1:500 
and 1:1000 showed only very little potential for effective infection (depicted in Appendix III, Figure 
8.10). Hence, different approaches for increasing the infectivity of BIICs were tested. For instance, 
the effect of time for harvest of the BIIC was analyzed for different time points between 5 and 16 hpi, 
but none of these approaches led to remarkably increased infection.  
Due to the low infectivity arising from BIICs in our hands another approach for BIIC use was imple-
mented, where the protein should be expressed and recombinant virus should be amplified at the 
same time. BIICs are much more infective in Sf21 than in Hi5 cells, because Sf21 are better suited for 
baculovirus amplification (Wilde et al., 2014). In contrast to Hi5 cells, Sf21 cells can produce intact 
virus particles from BIICs that should be capable to infect cells for protein production. Thus, a combi-
nation of Sf21 and Hi5 cells was investigated for its ability for enhanced protein production due to 
better infectivity. The cells were infected with conditioned medium containing the virus (extracellular 
virus stock) or with BIICs (1:400) in order to test the hypothesized increase in infectivity. For this 
purpose expression was tested for one extracellular virus stock and two BIIC stocks in parallel, so that 
we were able to compare the infectivity and protein expression between those different virus stocks 
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and the used cell setup. Infection was monitored by determining growth kinetics of suspension 
cultures as well as their mean cell diameter shown in Figure 3.13.  
 
Figure 3.13: Infection test of Hi5 cells and a combination of Hi5 and Sf21 cells infected with BIICs or virus stock 
Hi5 suspension cultures with a cell density of ~ 0.75 × 10
6
 cells/mL and suspension cultures with 90 % Hi5 and 10 % Sf21 
cells with an initial cell density of ~ 0.5 × 10
6
 cells/mL were infected with extracellular virus stock (VA) or two different BIIC 
stocks (BIICs_716 and BIICs_719). The cultures were expanded 24 hpi when the number of cells reached 2 × 10
6
 cells/mL or 
more. Cell count and viability were assessed with the Guava EasyCyte flow cytometer. The mean cell diameter was analyzed 
with CASY counter. Significant increase in cell diameter and stagnation of cell proliferation indicate successful infection.  
Both, Hi5 cells as well as the combination of Hi5 and Sf21 cells infected with BIICs do not show any 
signs of infection within the first 48 hpi. No significant increase in diameter was observed nor 
reduced proliferation. Infection slightly starts within these cultures between 48 hpi and 72 hpi, while 
as late as 96 hpi a significant decrease in cell growth and increase in cell diameter was observed. In 
contrast to that, both setups infected with extracellular virus stock (VA) were successfully infected 
within 24 hpi, as shown in Figure 3.13. Infection is indicated by an increase of the mean cell diameter 
of about 5 µm and decreased cell growth. However, no obvious differences concerning infection 
efficiency were obtained between the homogenous Hi5 expression cultures and the mixture of Hi5 
and Sf21 cells. The supernatants were harvested (at 72 hpi or 96 hpi) and subsequently analyzed for 
recombinant protein expression via western blot (Appendix III, Figure 8.11). Besides, some of the 
cultures were used for purification using the Profinia protein purification system (Appendix III, Figure 
8.12). However, no increase in protein expression was detectable for any of the tested setups and 
the yield for recombinant HA was only between 2 and 3 mg/L.  
3.3.2 Transient gene expression in Hi5 cells 
The previous attempts showed that recombinant H1 expression in Hi5 insect cells was qualified. 
However, efforts for up-scaling the process by using BIICs were not very promising. Meanwhile our 
research group established a protocol for transient gene expression (TGE) in Hi5 insect cells, because 
high expression levels were recently observed in Hi5 cells with the viral OpIE2 promoter (Bleckmann 
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et al., 2015). With this protocol yields for recombinant protein expression in Hi5 cells were achieved 
in our department that lie in the range of expression via BEVS, while expression was much faster. 
Besides, no problems concerning viral infectivity or stability occur, making it a well suited alternative 
to BEVS. Thus, the protocol should be used in order to test its ability for recombinant HA expression 
and for its capability for process scale-up.  
In order to analyze the potential of TGE in Hi5 cells for recombinant H1 expression four suspension 
cultures of 350 mL were used in parallel for transient transfection (2.5.6 and 2.6.2). Transfection 
efficiency was determined by fluorescence measurements due to the co-transfected pOpIE2-eGFP 
plasmid. Besides, cell count and viability were observed every 24 h during cultivation. The obtained 
data of growth kinetics and transfection efficiency is depicted in Figure 3.14. The cells stayed in the 
exponential growth phase and at a viability of about 80 % without addition of fresh media within 
72 h of cultivation. Besides, quite uniform transfection efficiencies of 64 – 70 % were observed in the 
individual cultures, indicating a good reproducibility and reliable results.  
 
Figure 3.14: Growth kinetics and transfection efficiency of Hi5 insect cells expressing H1 upon TGE 
Hi5 suspension cultures with a cell density of 1 × 10
6
 cells/mL were transfected with 95 % pOpIE2-H1 and 5 % pOpIE2-eGFP. 
Expression of eGFP can thus be used to measure transfection efficiency. Cell count, viability and fluorescence were assessed 
with the Guava EasyCyte flow cytometer.  
Supernatants were analyzed for recombinant protein expression at 24, 48 and 72 hpt (hours post 
transfection) via western blot incubated with His-tag primary mAb and secondary goat-anti-mouse 
AP-conjugated pAb in order to analyze the amount and quality of recombinant H1 at different time 
points, depicted in Appendix III, Figure 8.13. Due to this successful H1 detection, purification with an 
ÄKTA purification system using HisTrap excel columns was conducted as established for BEVS derived 
H1 in 3.2.2. As already indicated there the imidazole concentration in the washing buffer was 
increased for the reduction of impurities due to stronger binding of the target protein according to 
the trimeric His tag (3.2.2). Elution fractions of 1 mL were analyzed by SDS-PAGE. Purification of H1 
via TGE in Hi5 insect cells was very efficient as depicted in Figure 3.15. The elution fractions (11-17) 
were collected, dialyzed, concentrated and used for thrombin cleavage (3.2.3), SEC (3.2.4) and 
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reverse Strep-Tactin purification (3.2.5) before they were used for crystallization set-ups (3.4.1). With 
this method of TGE in Hi5 cells a total amount of 8.2 mg pure H1 was successfully purified 
corresponding to ca. 6 mg recombinant H1 per liter.    
 
 
 
 
 
 
Figure 3.15: Purification of TGE derived H1 with HisTrap excel  
H1 was expressed upon TGE in Hi5 cells and was subsequently subjected to HisTrap excel purification. The SDS gel was 
stained with InstantBlue. The samples of different fractions are presented. M = P PageRuler™ Plus Protein Ladder, SN = 
crude supernatant after harvesting, Ft = flow through, 1 - 5 = wash fractions, 11 – 17 = elution fractions.  
The obtained product titer of 6 mg/L pure H1 corresponds to about 70 % of the average titer of H1 
purifications after expression via BEVS. Yet, the expression of the H3 protein even increased with an 
average titer of 13.4 mg/L up to four-fold compared to BEVS. Besides, only very low variations in 
purified protein titer between the individual experiments were observed via TGE. 
Moreover, in contrast to BEVS, in case of TGE no expression experiment failed, but all were subjected 
to purification, while the expression via BEVS was aborted occasionally due to low or even no 
infection. This clearly indicates an advantage over the expression via BEVS, because it prevents 
phases without recombinant protein production within the process. Taking the protein quality into 
consideration another advantage of TGE in relation to BEVS was observed. During protein expression 
via BEVS a fairly quick decrease in viability can happen, as it was observed in Figure 3.3 in section 
3.1.1 for H1. This decrease in viability results in cell lysis, which causes the release of proteases into 
the cell culture supernatant. The target protein thus is susceptible to degradation by those proteases 
resulting in reduced unprocessed protein of good quality that will be co-purified with those degraded 
contaminants (depicted in Figure 3.4). The non-lytic nature of virus-free expression systems like TGE 
on the other hand prevents degradation and thus ensures an overall increased product quality 
(Bleckmann, 2016).  
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3.4 Crystallization of recombinant HA of the subtypes H1 and H3  
Large scale expression, further purification experiments and crystallization setups were performed 
with HA subtypes H1 and H3 only, because H7 was already cleaved by host proteases during 
purification. Since only the unprocessed/uncleaved HA0 can be used to determine the structure of 
the HA cleavage site, cleaved H7 was not appropriate for this approach.  
The purified trimeric H1 protein derived from baculoviral expression in Hi5 insect cells was used for 
initial crystallization screening using commercially available screens. Jörn Krausze (HZI Braunschweig) 
carried out the very first setups with the sitting drop vapor diffusion method with protein concen-
trations in the range of 3 – 5 mg/mL. However, no crystals could be observed until the concentration 
was increased up to 10 mg/mL. Hence, 10 mg/mL was used as a standard for further crystallization 
experiments. Protein and reservoir volume ratio was set to 1 : 1 (0.2 μL : 0.2 μL) with Honey bee 
robot and crystallization was carried out at 19 °C. With this setup the first crystals started to grow in 
various sizes and shapes after two – 13 days, depicted in Figure 3.16. Their buffer conditions are 
listed in Appendix IV, Table 8-1. 
 
Figure 3.16: Initial hits of H1 crystallization 
Initial hits of H1 crystals obtained from expression via BEVS. The harvested supernatant was diafiltered with the KrosFlow® 
research IIi TFF system, subjected to HisTALON™ purification and thrombin digestion. The trimeric protein was then isolated 
by SEC with a S200 16/60 column and concentrated to 10 mg/mL with VivaSpin concentrators. Crystallization was carried 
out by Jörn Krausze (HZI) at 19 °C with 1:1 protein to reservoir volume by using commercial available screens. Observed 
crystals grew after two – 13 days in the conditions listed in Appendix IV, Table 8-1.  
Additionally, crystallization setups were performed with 10 mg/mL trimeric H3 derived from 
baculoviral expression in Hi5 insect cells. The H3 was purified by diafiltration, HisTALON™ affinity 
chromatography, thrombin digestion and SEC with usage of a Superdex 200 Increase 10/300 GL 
column. For initial screening the commercial screen JCSG+ was used, because it yielded in several hits 
for the first H1 crystallization trials. Crystallization again was performed with the sitting drop vapor 
diffusion method as described in 2.8.1. The first crystals within this setup started to grow after five 
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days and had a highly branched shape (Figure 3.17 A and B). The next crystals with a much more 
uniform triangle shape were first observed at day 8 (Figure 3.17 C). While the last very nice shaped 
crystal occurred after 13 days and continued to grow further until it was harvested, flash frozen and 
tested in-house on day 21. The buffer conditions of each crystal are listed in Appendix IV, Table 8-2.   
 
Figure 3.17: Initial hits of H3 crystallization 
Initial hits of H3 crystals obtained from expression via BEVS. The harvested supernatant was diafiltered with the KrosFlow® 
research IIi TFF system, subjected to HisTALON™ purification and thrombin digestion. The trimeric protein was then isolated 
by SEC with a S200 Increase 10/300 GL column and concentrated to 10 mg/mL with VivaSpin concentrators. Crystallization 
was carried out at 19 °C with 1:1 protein to reservoir volume by using commercial available screens. Observed crystals grew 
after five – 13 days in the conditions listed in Appendix IV, Table 8-2. 
Promising H1 and H3 crystals were used in-house or at synchrotrons for first diffraction experiments 
in order to test their ability for structure determination upon X-ray crystallography. The best results 
were obtained with H1 crystal depicted in Figure 3.16 D which had a resolution of up to 2.7 Å and H3 
crystal depicted in Figure 3.17 D with a resolution of up to 1.6 Å. The H3 crystal already obtained 
quite high resolution; however, ice rings that occurred due to crystal freezing interfered with the 
diffraction pattern of the crystal. Furthermore, data analysis demonstrated low electron density at 
the location of the cleavage site, thus indicating an open loop structure due to protease cleavage. In 
case of H1 the resolution was desired to be higher in order to get more detailed information of the 
H1 cleavage loop. Besides, the crystal is twinned and a twinned crystal is not very well suited for 
structure determination. The twinning prevents simple diffraction patterns and thus hampers 
structure determination, because it complicates data analysis. Hence, after those initial hits, it was 
tried to further optimize the crystallization conditions in order to obtain crystals of better quality for 
X-ray data collection as described in 3.4.1.  
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3.4.1 Crystal optimization 
For crystal optimization random screens were generated based on the buffer conditions of initial hits 
by using the Formulator liquid handling system (Formulatrix). The first optimization trial was set up 
with H1 protein derived from TGE in Hi5 insect cells, purified with the optimized HisTrap excel 
strategy, subjected to thrombin cleavage and finally SEC was performed using a Superdex 200 
Increase 10/300 GL column for trimer isolation. Due to the first hits in the JCSG+ screen for both H1 
and H3, this screen was used in parallel to the first self-prepared screen, called Random Screen RI. 
This screen was created based on the conditions of the H3 crystal shown in Figure 3.17 D, since this 
crystal already obtained a pretty good diffraction pattern.  
The very first crystals in this setup grown in JCSG+ screen were already observed within one week, 
depicted in Appendix IV, Figure 8.14. However, they did not have a nice shape that would result in a 
good in reflection pattern, since they are kind of intergrown crystals (Appendix IV, Figure 8.14 D). In 
contrast to the JCSG+ screen no crystals obtained within the first week in RI. First crystals were 
observed only after 33 days, because the imager system was out of order in between, but then a 
diverse variability of crystals ranging from plates and needles to 3-D crystals was noticed in 
crystallization screen RI, depicted in Appendix IV, Figure 8.14 A - C. The crystals were tested for their 
diffraction pattern at our in-house device or were analyzed at Swiss Light Source (SLS) at X06DA/PXIII 
beamline. However, none of those crystals resulted in a better diffraction pattern than previous ones 
and thus were not utilized for data collection and structure determination. The crystallization 
conditions of these first auspicious hits were used for the next random screen optimization (RII) with 
the objective of directing crystal growth in a more uniform way. 
The second optimization trial was conducted with H1 protein derived from baculoviral expression in 
Hi5 insect cells, purified with optimized HisTrap excel strategy, subjected to thrombin cleavage and 
trimer isolation by SEC using a Superdex 200 Increase 10/300 GL column. Here random screen RII, 
which was created upon the first optimization trial, was used in parallel to the commercial screens 
JCSG+ and PEG Suite I. However, this time no crystals grew within the first three weeks in those two 
commercial screens. The plates were imaged again at day 82 to analyze whether new crystals 
occurred. Indeed, first crystals were eventually observed in PEG Suite I, depicted in Appendix IV, 
Figure 8.15. The crystals were quite big, but mostly intergrown crystals or plates. The first crystals in 
random screen RII occurred already after three days, followed by smaller ones with a smoother 
surface on day 18 (Appendix IV, Figure 8.16 A). The only other crystals within this screen were also 
observed as late as day 82 (Appendix IV, Figure 8.16 B). In the JCSG+ screen no crystals were 
observed at all. Several of those crystals were used for diffraction analysis. Nevertheless, none of 
them exhibited a diffraction pattern suitable for data collection.   
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The last optimization trial was conducted with H1 derived from both baculoviral expression and TGE 
in Hi5 insect cells, purified with optimized HisTrap excel strategy, subjected to thrombin cleavage and 
trimer isolation by SEC using a Superdex 200 Increase 10/300 GL column. Afterwards the protein was 
additionally purified with magnetic Strep-Tactin beads in order to remove potential contamination 
with protein that was not successfully cleaved with thrombin, which would still harbor the hetero-
logous trimerization domain or other tagged contaminants (3.2.5). This step was implemented to 
ensure a homogenous protein sample that should result in uniform crystallization and improved 
reproducibility.  
For the last H1 crystal optimization a new screen was generated that is based on the conditions of 
the H1 crystal depicted in Figure 3.16 D (25% (v/v) PEG MME 550 + 0.1 M HEPES pH 7.5). This screen, 
called H1-Grid, covers a pH range of 7.2 - 7.8 and besides different PEG MME 550 concentrations in 
the range of 20 – 30 % (v/v) and was thus supposed to generate crystals similar to the so far best 
crystal of H1. Next to this new screen the commercial screen PEG Suite I and random screen RI were 
used with both protein preparations. However, the only crystals within this setup were observed in 
PEG Suite I on day 12 (Appendix IV, Figure 8.17 A) and 21 (Appendix IV, Figure 8.17 B) with H1 
derived from baculoviral expression. Whereas no grow of crystals was observed in the other tested 
screens.  
For H3 crystal optimization the commercial screens JSCG+ and PEG Suite I as well as self-prepared 
random screens RI, RII and RIII were utilized. The random screen RIII was created upon the observa-
tion that both H1 and H3 crystals tend to grow in various conditions containing PEG and di-sodium 
malonate (second H1 crystal optimization trial, H3 crystal in Figure 3.17 D). The H3 protein used for 
crystal optimization was expressed via TGE in Hi5 insect cells, purified with optimized HisTrap excel 
strategy, subjected to thrombin cleavage, reverse Strep-Tactin purification and trimer isolation by 
SEC using a Superdex 200 Increase 10/300 GL column.  
After two – five days the first H3 crystals started to grow in random screen RI (Figure 3.18 A and B) 
and JCSG+ (Figure 3.18 C and D). The next crystals started to grow on day 17 (Figure 3.18 E - G). One 
of these continued growing until it was harvested at day 32. Figure 3.18 H depicts the crystal with its 
final size at day 32. The crystals depicted in Figure 3.18 A, E and H were harvested at day 32 and were 
tested for their diffraction potential at “Deutsches Elektronen Synchrotron” (DESY) PETRA III beam-
line, but only the crystal in Figure 3.18 H, exhibited a diffraction pattern suitable for data collection.   
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Figure 3.18: H3 crystals of crystal optimization 
H3 crystals obtained in the optimization trial with H3 derived from TGE in Hi5 insect cells. The cell culture supernatant was 
directly subjected to HisTrap excel purification, followed by thrombin cleavage, reverse Strep-Tactin purification and SEC 
with a S200 Increase 10/300 GL column for trimer isolation. Samples were concentrated to 10 mg/mL and crystallization 
was carried out at 19 °C with 1:1 protein to reservoir volume. The first hits of H3 obtained in the commercial screen JCSG+ 
and random screen RI after two – five days (A – D). At day 17 more crystals of different size and shape were observed (E - 
G). The crystal depicted in F further grew to day 32, when it was harvested (H).The buffer conditions of each depicted 
crystal are listed in Appendix IV, Table 8-7.  
3.4.2 Data collection and structure determination 
The best diffracting H1 and H3 crystals resulting from the preceding optimization trials were used for 
data collection and their datasets were then applied to molecular replacement by using the structure 
of another HA (PDB ID: 1HA0) to determine its distinct structure.  
In case of H1 the best diffracting crystal, depicted in Figure 3.19 A, was a twinned crystal with a 
relative poor diffraction up to 2.7 Å. The twinning of the crystal tremendous hampers structure 
determination which was performed by Jörn Krausze (HZI). The diffracting pattern was sufficient 
enough for a first rough structural elucidation, but no detailed information could be acquired from 
this dataset. Furthermore, it was not possible to define the structure over the complete ectodomain 
sequence. In some parts of the protein the electron density is so poorly defined that it was not 
possible to incorporate the particular AA, which leads to some gaps in the H1 model. This also 
includes the proteolytic cleavage site, so that unfortunately no structural information of the cleavage 
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loop could be obtained. Either, it was already processed by proteolytic cleavage or it was just not 
defined in the available electron density.  
The H3 structure elucidation was performed with the help of Peer Lukat (HZI). In contrast to H1 the 
best diffracting H3 crystal, depicted in Figure 3.19 B, exhibits a very high resolution of 1.45 Å. The 
statistics of data collection and data refinement are listed in Appendix IV, Table 8-8 and Table 8-9. 
The dataset resulting from this crystal reveals a very good defined electron density map that enabled 
detailed insights into the H3 structure. However, it was unambiguous that the obtained structure 
belongs to a proteolytic cleaved protein as it was already observed for the first H3 crystal of good 
diffraction quality (Figure 3.17 D). Thus, a well-defined H3 structure was gained, but still we were not 
able to get structural information of its cleavage loop.  
 
Figure 3.19: H1 and H3 crystals used for data collection and structure determination 
A: The best diffracting H1 crystal was obtained from the first crystallization setup with BEVS derived H1 in a crystallization 
buffer composition of 25% (v/v) PEG monomethyl ether (MME) 550 + 0.1 M HEPES pH 7.5. It started to grow after 3 days 
and continued growing until it was harvested at day 25. B: The best diffracting H3 crystal was obtained from the very last 
optimization trial with H3 derived from TGE in Hi5 cells. The crystal started to grow at day 17 in a crystallization buffer of 
0.1 M di-Sodium malonate + 23.3 % w/v PEG 3350 + 0.1 M HEPES pH 7.889. The crystal further grew until it reached its final 
size at day 32, when it was harvested.  
The structure of recombinant H1 and H3, depicted in Figure 3.20 as a cartoon diagram of α-helices 
and β-sheets, represent their overall trimeric architecture. Each HA monomer is presented in 
different colors. Most of their HA1 subunits folds into the globular head domain, while HA2 forms a 
stalk that projects it outward from the surface of the virus. The N-terminus of HA2 that comprises the 
fusion peptide, marked in yellow, points to the inside of the threefold axis as it is common for the HA 
pre-fusion state. Additionally, both proteins carry N-linked oligosaccharides at their glycosylation 
sites that are not depicted in Figure 3.20. A figure of one H3 monomer with the visible N-linked oligo-
saccharides at its glycosylation sites is depicted in Figure 3.21.  
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Figure 3.20: Structure of recombinant H1 and H3 
Cartoon diagram of recombinant H1 (A) and H3 (B) structure. Each monomer is presented in different colors (H1: cyan, grey 
and green, H3: Red, blue and grey). The sequence of each fusion peptide is shown in yellow. The figures were drawn with 
the program PyMOL. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.21: H3 monomeric structure with N-glycosylation sites 
One Monomer of trimeric H3 is depicted in two different views with 90 ° rotation with its occupied N-glycosylation sites. 
Each glycosylation site is indicated with the corresponding asparagine and its AA position (e.g. ASN-8). N-linked glycans 
were incorporated in the structure as far as they were clearly visible in the electron density (the figure was drawn with the 
program PyMOL by Peer Lukat, HZI).  
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All in all, recombinant HA of the subtypes H1 and H3 was successfully expressed in Hi5 insect cells via 
BEVS and TGE in its uncleaved, non-modified HA0 pre-fusion state for crystallization studies. 
Additionally, an efficient purification strategy was developed and the production process was 
analyzed for its potential for process up-scaling. Eventually, a protocol was established for large scale 
HA expression that was reliable, economic, easy to handle, comparatively fast and accessible for HA 
production in bioreactor dimensions. Among the different expression systems evaluated for 
recombinant HA expression the method of TGE in Hi5 insect cells pointed out to be advantageous as 
it not only allows fast and easy expression of homogenous HA, but is also very successful for process 
up-scaling. Overall, the production process and its optimized downstream processing resulted in very 
pure protein of high-quality. Crystallization setups with recombinant H1 and H3 led to a diverse 
range of crystals. Nevertheless, the structures that were derived from these crystals did not obtain 
an intact cleavage loop, so that unfortunately no structural information of the different cleavage 
loops was acquired. Further attempts need to be conducted to overcome this obstacle.  
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4 Hepatitis surface proteins  
4.1 Recombinant E2 expression 
HCV infections constitute a major global health problem being one of the main causes of chronic liver 
disease with approximately 130 – 170 million people infected worldwide (World Health Organization, 
2017). Still, there is no effective vaccine against HCV available. The envelope glycoproteins E1 and E2 
of HCV are critical to mediate virus receptor interactions and to permit virus uptake into human liver 
cells. Besides they are the target of neutralizing antibodies, which inactivate circulating viruses in 
vivo. However, HCV has evolved various strategies that ensure virus persistence in the presence of 
large amounts of glycoprotein-specific antibodies (von Hahn et al., 2007). Therefore this part of the 
project deals with the expression and purification of HCV protein variants that ought to re-direct 
antibody responses towards hidden and more conserved viral epitopes.  
The first strategy to express such glycoprotein variants encompasses both envelope proteins co-
expressed together with the last 60 residues (AA 175 - 191) of the core protein. This last core domain 
corresponds to the signal sequence for E1 (Polyak et al., 2006) and is followed by the full-length 
envelope glycoproteins E1 (AA 192 – 383) and E2 (AA 384 – 750) from the HCV genotype 2a (isolate 
HC-J6, Taxonomy ID: 11113). The different variants of this cE1E2 construct include the wildtype (wt) 
of E1 and E2 as well as variations of E2 in combination with wt E1. In order to re-direct antibody 
responses a few primary approaches were tested. The first variant (cE1E2ΔHVR1) comprises the 
deletion of HVR1, which is the most variable domain of the E2 protein that is known to act as an 
immune decoy to prevent effective antibody neutralization (von Hahn et al., 2007; Haid et al., 2012). 
The second variant (cE1E2ΔHVR1-N534A) combines this deletion with the inactivation of a glyco-
sylation site within E2 through an AA exchange of Asparagine to Alanine at position 534 (numbering 
corresponds to AA position in HCV polyprotein). This glycosylation site (N6; N532/N534 depending on 
HCV genotype) was found to be highly conserved between various genotypes (98 %) and it was 
identified through various mutational studies to mask epitopes with its glycan residues (Helle et al., 
2007, 2010). This modification should thus induce the neutralizing activity of anti-HCV antibodies 
compared to the wt protein. For detection and purification, a C-terminal fusion with to different tags 
was generated to each construct. Upstream of the tags there was a TEV protease cleavage site 
inserted for removing the tags after purification. A schematic overview of the constructs used for 
E1E2 co-expression can be found in Figure 4.1. 
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Figure 4.1: Schematic overview of cE1E2 constructs for recombinant E1E2 co-expression 
The cE1E2 constructs are N-terminally fused to the last 60 AA of core protein (core 131-191), followed by full-length E1 and 
E2. C-terminally, an Avi-tag (BirA) and an 8xHis tag are fused to the proteins for purification and detection. Upstream of the 
tags, a TEV protease site is located to cleave the tags off. Transmembrane domains (TMD), hypervariable regions within the 
E2 ectodomain (HVR), and the mutated glycosylation site in cE1E2ΔHVR1-N534 are indicated. The amino acid numbering 
corresponds to the HCV polyprotein.   
Additionally, another strategy was pursued dealing with the expression of secreted E2 variants (sE2). 
For this approach the same E2 variations were constructed with an N-terminal IgG secretion signal 
(IgG ss) fused to E2, which ends either at AA position 661 or 688, thus comprising the whole ecto-
domain or even extend to part of the E2 stem region. Expression was already described by various 
groups to be successful for E2 truncations ending at AA 661 (Michalak et al., 1997; Dubuisson et al., 
2000; Rodríguez-Rodríguez et al., 2009; Tello et al., 2010; McCaffrey et al., 2012) and to be 
independent of E1 co-expression (Michalak et al., 1997; McCaffrey et al., 2012). Next to that an 
additional wt sE2 variant (sE2(1a)wt, AA 384-661, (Li, 2014)) ending at AA 661 of genotype 1a (isolate 
H77, Taxonomy ID: 11108) was used. This variant is N-terminally fused to tissue plasminogen 
activator (tpa) secretion signal and comprises a C-terminal His-tag. A schematic overview of these sE2 
constructs is depicted in Figure 4.2.  
 
Figure 4.2: Schematic overview of sE2 variants used for recombinant E2 expression 
The sE2(2a) constructs are N-terminally fused to the IgG secretion signal (IgG ss) to allow secretion in the supernatant, 
followed by E2 ectodomain ending either at AA 661 or 688. C-terminally, an Avi-tag (BirA) and an 8xHis tag are fused to the 
proteins for purification and detection. Upstream of the tags, a TEV protease site is located to cleave the tags off. Whereas, 
the sE2(1a)wt variant is N-terminally fused to tpa secretion signal (tpa ss) and C-terminally to an 6xHis tag. The numbering 
of AA corresponds to the HCV polyprotein.   
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4.1.1 Co-expression of E1E2 in HEK293-6E cells 
For co-expression of the HCV E1 and E2 glycoproteins the different coreE1E2 variants of genotype 2a 
were cloned into the pFlpBtM-III vector (Steffen Meyer, HZI; unpublished work based on Meyer et 
al., 2013) and were transiently transfected in HEK293-6E cells. The expression of the secreted E2 
construct of genotype 1a (sE2(1a)wt, AA 384-661) in a pcDNA 3.1-tpa eukaryotic expression vector 
was performed in parallel and served as control for recombinant E2 expression. Transfection was 
conducted according to the protocol by Jäger et al. 2015, described in detail in 2.5.5. Co-transfection 
of pTTo/GFPq was used to control the transfection rates via fluorescence measurements by flow 
cytometry of daily samples. Valproic acid was added 96 hpt to a final concentration of 3.75 mmol/l in 
order to possibly increase the recombinant protein levels and each culture was harvested 168 hpt. 
With this setup about 60 – 75 % of the cells expressed GFPq after 48 hpt, indicating successful 
transfection. Samples of cell culture supernatants were taken every 24 h and were analyzed for 
recombinant protein expression by SDS-PAGE and Western blot. However, upon detection with anti-
His mAb mainly higher molecular weight bands that seem not to enter the gels were observed, which 
could correspond to aggregates (data not shown). Such aggregates have been commonly observed 
upon heterologous E2 expression by various research groups (Michalak et al., 1997; Whidby et al., 
2009; Tello et al., 2010; Neyshabouri et al., 2012; Khan et al., 2014; Li, 2014). In fact, it is so common 
that a non-productive folding pathway has been proposed to be a physiologically relevant part of the 
HCV life cycle (Whidby et al., 2009). 
In another set-up transfection was carried out as described before, but culture supernatants were 
already harvested 96 hpt due to low viability after valproic acid addition in the previous experiment. 
Transfection efficiencies were quantified via fluorescence measurements as depicted in Figure 4.3. 
They vary widely between these cultures, ranging from 74 % for the cE1E2ΔHVR1-N534A variant to 
as low as 17 % for cE1E2ΔHVR1.  
 
Figure 4.3: Graphical overview of transfection efficiencies of HEK 293-6E cells transfected with cE1E2 constructs 
The GFPq expression was monitored as a control for transfection efficiency by flow cytometry. Fluorescence was 
determined at a Guava EasyCyte flow cytometer using a 488 nm laser for extinction. 
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This time both, supernatants and cell lysates (2.6.5), were analyzed for the presence of the glyco-
proteins in order to verify successful secretion. Detection with anti-His mAb, however, resulted in a 
pattern of only unspecific protein bands. Therefore the mouse mAb, AP33 (Potter et al. 2012; 
prepared by Tanvi Khera at Twincore) that recognizes a conserved, linear epitope on E2, was used for 
detection. The cE1E2 constructs have a theoretical size of about 70 kDa and 31 kDa for sE2(1a)wt, 
respectively. However, N-linked glycans constitute nearly 50 % of the molecular weight in the E2 
ectodomain (Goffard et al., 2005; Falson et al., 2015), thus increasing its size. In case of sE2(1a)wt the 
protein was reported to migrate on SDS-PAGE at a size about 55 kDa due to its glycosylation upon 
expression in HEK 293-6E cells (Li, 2014). Indeed, a protein band of about that size was detected 
upon western blot analysis in the supernatant and cell lysate (depicted in Figure 4.4), which 
accumulates in the supernatant during the experiment. This band appears quite smeary, because of 
heterogeneous glycosylation of the protein. In case of cE1E2(2a) variants, however, only very slight 
expression was observed. While transfection with cE1E2ΔHVR1-N534A was quite efficient with 74 %, 
the expression was barely detectable. While expression of cE1E2(2a)wt and cE1E2ΔHVR1 variants 
was slightly better despite their obvious lower transfection efficiencies of 51 % and 17 %, 
respectively. All in all, expression of the cE1E2(2a) variants was quite low. Furthermore, the different 
protein variants did not accumulate during the experiment, neither in the supernatant nor in the cell 
lysate.  
Since satisfying expression was only detected for the E2661 variant, sE2(1a)wt, further co-expression 
experiments were adjourned for a start, while more emphasis was put on the recombinant sE2 
expression, that will be covered in the next chapters.  
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Figure 4.4: Western blot analysis of HCV glycoprotein expression in HEK293-6E cells  
Supernatants (SN) and cell lysates (S: soluble, IS: insoluble) of HEK293-6E cells transiently transfected with cE1E2 variants or 
sE2(1a)wt, as indicated above, were taken 24, 48 and 96 hpt and were analyzed by Western blots using E2 specific mouse 
monoclonal antibody, AP33, and a secondary goat-anti-mouse AP-conjugated pAb. Colorimetric staining was done with NBT 
and BCIP. M: PageRuler Plus Prestained, PK: positive control (cell lysate sample containing E2 from Tanvi Khera).   
 
4.1.2 sE2 expression in HEK 293-6E cells 
For the approach of recombinant expression of secreted E2, the three variants of genotype 2a as well 
as sE2(1a)wt were used for transient expression in HEK293-6E cells, as already described in 4.1.1 for 
E1E2 co-expression. The new genotype 2a constructs contain either the full-length ectodomain 
including the first residues of E2 stem (688) or the E2 ectodomain up to residue 661 that already led 
to successful expression and secretion for sE2(1a)wt in the transient HEK293-6E system (see section 
4.1.1). Besides, expression and secretion of soluble E2 constructs ending at AA position 661 was 
already described to be successful and independent of E1 (see section 4.1). The truncated sE2 
variants were generated via PCR (2.4.1) and subsequently cloned into pFlpBtM-III vectors thereby 
obtaining the IgG secretion signal and tags for purification. Upon transient expression in HEK 293-6E 
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cells growth kinetics and transfection efficiencies were monitored. Transfection efficiencies of about 
30 % up to 60 % were observed for the different variants and are displayed in Figure 4.5.  
 
Figure 4.5: Graphical overview of transfection efficiency of HEK 293-6E cells transfected with sE2 constructs  
The GFPq expression was monitored as a control for transfection efficiency by flow cytometry. Fluorescence was 
determined at a Guava EasyCyte flow cytometer using a 488 nm laser for extinction. 
Cultures were harvested 96 hpt and expression was analyzed via western blot using both an anti-His 
(Figure 4.6 A) and anti-E2 mAb (Figure 4.6 B) combined with a secondary goat-anti-mouse AP-
conjugated pAb. Additional samples of HEK derived sE2(1a)wt (4.1.1) were used as positive controls 
for E2 expression. In order to determine unspecific signals supernatants of untransfected HEK cells as 
well as cells transfected with an empty pFlpBtM-III vector served as negative control.  
 
 
Figure 4.6: Western blot analysis of sE2 expression in HEK293-6E cells 
Samples of culture supernatants of transiently transfected HEK293-6E cells were analyzed for the presence of sE2 variants 
by Western blot. Detection was performed with primary anti-His mAb (A) and anti-E2 mAb AP33 (B) together with a 
secondary goat-anti-mouse AP-conjugated pAb. Colorimetric staining was done with NBT and BCIP. M: PageRuler Plus 
Prestained, 1-3: sE2-661 variants, 1: sE2(2a)wt 2: sE2(2a)ΔHVR1, 3: sE2(2a)N534A, 4-6: sE2-688 variants, 4: sE2(2a) wt, 5: 
sE2(2a) ΔHVR1, 6: sE2(2a) N534A, 7-10: sE2(1a)wt, 11: untransfected HEK 293-6E cells, 12: cells transfected with pFlpBtM-III 
(empty vector), all samples of crude supernatants were taken at 96 hpt, except for 9 - 10, taken at 168 hpt. 
Detection with anti-His mAb resulted in a pattern of only unspecific protein bands (Figure 4.6 A), 
since the negative controls exhibit the same pattern as the other samples. Only for sE2(1a)wt a 
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stronger signal due to E2 expression was observed next to those unspecific bands. The E2-specific 
antibody AP33, however, allowed E2 detection within all expression cultures (Figure 4.6 B), whereas 
no signals were observed within the negative controls. Expression was detectable, but still quite low 
for the diverse sE2(2a) variants, yet a strong signal resulted from sE2(1a)wt within both 96 hpt and 
168 hpt samples. These samples also seem to contain higher oligomeric states and maybe even 
aggregates of the E2 protein. Moreover, it is conspicuous that the recombinant sE2 proteins are 
highly glycosylated since they appear as very smeary protein bands due to their heterogeneous 
glycan moieties.   
4.1.3 sE2 Expression in Hi5 cells 
Due to quite poor expression in HEK 293-6E cells and their large amount of heterogeneous glyco-
sylation, sE2 expression was also performed via transient gene expression in Hi5 cells (2.5.6). For this 
approach each construct was cloned with an IgG secretion signal and tags into the pOpIE2 vector that 
contains the strongest immediate early baculoviral promoter OpIE2 suitable for transient expression 
in absence of viral factors (Bleckmann et al., 2015). Cloning and first expression tests were conducted 
by Mirjam Sommer and are reported in her bachelor thesis (Sommer, 2016). Here, the variants 
containing the E2 ectodomain to AA 661 showed slightly better expression. Based on these results 
only those variants were used for establishing purification and expression strategies. 
First expression experiments were performed in small scale (20 mL) with the three sE2(2a) variants 
and sE2(1a)wt. The suspension cultures were cultivated for 96 h and growth kinetics and transfection 
efficiencies were monitored via FACS due to eGFP co-expression. Fluorescence characteristics are 
presented in Figure 4.7, indicating transfection efficiencies of 60 – 70 % among sE2 variants. The 
decrease of fluorescent cells after 72 hpt corresponds to a significant decrease in viability.  
 
Figure 4.7: Transfection efficiencies of Hi5 insect cells transfected with sE2 constructs 
The GFPq expression was monitored as a control for transfection efficiency by flow cytometry. Fluorescence was 
determined at a Guava EasyCyte flow cytometer using a 488 nm laser for extinction. 
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After 96 hpt cultures were harvested and subsequently analyzed for recombinant E2 expression by 
small scale purification with magnetic His beads (His Mag Sepharose excel, GE Healthcare). Those 
beads are advantageous for analysis of secreted proteins derived from insect cells as they can 
directly purify his-tagged proteins from the crude cell culture supernatant. Recombinant E2 
expression was analyzed using SDS-PAGE and western blot (Figure 4.8).  
 
 
 
 
 
 
 
Figure 4.8: small scale purification of sE2 variants derived from transient expression in Hi5 cells  
Samples of culture supernatants (SN) and magnetic His beads elution samples (B) of transiently transfected Hi5 cells were 
analyzed for the presence of sE2. The SDS gel was stained with InstantBlue. The Western blot was performed with primary 
anti-His mAb together with a secondary goat-anti-mouse AP-conjugated pAb. Colorimetric AP staining was done with NBT 
and BCIP. M: PageRuler Prestained, 1: sE2(2a)wt 2: sE2(2a)ΔHVR1, 3: sE2(2a)N534A, 4: sE2(1a)wt, all samples of crude 
supernatants were taken at 96 hpt, elution samples correspond to a 50-fold concentration.   
Expression and secretion of sE2 variants was verified via western blot analysis. All four variants were 
detected not only in the purified and thus concentrated samples but also to a lesser extent in each 
cell culture supernatant. Judging from the minor smear of the protein bands the proteins are likely 
glycosylated but not as much as HEK derived proteins. Besides, in contrast to HEK cell supernatants, 
no unspecific signals were obtained using anti-His mAb. The protein bands of roughly purified E2 
were subjected to mass spectrometry for further identification by the MS platform of the research 
group Cellular Proteomics at the HZI (2.7.4).  
Based on these initial achievements in small scale, large scale expression was performed. Here, 
supernatants were already harvested 72 hpt, because of the low viability observed in the initial 
experiments after 72 hpt. The establishment of the purification strategy for sE2 variants is explained 
in detail in section 4.2. 
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4.2 Establishing purification strategy of recombinant sE2 
After successful detection of sE2 expression the secreted recombinant protein variants should be 
further purified. For affinity purification the supernatants were harvested in two steps as described 
in 2.6.10. Thereafter the supernatants were directly loaded onto HisTrap excel columns (GE 
Healthcare) with the use of ÄKTA chromatography system and purification was performed according 
to the manufacturers protocol. Compared to HA purification (3.2.2) the amount of imidazole in the 
washing buffer was as low as the recommended 30 mM (6 % buffer B), because of the monomeric 
nature of the sE2 proteins compared to the trimeric HA. Elution fractions of 1 mL were analyzed by 
SDS-PAGE as shown in Figure 4.9 A for samples derived from purification of the glycosylation mutant 
sE2(2a)ΔHVR1-N534A. E2 capture was effective, but still some undesirable impurities remained. 
Accordingly, further polishing of sE2(2a)ΔHVR1-N534A was performed with Talon metal affinity resin 
as it was already successful in increasing the purity of insect cell derived HA proteins after Ni-NTA 
purifications (see 3.2 for comparison).  
After dialysis HisTalon purification was performed according to the manufacturers’ protocol using an 
ÄKTA chromatography system, however, the purity of the sample did not increase upon this 
additional purification (Figure 4.9 B). So the buffer again was exchanged by dialysis and purification 
was repeated with HisTrap excel columns with more stringent washing conditions (50 mM imidazole, 
10 % buffer B). With this improved protocol the amount of impurities could be markedly reduced 
(Figure 4.9 B), but only as low as 1.2 mg of the E2 protein remained after this three-step purification 
procedure, representing a loss of 2/3 of the amount after the first purification step and thus does not 
correspond to the removed impurities.  
RESULTS 
 
 
 97 
 
Figure 4.9: SDS-PAGE analysis of affinity purification strategies for sE2(2a)ΔHVR1-N534A  
Purification of sE2(2a)ΔHVR1-N534A was analyzed with an ÄKTAFPLC and the samples of different fractions were loaded 
onto the gel. A: HisTrap excel purification according to manufacturers` protocol. B: HisTalon purification according to 
manufacturers` protocol. C: HisTrap excel purification with more stringent washing conditions. Staining of the SDS gel was 
performed with InstantBlue. M: PageRuler Prestained Plus, SN: cell culture supernatant, Ft: Flow through of purification 
column, W: Wash fraction, v.: sample prior following purification, numbers correspond to numbering of elution fractions.  
For the next purifications the stringent washing protocol was applied right after harvesting of the 
supernatant. With this new protocol quite pure protein could be acquired with just one purification 
step resulting in significantly less protein loss and thus higher protein yields. The SDS-PAGE showing 
purification analysis of sE2(2a)ΔHVR1 with a total yield of 6.5 mg/l expression culture is shown in an 
exemplary way in Figure 4.10.  
 
 
 
 
 
Figure 4.10: SDS-PAGE analysis of HisTrap excel sE2(2a)ΔHVR1 purification with adjusted protocol 
Purification of sE2(2a)ΔHVR1 with adjusted stringent washing protocol was analyzed with an ÄKTAFPLC and the samples of 
different fractions were loaded onto the gel. Staining of the SDS gel was performed with InstantBlue. M: PageRuler 
Prestained Plus, SN: cell culture supernatant, Ft: Flow through of purification, 5: Wash fraction 5, 15 - 33: elution fractions. 
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The affinity purified proteins were then applied to size exclusion chromatography (SEC) for further 
purification. SEC was first performed using a S75 10/300 GL column with 1.5mg sE2(2a)wt in 20 mM 
TrisHCl 50 mM NaCl buffer at pH 7.4. Unfortunately, upon this approach the protein eluted in the 
void volume of the column (Figure 4.11 A) indicating protein aggregation. Fractionated samples were 
analyzed via SDS-PAGE, but only a very faint band of the E2 protein was visible (data not shown). 
Consequently, another SEC was performed using a S200 10/300 HR column in order to distinguish 
between higher oligomers of E2 and protein aggregates (Figure 4.11 B). Besides, 10 % glycerol was 
added to buffer and sample to avoid aggregation by minimizing hydrophobic interactions. 
Nevertheless, the major part of the E2 protein again eluted in the void volume and close behind. 
However, the peak now was much broader and had a little shoulder at about 14 mL Ve. Roughly 
there, monomeric HA eluted during SEC using that kind of column at Ve = 15 mL (see Figure 3.10 and 
Figure 3.11 in section 3.2.4. for comparison). This indicates a protein size of about 70 kDa, which 
could pretty much correspond to sE2 dimers. Calculation of the protein size corresponding to that 
shoulder also results in 70 kDa, confirming the data. The maximum of this peak correlates to a 
protein size of about 450 kDa according to the calibration curve of the column, thereby indicating a 
great amount of higher oligomers and aggregates within the sample.  
Due to the observation that the E2 protein still tends to aggregate and form higher oligomers via SEC 
a second buffer adjustment was implemented by adding 2 mM TCEP to hinder non-native disulfide 
bridges and by further increasing the salt concentration up to 500 mM NaCl thereby increasing the 
ionic strength. With this buffer adjustments SEC was performed for sE2(2a)ΔHVR1-N534A (Figure 
4.11 C) and sE2(1a)wt (Figure 4.11 D) using a S200 10/300 HR column. These modifications led to a 
shift towards lower molecular weights, but in case of sE2(2a)ΔHVR1-N534A the major part of the 
protein still eluted as higher oligomers and aggregates with the maximum at a protein size of about 
480 kDa. The second peak lies in the range between 14 mL and 17 mL indicating sizes from 70 kDa to 
18 kDa with a maximum at about 15 mL that corresponds to a calculated size of 43 kDa. It reaches 
two-thirds of the major peak indicating a remarkably increase compared to the little shoulder ob-
served with the very first buffer adjustment in Figure 4.11 B. For the variant sE2(1a)wt the elution 
profile looked similar, but the major peak starts a little bit later thus shifting its maximum to a size of 
about 250 kDa and the smaller peak corresponding to lower molecular weights reaches its maximum 
at a size of about 40 kDa.  
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Figure 4.11: Size exclusion chromatography of sE2 variants  
A: Size exclusion chromatography (SEC) with Superdex 75 10/300 GL column of sE2(2a)wt in 20mM TrisHCl pH 7.4, 50mM 
NaCl, B: SEC with Superdex 200 10/300 HR of sE2(2a)ΔHVR1 in 20mM TrisHCl pH 7.4, 50mM NaCl, 10% glycerol, C: SEC with 
Superdex 200 10/300 HR of sE2(2a)ΔHVR1-N534A in 20mM TrisHCl pH 7.4, 500mM NaCl, 2mM TCEP, 10% glycerol, D: SEC 
with Superdex 200 10/300 HR of sE2(1a)wt in 20mM TrisHCl pH 7.4, 500mM NaCl, 2mM TCEP, 10% glycerol.  
Thereupon thermal stability assays were performed in order to further improve the buffer com-
position. However, this method was unrewarding due to binding of the reporter dye SYPRO Orange 
prior to protein unfolding. Possibly this is due to large hydrophobic parts of the E2 surface that were 
described for epitopes involved in protein-protein interactions (Kong et al., 2012; Kong et al., 2015; 
Freedman et al., 2016).  Since buffer optimization would need more time than left for finishing this 
thesis, the affinity purified proteins were used for further analysis.  
4.3 Characterization of recombinant sE2 variants 
In order to further analyze the oligomeric state of the sE2 variants, several protocols for native gels 
were performed, but none of them displayed distinct protein bands, but instead resulted in an 
overall smear. Hence, non-reducing SDS-PAGE was performed, according to the strategy that was 
published by Li (Li, 2014). With this approach for the first time protein bands of different size were 
detected for all sE2 variants that probably correspond to monomeric, dimeric, trimeric and higher 
oligomers according to their size, depicted in Figure 4.12.  
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Figure 4.12: Oligomeric state of sE2 variants in reducing and non-reducing SDS-PAGE 
A: Reducing SDS-PAGE was performed with 5 µg of each sE2 variant as a quality check prior to further analysis. B: Non-
reducing SDS-PAGE was performed to analyze the oligomeric state. Loading buffer without BME was added to samples of 
10 µg of each variant without boiling the sample. M1: PageRuler Prestained Plus, 2a: sE2(2a)wt, ΔH: sE2(2a)wtΔHVR1, NA: 
sE2(2a)wtΔHVR1-N534A, 1a: sE2(1a)wt, M2: PageRuler Prestained. 
4.3.1 Secondary structure analysis 
As it was not possible to determine the 3-dimensional structures of the sE2 variants within the scope 
of this project, Circular dichroism (CD) spectroscopy was employed for analyzing their secondary 
structure composition. This technique is widely used for rapid determination of secondary structure 
and folding properties of recombinant proteins (Greenfield, 2006). Signal-to-noise correction of each 
measurement was achieved by recording ten spectra per sample. For buffer signal correction, a 
spectrum was recorded with buffer only using the same experimental setup and the identical quartz 
cuvette. The buffer spectrum was subtracted from the other spectra prior to data analysis. The 
obtained spectra of the analyzed sE2 variants are indicated in Figure 4.13.  
The typical CD spectrum of α-helical proteins has two minima at 208 nm and 220 nm with the same 
intensity and a maximum at 192 nm (Holzwarth and Doty, 1965). In contrast to that proteins with 
well-defined antiparallel β-sheets possess a single minima at 217/218 nm and a maximum at around 
195 nm (Greenfield and Fasman, 1969), while the random-coil element displays a minimum around 
200 nm (von Bergen et al., 2005). The sE2 variants showed similar overall spectra that are related to 
CD spectra published for different E2 and E1E2 constructs (Whidby et al., 2009; Rodríguez-Rodríguez 
et al., 2009; Krey et al., 2010; Tello et al., 2015; Castelli et al., 2017). All of the displayed variants 
exhibit minima at around 207 – 209 nm and all but sE2(2a)ΔHVR1 have a little shoulder at 211 – 
216 nm.  
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Figure 4.13: CD spectra of sE2 variants 
The far-UV spectra of recombinant sE2 variants were obtained with a J815 CD Spectrometer (JASCO) in 1 mm quartz 
cuvettes (Hellma analytics). The displayed proteins were applied in 20 mM TrisHCl pH 7.4, 50 mM NaCl and were diluted 
depending on initial measurements.  
These spectra were further used for secondary structure prediction using the online secondary 
structure prediction tool K2D3 (Louis-Jeune, Andrade-Navarro and Perez-Iratxeta, 2012). The thereby 
predicted secondary structure elements of each protein are listed in Table 4-1.  
Table 4-1: Predicted secondary structure elements of sE2 variants by K2D3 prediction tool 
SE2 variant α-helix β-strand 
sE2(1a)wt 16.47 % 25.67 % 
sE2(2a)wt  6.02 % 37.05 % 
E2(2a)ΔHVR1 8.56 % 34.01 % 
sE2(2a)ΔHVR1-N534 11.29 % 29.93 % 
 
The published structures of the E2 core domain have a globular fold comprising mostly beta-strands 
and random coils (Kong et al., 2013; Khan et al., 2014). Thus, the accuracy of secondary structure 
prediction by these methods is not too high for the sE2 variants. High accuracy is only obtained when 
predicting α-helical content in proteins, because these helical structures have a well-defined 
backbone conformation that produces very similar spectra. The estimation of extended β-strand 
content, however, is unfortunately far less accurate. Referring to published secondary structure 
determinations of various E2 or E1E2 variants the predicted secondary structure elements lie in the 
range of 5 – 13 % α-helices, 30 – 50 % extended β-sheets and 40 – 60 % non-ordered structures 
(Whidby et al., 2009; Rodríguez-Rodríguez et al., 2009; Krey et al., 2010; Tello et al., 2015; Castelli et 
al., 2017). Compared to these observations the prediction for the distinct elements of sE2 variants of 
genotype 2a fits quite well. In case of sE2 of genotype 1a the α-helical content was predicted to be 
little bit higher, while the β-strand content was a little reduced. However, they still lie in the roughly 
same range as the published ones. Discrepancies in secondary structure determination are likely due 
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to the usage of the different constructs expressed with or in absence of E1 and due to the lack of 
accuracy for secondary structure elements other than α-helices.  
4.3.2 Glycosylation analysis of sE2 variants 
Since E2 is usually heavily glycosylated, the glycosylation of the sE2 variants was analyzed. Glycans 
have been shown to be essential for proper folding and functioning of glycoproteins. Indeed, it was 
already shown that nine out of the 11 glycosylation sites with the E2 protein are strongly conserved 
(Goffard and Dubuisson, 2003). All of those sites lie within the E2 ectodomain and thus are covered 
within the recombinant sE2 variants created during this project. Therefore glycosylation analysis was 
performed exemplary with the two recombinant variants sE2(1a)wt and sE2(2a)ΔHVR1. For this 
approach deglycosylation analysis was performed by usage of two different endoglycosidases and 
the glycosylation of the proteins was verified by mass spectrometry.  
While PNGase F removes almost all types of N-linked glycosylation except when the α(1–3) core is 
fucosylated, Endo H removes only high mannose and some hybrid types of N-linked carbohydrates. 
The experiments were performed with both native and denatured proteins according to the 
manufacturers’ protocol. With this approach it is possible to analyze the potential of each endoglyco-
sidase to fully deglycosylate the proteins under native conditions, while deglycosylation with 
denatured protein serves as kind of positive control. Samples were taken at different time points 
after the start of the experiments. The first samples were taken after the recommended incubation 
time of 1 h in case of Endo H and 4 h in case of PNGase F, respectively. Additionally incubation was 
prolonged up to 24 h incubation to analyze if prolonged incubation is necessary for the complete 
removing of glycans. Last but not least negative controls were used with equal conditions without 
endoglycosidases that were incubated for 24 h in order to test their stability under these conditions. 
The deglycosylation experiment was analyzed via SDS-PAGE, depicted in Figure 4.14.  
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Both analyzed sE2 variants were only marginally affected by the different deglycosylation setups. 
While sE2(1a)wt seemed to be not deglycosylated at all after treatment with Endo H, the protein 
bands of Endo H treated sE2(2a)ΔHVR1 display a slight decrease in size. Deglycosylation of both 
variants with PNGase F, however, results in a much more smeary protein band that is also decreased 
little in size. All in all, the proteins are not sensitive to be fully deglycosylated neither by Endo H nor 
PNGase F. Moreover, deglycosylation with PNGase F even increases the heterogeneity by the 
attached glycans and thus is inappropriate for crystallization setups.  
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Figure 4.14: Deglycosylation analysis of sE2(1a)wt and sE2(2a)ΔHVR1 
Deglycosylation was performed with 4 µg of sE2(1a)wt (A) and sE2(2a)ΔHVR1 (B) per sample. M: PageRuler Prestained Plus, 1: 
sample prior to deglycosylation, 2 – 5: samples of deglycosylation with EndoH, 2: deglycosylation under native conditions after 
1 h incubation, 3: deglycosylation under native conditions after 24 h incubation, 4: deglycosylation of denatured protein after 
1 h incubation, 5: deglycosylation of denatured protein after 24 h incubation, 6: negative control, 7: sample prior to deglyco-
sylation, 8 – 11: samples of deglycosylation with PNGaseF, 8: deglycosylation under native conditions after 4 h incubation, 9: 
deglycosylation under native conditions after 24 h incubation, 10: deglycosylation of denatured protein after 4 h incubation, 
11: deglycosylation of denatured protein after 24 h incubation, 12: negative control.  
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4.3.3 Functional analysis of sE2 variants 
In order to analyze their competence as functional antigens the different sE2 variants were used in 
inhibition assays and in vaccination studies of mice by our cooperation partners at Twincore and HZI.  
At first, a dose-dependent inhibition assay was conducted by Tanvi Khera at Twincore with each 
recombinant sE2 variant for analyzing their potential to inhibit HCV infection, depicted in Figure 4.15. 
For this assay Huh 7.5 cells are used, that are highly permissive for HCV replication (Blight, McKeating 
and Rice, 2002). The protein variants were mixed with jc1 reporter virus (genotype 2) prior to 4 h 
incubation with Huh 7.5 hepatocyte cells. After 4 h additional media was added and the infection was 
stopped at 72 h. The inhibition data is normalized to the signal corresponding to the control, so that 
the signal for virus only was set to 100. Inhibition is indicated by low luciferase signals.  
Notably, an inhibition effect of the buffer was observed in all analyzed samples. Nevertheless, 
greater inhibition was detected with the sE2(2a) variants in a dose-dependent manner, whereas no 
further effect was observed within the negative control H1. Remarkably, the sE2(1a)wt variant 
displays an inhibitory effect that seems to decrease with higher doses. Inhibition induced by the 
E2(2b) control protein appeared to have a minor effect compared to the recombinant sE2 variants 
produced in the scope of this thesis. However, it should be noted that no buffer effect was observed 
within this control sample, resulting in overall higher signals. For a detailed comparison the 
experiments would need to be repeated with all protein samples applied in the same buffer. Even so, 
an obvious inhibitory effect was observed for all tested sE2 variants confirming proper folding and 
functionality.  
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Figure 4.15: HCV inhibition assay 
Dose-dependent inhibition of infection by recombinant sE2 variants was analyzed. Huh 7.5 cells were incubated with 
recombinant sE2 variants in the corresponding recombinant protein concentration and were infected with HCV jc1 reporter 
virus. An E2 variant of genotype 2b was used as control for comparing the inhibition effect with another recombinant E2 
protein. Recombinant hemagglutinin H1 derived from the same expression host as the applied sE2 proteins was used as 
negative control. Infection was determined by renilla luciferase. The columns represent mean values of technical triplicates 
in a representative experiment, bars indicate mean deviation. A signal of 100 corresponds to the mean value of the 
infection in the presence of the control (virus only). Experiments and evaluation was performed by Tanvi Kehra (Twincore).  
Besides, the vaccination of five mice per sE2 variant was performed at the department of 
Vaccinology and Applied Microbiology at the HZI. Primary immunization was followed by two 
immunization boosts at an interval of 14 days, as depicted in Figure 4.16. 14 days after the last dose 
the mice were euthanized and their blood was analyzed for the production of wt E2-specific IgG 
antibodies.  
 
 
 
Figure 4.16: sE2 vaccination strategy 
Schematic representation of the vaccination strategy performed at the department of Vaccinology and Applied Micro-
biology at the HZI. Primary immunization on day 0 was followed by two immunization boosts on day 14 and 28. The sera 
were analyzed 14 days after the third immunization on day 42.  
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The sera of euthanized mice were analyzed for wt E2-specific IgG antibodies by Kai Schulze and 
Thomas Ebensen (HZI) via ELISA. The data was kindly provided by Kai Schulze. As depicted in Figure 
4.17 vaccination led to the production of E2-specific antibodies for all four tested variants.  
 
Figure 4.17: ELISA with sera of immunized mice after third immunization boost  
The sera of mice immunized with recombinant sE2 variants were analyzed for wt E2-specific IgG antibodies after the third 
immunization boost on day 42. Sera were diluted by end point dilution (e.p.d.) and measurement was performed after 5 
min. of incubation with the substrate. PBS was used as negative control, n = 5 mice per group, * p < 0.05.  
The sera of vaccinated animals are currently under investigation for assessing the cross-neutralizing 
activity of those E2-specific antibodies by Tanvi Khera at Twincore. Cross-neutralizing antibodies are 
needed in order to protect against as many HCV strains as possible. 
Overall, a strategy for efficient expression of four different recombinant secreted E2 ectodomain 
variants was established. First, the most suitable expression constructs and expression system were 
evaluated. Thereby the TGE in Hi5 insect cells was identified as the most qualified expression system. 
Subsequently, an efficient downstream processing was established and the whole production 
process was optimized. This approach led to remarkably increased protein titers of 6 – 11 mg/L for 
the different sE2 variants. Stepwise performed buffer adjustments were effective for shifting the SEC 
elution profile from mostly aggregates towards higher monomer and dimer compositions, albeit the 
major part of the samples remained as higher oligomers. Further attempts for monomer isolation 
should be performed in the future. Moreover, the purified E2 variants were applied to biochemical 
analysis and vaccination studies for further analysis of their structure and function. First results 
clearly indicate proper folding and functionality of biologically active protein variants. The antigenic 
properties of those recombinant sE2 variants have to be further evaluated as soon as new data is 
available.  
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5 Discussion 
5.1 Recombinant HA expression 
Influenza A infection is a serious threat to human health affecting millions of people every year. The 
infection process is initiated through binding and fusion of the viral to the host cell membrane via the 
surface glycoprotein HA that needs to be cleaved by host cell proteases into its active form prior to 
fusion. In order to get deeper insights into HA cleavage activation structural analysis of the 
uncleaved, non-modified cleavage loop of HA subtypes with differences in protease specificity was 
intended. Besides, a protocol for large scale expression and purification of HA of the H1N1 strain 
A/Puerto Rico/8/34 should be developed for its application in transfollicular vaccination strategies. 
For recombinant expression of unprocessed HA homotrimers the HA ectodomain was fused to a C-
terminal ‘foldon’ sequence (Figure 3.1) from the bacteriophage T4 fibritin (Tao et al., 1997) that was 
already used for successful trimerization before (Stevens et al., 2004; Lu, Welsh and Swartz, 2014)  
5.1.1 Evaluation of the most suitable expression host for recombinant HA expression  
In order to find the most suitable expression host expression was initially tested for HA of different 
subtypes in the multi host expression system (Meyer et al., 2013). It comprises transient transfection 
of HEK293-6E in serum-free suspension culture, expression via BEVS and stable CHO production cell 
lines generated by RMCE. Next to that, TGE in Hi5 insect cells was analyzed for its potential of 
recombinant expression of unprocessed HA after its successful establishment in our laboratories in 
the course of this thesis (discussed later).  
Recombinant HA of the subtypes H1, H3 and H7 was successfully expressed and purified in Hi5 cells. 
While H1 and H3 were predominantly purified in its uncleaved form, high amounts of H7 were 
already cleaved by host proteases during insect cell cultivation and purification. In case of transient 
transfection of HEK293-6E cells recombinant HA expression was detectable for all three HA subtypes 
during small scale expression experiments. The expression and subsequent purification of H1 in large 
scale, however, led to protein that was not very stable and tended to precipitate after purification. 
Stable HA-expressing glycosylation deficient CHO cell lines were successfully generated and isolated. 
However, too little HA expression was detectable within the isolated clones so that this approach 
was not pursued further.  
One key criterion for structure elucidation of glycoproteins is a short and uniform glycosylation. In 
order to analyze the suitability of the recombinant HA glycovariants for crystallization they were 
subjected to deglycosylation experiments and analysis by mass spectrometry. The glycosylation of H1 
derived from Hi5 cells should not hinder crystallization, which indeed was proven in crystallization 
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setups in section 3.4. The more diverse glycosylation of H1 transiently expressed in HEK293-6E cells 
on the contrary would probably do (Chang et al., 2007; Davis and Crispin, 2010; Nettleship, 2012). 
Whereas lepidoptera cell lines are widely used for heterologous protein expression for crystallization 
since they offer a quite simple glycosylation pattern (Tomiya et al., 2004; Nettleship et al., 2010; 
Nettleship, 2012). Moreover, the HEK-derived glycosylation could not be removed with endoglyco-
sidases without significant protein degradation. All in all, the results indicated that HA produced in 
Hi5 cells is much more suitable for structural analysis than HA produced in HEK293-6E cells.  
In fact, insect cells already have been reported to be a suitable expression host for recombinant HA 
expression (Stevens et al., 2004; Wang et al., 2006; X. Li et al., 2015). Besides, they represent two of 
the most common cell lines for protein crystallization following E. coli with 4300 and 1335 entries in 
the PDB for S. frugiperda and T. ni, respectively (PDB Data Distribution by Expression Organism, 
status June 2018). Moreover, the recombinant H1 expressed in Hi5 insect cells in the scope of this 
thesis was already successfully analyzed for its proteolytic activation by the host serine protease 
TMPRSS2. This enzymatic in vitro assay clearly indicated a properly folded HA that was susceptible to 
proteolytic activation by this HA-specific protease (Schinkowski, 2017). 
5.1.2 HA production process up-scaling  
The first approaches for up-scaling the HA production process concerned the attempt to apply the 
TIPS method by Wasilko and Lee. This method is suitable for large scale expression, because it is 
based on the application of cryopreserved BIIC stocks for infection and recombinant protein 
expression. Thus, it was very promising for process up-scaling as it saves time, is easy to handle and 
additionally provides long-term stable storage of recombinant virus thereby increasing product 
reproducibility (Wasilko and Lee, 2006; Wasilko et al., 2009). Despite various reports of its successful 
implementation (Emmons et al., 2009; Cecchini, Virag and Kotin, 2011; Chen, 2016; Scholz and 
Suppmann, 2016, 2017), this method was not very convenient in the scope of this project. Even after 
several adjustments and approaches for increasing the infectivity, the infection of the cells was not 
comparable to that achieved with extracellularly virus stocks before. According to those non-
reproducible problems concerning the infection with BIICs, other efforts for increasing the product 
titer were carried out.  
Since previous results showed that Hi5 insect cells are qualified for recombinant HA expression (see 
section 3.1), the method of TGE in Hi5 cells was analyzed for its potential for process up-scaling with 
reproducible product titer. Just like TIPS method, it is very suitable for production in large scales, 
even when it comes to large bioreactors, as the handling is comparable easy (Shen et al., 2015). Via 
TGE no problems regarding sterile addition of transfection reagents and DNA occur as it would be the 
case for external virus stocks on bioreactor scale. With this TGE method in Hi5 cells a constantly high 
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titer of recombinant HA was achieved. Additionally, compared to BEVS the process was much more 
reproducible and less elaborate, since the cumbersome preparation of fresh and highly infective virus 
stocks prior to expression experiments can be avoided by applying this TGE method. Moreover, the 
non-lytic nature of virus-free expression systems prevents degradation and thus ensures an overall 
increased product quality (Bleckmann, 2016) which in fact was observed for recombinant HA 
expression (see section 3.3.2).  
5.1.3 Optimization of HA downstream processing  
The HA purity was increased by replacing Ni-NTA by HisTALON purification, because the applied 
matrix exhibit less nonspecific protein binding than the Ni2+–NTA resin (Bornhorst & Falke 2000). For 
the subtype H7, however, most of the purified protein was already cleaved into its subunits HA1 and 
HA2 during the purification steps. With this strategy for H1 very pure protein with a five-fold increase 
of product titer was acquired compared to the two-step purification before. The purified protein was 
used for further analysis comprising thrombin cleavage and SEC. Cleavage of HA with thrombin was 
necessary to remove the heterologous trimerization domain consisting of foldon and tags. While SEC 
was performed in order to isolate the trimeric HA without any contaminants. In order to ensure the 
separation of trimeric and monomeric HA, a column with a suitable pore size range was used. Buffer 
adjustments were investigated and it was found that increased trimer isolation was achieved by 
reducing the ionic strength of the buffer during SEC.  
After the establishment of this purification strategy the process was analyzed for its potential for 
further optimizations. The previous strategy encompasses a HA capture from the supernatant in two 
steps. The harvested cell culture supernatant needed to be buffer exchanged by diafiltration before it 
was subjected to HisTALON purification. By the use of HisTrap excel columns the supernatants 
containing the secreted histidine-tagged proteins could be directly loaded onto the column for 
affinity purification. The implementation of this material was very effective and thus replaced the 
more cumbersome and time-consuming previous procedure. With this changed protocol the overall 
purification process was some days up to more than a week faster, depending on the applied 
expression volume. Overall, the process was not only faster and less work-intense, but the saved 
time and the gentle process also improved the product quality. Especially in large scale purifications 
or when it comes to purification in bioreactor scale this implementation is a great improvement.  
Last but not least the purification process was complemented by a final reverse Strep-Tactin 
purification step that was implemented before or after SEC to ensure the complete removal of 
tagged contaminants. This approach was very effective by the use of both magnetic beads for small 
scale and with Strep-Tactin columns for larger volumes. This additional purification step further 
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increased the purity of HA samples for crystallization experiments and thus should facilitate crystal 
growth.  
5.1.4 Crystallization of recombinant HA of the subtypes H1 and H3 
The first crystallization setups with H1 and H3 resulted in several crystals of diverse size and shape. In 
order to generate better diffraction-quality crystals those initial hits were subjected to crystal 
optimization by individual customized screens. In case of H1, however, the diverse optimization trials 
did not increase the diffraction of the obtained crystals. Hence, the best diffracting H1 crystal 
exhibited quite poor diffraction. Furthermore, structure determination was tremendous hampered 
by the twinned nature of this crystal. Twinning is unflavored and can lead to problems in X-ray 
crystallography since a twinned crystal does not produce a simple diffraction pattern (Yeates, 1997). 
So unfortunately, no structural information of the H1 cleavage loop could be obtained. Crystallization 
of H3 on the contrary, already resulted in a crystal with quite high resolution in the very first 
crystallization setup. However, data analysis demonstrated low electron density at the location of the 
cleavage site, thus indicating an open loop structure due to protease cleavage. During crystal 
optimization a H3 crystal was obtained which exhibits a very high resolution of 1.45 Å. The resulting 
dataset reveals a very good defined electron density map enabling detailed insights into the H3 
structure. Nevertheless, it was obvious that the obtained structure again belongs to a proteolytic 
cleaved protein. Thus, a well-defined H3 structure was gained, but still no structural information of 
the H3 cleavage loop was acquired so far.  
The lack of diffraction-quality HA crystals with an intact cleavage loop raises the question if the 
uncleaved HA may hamper crystallization due to higher flexibility. This hypothesis is supported by the 
observation that most crystallized HAs either contain a modified cleavage site (Chen et al., 1998) or 
have been proteolytic cleaved prior to crystallization (Skehel et al., 1984; Ha et al., 2002; Russell et 
al., 2004; Stevens et al., 2006; Yang, Carney and Stevens, 2010; Ni, Kondrashkina and Wang, 2015; 
Yang et al., 2015). Indeed, so far there is only one H1 HA0 structure of the strain A/South 
Carolina/1/18 deposited in the PDB, which harbors an intact cleavage site (PDB ID: 1RD8, Stevens et 
al. 2004). While in case of H3, the only available H3 HA0 crystal structure contains a mutated 
cleavage site (PDB ID: 1HA0, Chen et al. 1998). Furthermore, it was already reported that the 
flexibility of the cleavage loop of a H2 variant prevented modelling, since no electron density could 
be observed for the associated HA1 and HA2 residues (Zhu et al., 2013). Moreover, a H17 variant was 
expressed and purified as HA0 precursor, the solved structure, however, was found to belong to the 
cleaved variant (Sun et al., 2013). All together these findings further support the hypothesis that 
uncleaved HA hampers crystal formation. However, it remains to be tested if the flexibility of the HA 
cleavage loop indeed hinders crystallization.   
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5.2 Recombinant E2 expression 
HCV infections constitute a major global health problem with increasing infection rates within the 
last years (Centers for Disease Control and Prevention, 2017). However, very little is known about the 
structural properties of the HCV envelope glycoproteins E1 and E2. Especially a complete picture of 
the E1E2 heterodimeric complex is still missing. Moreover, the generation of effective vaccines is 
hampered by various strategies of HCV for evading the host immune system. It is therefore an 
important task to obtain detailed structural information of the glycoproteins and to produce antigens 
that stimulate the production of broadly neutralizing antibodies.   
5.2.1 Selection of the right expression host and expression constructs 
For the recombinant expression of E2 for functional and structural analysis different variants were 
generated that ought to re-direct antibody responses towards more conserved viral epitopes. Next to 
two wt E2 proteins derived from the genotypes 1a and 2a those variants encompass the E2 protein of 
genotype 2a without its most variable domain (ΔHVR1) and a variant that combines this deletion 
with the mutation of a glycosylation site involved in epitope masking (ΔHVR1-N534A). These variants 
were first used in full-length for co-expression with wt E1 together with the last 60 AA of core protein 
(cE1E2) and for stand-alone expression of the E2 ectodomain up to either AA 661 or 688 (sE2) in the 
transient HEK293-6E system. Upon this co-expression strategy, however, no satisfying expression was 
detected, so more emphasis was put on the recombinant expression of the sE2 variants.  
Recombinant expression of soluble E2 variants ending at AA position 661 was working upon transient 
transfection in both HEK293-6E cells and Hi5 insect cells. For this truncated E2 protein successful 
expression and secretion has already been reported (Michalak et al., 1997; Dubuisson et al., 2000; 
Rodríguez-Rodríguez et al., 2009; Tello et al., 2010; McCaffrey et al., 2012). sE2 expression in Hi5 
insect cells, however, was found to be advantageous compared to its expression in HEK293-6E cells. 
Moreover, all variants expressed in HEK293-6E cells were highly glycosylated which would probably 
hinder crystallization, since the N-linked glycans make up approximately half of the mass of the E2 
protein (Goffard et al., 2005; Falson et al., 2015). Upon expression via TGE in Hi5 insect cells, no 
unspecific signals were detected and the proteins did not exhibit bands of higher oligomers. 
Moreover, the proteins seem to have less heterogeneous glycosylation as observed before in the 
proteins derived from HEK cells. Hence, Hi5 insect cells emerged to be the expression host of choice 
and large scale expression was performed in order to establish an appropriate purification strategy.  
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5.2.2 Development of E2 purification strategy 
For the development of a suitable purification strategy for the recombinant sE2 variants first of all 
purification with HisTrap excel columns was implemented, because it was very efficient and advanta-
geous for HA purification. The protocol was adapted to that used for HA, because the monomeric E2 
proteins possess only one His tag compared to the trimeric HA. However, this approach needed to be 
further optimized in order to get a higher degree of purity. The application of this changed protocol 
resulted in quite pure protein with significantly less protein loss and thus much higher yields up to 
11 mg/L.  
For further polishing, the proteins were subsequently subjected to SEC. In the very first SEC the 
applied protein sample eluted in the void volume of the column, indicating protein aggregation. 
Stepwise performed buffer adjustments led to a shift of the elution profile from mostly aggregates 
towards higher monomer and dimer compositions by increasing the ionic strength and minimizing 
hydrophobic interactions. However, the major part of the protein still elutes as higher oligomers and 
aggregates. Additional approaches aiming at further improving the buffer composition had no effect 
so far. Indeed, it is a common observation by diverse research groups that recombinant E2 has a high 
tendency to build higher oligomers and aggregates (McCaffrey et al. 2017; Orlova et al. 2015; Flint et 
al. 2000; Dubuisson et al. 1997; Krey et al. 2010; Whidby et al. 2009; Michalak et al. 1997) . Actually, 
a non-productive folding pathway has even been proposed as a physiologically relevant part of the 
HCV life cycle (Dubuisson, 2000). Taken together, this clearly indicates that it is not a trivial task to 
solve this common problem of E2 aggregation. Besides, this could be a hint that the best way for 
solving the aggregation problem, is to focus on E1 and E2 co-expression since heterodimer formation 
upon co-expression could be preferred to E2 self-association. 
5.2.3 Characterization of recombinant sE2 variants 
In order to characterize the recombinant sE2 variants non-reducing SDS-PAGE, CD spectroscopy and 
glycosylation analysis was performed. By the use of non-reducing SDS-PAGE the oligomeric state of 
the purified sE2 variants was found to be made up of monomers, dimers, trimers and higher oligo-
mers as it was often observed before (Lee et al., 1997; Whidby et al., 2009; Afzal et al., 2014; Ortega-
Atienza et al., 2014). Moreover, CD spectroscopy was employed and a secondary structure prediction 
was performed with the obtained spectra. The major part of the sE2 variants comprises non-ordered 
structures and β-sheets with a small amount of α-helices, thus indicating a correct fold. The acquired 
results are in accordance with published secondary structure determinations of different recom-
binant E2 or E1E2 proteins (Rodríguez-Rodríguez et al. 2009; Whidby et al. 2009; Krey et al. 2010; 
Tello et al. 2015; Castelli et al. 2017).  
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Furthermore the sE2 variants were used to analyze their competence as functional antigens by our 
cooperation partners at Twincore and HZI. A dose-dependent inhibition assay was performed with 
each recombinant sE2 variant for analyzing their potential to inhibit HCV infection. Upon this assay 
an obvious inhibitory effect was observed for all recombinant sE2 variants. Besides, vaccination of 
humanized mice induced production of E2-specific antibodies in case of all four tested variants. 
These antibodies are currently under investigation for assessing their cross-neutralizing activity at 
Twincore. Taken together these first results clearly indicate proper folding and functionality of 
biologically active E2 variants. Their antigenic properties have to be further evaluated as soon as new 
data is available.  
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6 Conclusions and outlook  
In this thesis the expression and purification of biological active viral surface proteins of IAV and HCV 
has been established. The purified proteins were produced for the generation of new antigens for 
vaccination and for the investigation of their structure and function relations. The newly established 
TGE method in Hi5 insect cells was demonstrated as a powerful expression system for recombinant 
expression of viral surface glycoproteins. 
In the first part of this thesis, a method was developed for the secretory expression of the full-length 
ectodomain of IAV HA subtypes H1 and H3 in its uncleaved pre-fusion state. Hi5 insect cells were 
discovered to be the most suitable expression host for the recombinant production of HA precursors 
for crystallization studies. Moreover, a protocol was established for HA expression up-scaling that 
was reliable, economic, easy to handle, comparatively fast and accessible for a scale-up in bioreactor 
dimensions. Furthermore, the production process and its optimized downstream processing resulted 
in very pure protein of high-quality. As quality control the HA protein was used in functional assays to 
ensure that it was properly folded and susceptible to proteolytic activation by a HA-specific protease 
(Schinkowski, 2017) and to analyze its antigenic potential (Schulze, unpublished work).  
However, the major bottleneck within the scope of this project was the successful crystallization of 
the intact HA cleavage loop. Although it was possible to generate a diverse range of crystals of HA 
H1, none of them was of good diffraction quality, even after several rounds of crystal optimization. 
While H3 seems to tend to produce diffraction-quality crystals only after proteolytic cleavage in the 
crystallization plate, uncleaved H1 hardly causes any diffraction-quality crystal at all. It therefore 
should be investigated if uncleaved HA may hamper crystallization due to higher flexibility. In order 
to examine this hypothesis, both H1 and H3 proteins with mutated cleavage sites and proteolytic 
cleaved proteins could be submitted to crystallization. Besides, co-crystallization experiments with 
inactivated HA-specific proteases like Tmprss2-D343N (Schinkowski, 2017), that are desired anyway, 
could result in stabilization of the HA cleavage loop during crystal formation.   
In the second part of this thesis, a strategy for recombinant expression of secreted E2 ectodomain 
variants via TGE in Hi5 insect cells was established. This method was advantageous compared to TGE 
in HEK293-6E cells in many ways. First of all, the transfection was much more reliable resulting in 
more uniform transfection efficiencies. Besides, compared to transient expression in HEK cells, no 
unspecific signals were obtained in western blot analysis. Moreover, the purified proteins had a less 
heterogeneous glycosylation which is favorable for structural elucidation by crystallization. Last but 
not least, the TGE in Hi5 cells exhibited a much better expression.  
After the evaluation of the best expression constructs and expression system, the development of an 
appropriate purification strategy was a serious hurdle. The successful adaptation of the HisTrap excel 
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purification strategy yielded up to 6 - 11 mg recombinant E2 per L expression culture for the different 
sE2 variants. During further purification by SEC, however, the sE2 variants tend to form aggregates 
and higher oligomers. Stepwise performed buffer adjustments were effective for shifting the SEC 
elution profile from mostly aggregates towards higher monomer and dimer compositions. 
Nevertheless, the major part of the samples remained as higher oligomers and there was no time left 
for continuing buffer optimization.  
Next to further buffer optimization, another strategy to avoid E2 oligomerization and aggregation 
during the purification process could be an approach of E1 and E2 co-expression. Since heterodimer 
formation should be preferred to E2 self-association, the co-expression and co-purification could 
avoid those unwanted oligomers. Co-expression and subsequent E1E2 heterodimer purification 
would be advantageous for functional and structural analysis anyhow. Just recently a promising co-
expression strategy of Fc-tagged E1E2 was reported to form functional E1E2 heterodimers (Logan et 
al., 2017). Another strategy would be to produce VLPs in insect cells as it is a common approach for 
vaccination (Metz and Pijlman, 2011; Vicente et al., 2011). For example there are VLP-based vaccines 
available for influenza (Treanor et al., 2011) and vaccines against hepatitis E (Shrestha et al., 2007; 
Zhang et al., 2015). Moreover, only recently this approach was published to be very promising for the 
development of a HCV VLP-based vaccine (Torresi, 2017).  
The recombinant sE2 variants were able to inhibit HCV infection in a dose-dependent in vitro 
inhibition assay and to induce the production of E2-specific antibodies in mice. All in all, these first 
results indicate proper folding and functionality of biologically active E2 variants. Their antigenic 
properties, however, have to be further evaluated as soon as new data is available.  
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8 Appendix 
Appendix I 
 
Figure 8.1: Fluorescence microscopy of Sf21 cells transfected with recombinant bacmid DNA derived from pFlpBtM-II-H1 
Pictures were taken prior transfection (day 0) and 6 days post transfetion with evos microscope under white light and with 
GFP filter (470 nm excitation, 525 nm emission). Cells transfected with EMBacY reveal fluorescence in the green filter due to 
the encoded YFP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2: Growth kinetics, cell diameter and fluorescence of Sf21 cells infected with recombinant baculovirus  
The graphical data depicts the daily assessed growth and infection parameters. The cells were counted manually with a 
Neubauer hemocytometer. The vitality was assessed by trypan blue staining. The YFP expression of EmBacY was monitored 
by flow cytometry in the GFP channel (488 nm excitation). The mean cell diameter was analyzed with CASY counter. 
Significant increase in cell diameter of approximately 20 % and an amount of fluorescent cells (YFP fluorescence) of almost 
100 % 48 hpi indicate a successful infection.  
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Figure 8.3: Growth kinetics and transfection efficiency 
The graphical data depicts the daily assessed growth and transfection efficiency upon transient transfection in HEK293-6E 
cells. The cells were counted manually with a Neubauer hemocytometer. The vitality was assessed by trypan blue staining. 
The GFP expression of pTTo/GFP was monitored by flow cytometry in the GFP channel (488 nm excitation).  
 
 
 
 
 
 
 
Figure 8.4: SDS-PAGE of H1 HEK-purification 
The H1 protein was expressed in HEK392-6E cells after transient transfection. SDS-PAGE shows samples during cultivation 
as well as the elution fractions of the purification with Profinia and was stained with InstantBlue. M = P PageRuler™ Plus 
Protein Ladder, 0h/48h/72h/96h/168h = samples of the supernatant during cultivation at indicated time points, D-KF: 
Flowtrough Krosflow, Dia: sample after dialysis, sf: sample after sterile filtration, Ft = flow through, W = wash, E = eluate.  
 
Figure 8.5: Dynamic light scattering analysis of Hi5 and HEK 293-6E derived H1 
Dynamic light scattering (DLS) was performed with non-cleaved H1 expressed in Hi5 and HEK cells in order to confirm 
trimeric expression and to further investigate each size.  
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Appendix II 
 
 
 
 
 
Figure 8.6: SDS-PAGE of the expression and purification of H1 with HisTALON 
The H1 protein was expressed in Hi5 insect cells via BEVS using an EMBacY-pFlpBtM-II-H1 virus. SDS-PAGE shows samples 
during cultivation as well as the elution fractions of the purification with His TALON and was stained with InstantBlue. M = P 
PageRuler™ Plus Protein Ladder, 0h/24/48 = samples of the supernatant during cultivation at indicated time points 
(0h/24h/48h after infection), Ft = flow through, W1 = wash fraction 1, W2 = wash fraction 2, E1 – E12 = elution fractions 1 – 
12.  
 
Figure 8.7: Thrombin cleavage analysis with H1 and H3 
H1 and H3 protein samples were incubated with 2.5 U/mg thrombin and incubated at RT. At different time points cleavage 
was stopped by addition of loading buffer and incubation for 5 min. at 95 °C. Successful cleavage was observed through a 
reduction in size of about 10 kDa. For further verifying complete cleavage western blot analysis was performed in order to 
detect even small amounts of uncleaved HA. Western blot was performed using a primary mouse α-His mAb and a 
secondary goat AP-conjugated α-mouse pAb. Colorimetric AP staining of the western blot was done with NBT and BCIP. The 
SDS gel was stained with InstantBlue. M: PageRuler Prestained, 0h – 22h indicate the time point of each sample.  
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Figure 8.8: Dynamic light scattering analysis of uncleaved trimeric and cleaved monomeric H1 
Dynamic light scattering (DLS) experiments were performed to determine the molecular weight of uncleaved H1 (left hand 
site) and H1 that was thought to have dissociated into monomeric conformation (right hand site).  
 
 
 
 
 
 
 
 
Figure 8.9: Small scale H3-purification with mgnetic strep beads 
For removing tagged contaminants small scale purification of H3 was performed with magnetic beads (MagStrep "type3" XT 
beads, iba) according to the manufacturers’ protocol. H3 cleaved with Thrombin from SERVA or GE Healthcare (indicated 
above the gel) was incubated with 5 µl beads/ mg protein and eluted after 3 washing steps under denaturing conditions by 
addition of SDS gel loading buffer and boiling. M = P PageRuler™ Plus Protein Ladder, 1 = sample after thrombin cleavage, 2 
= supernatant containing purified protein, 3 = wash fraction, 4 = elution fraction.  
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Appendix III  
 
Figure 8.10: Infection kinetics of BIIC dilution test 
The graphical data depicts the daily assessed infection parameters after infection with different BIIC dilutions (1:1000 – 
1:20). The YFP expression of EmBacY was monitored by flow cytometry in the GFP channel (488 nm excitation). The mean 
cell diameter was analyzed with CASY counter. Significant increase in cell diameter and fluorescent cells (YFP fluorescence) 
indicate successful infection. A culture without infection was used as control (VK). 
 
 
Figure 8.11: Western blot analysis of H1 expression in Hi5 and Hi5 + Sf21 cells upon BIIC infection 
Different setups for the recombinant H1 expression using BIICs were tested for their potential in large scale. H1 was 
expressed via BEVS using an EMBacY-pFlpBtM-II-H1 virus stored in BIICs. Either Hi5 cells (1 + 3) or a combination of 90 % Hi5 
and 10 % Sf21 cells (2 + 4) was used. Besides different BIIC stocks were applied (BIIC 719: 1 + 2, BIIC 716: 3 + 4) in order to 
test their infectivity. The Western blot was performed with primary anti-His mAb together with a secondary goat-anti-
mouse AP-conjugated pAb. Colorimetric AP staining was done with NBT and BCIP. The samples of crude supernatant of the 
different setups are presented at different time points after infection as indicated above. M = P PageRuler™ Plus Protein 
Ladder, 1: Hi5 + BIIC 719, 2: Hi5 + Sf21 + BIIC 719, 3: Hi5 + BIIC 716, 4: Hi5 + Sf21 + BIIC 716.  
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Figure 8.12: SDS-PAGE and Western Blot analysis of H1 expression and purification with VA in Hi5 and Hi5 and Sf21 cells 
Suspension cultures of Hi5 cells (left hand site) and of Hi5 and Sf21 cells (right hand site) were infected with external virus 
stock (VA) and were purified with Profinia IMAC system after harvesting at 96 hpi. M = P PageRuler™ Plus Protein Ladder, 
SN = cell culture supernatant, Ft = flow through, W1 = wash fraction 1, W2 = wash fraction 2, E = eluate.   
 
 
Figure 8.13: SDS-PAGE and Western Blot analysis of H1 expression via TGE 
Recombinant H1 Expression via TGE was detected in crude culture supernatants by SDS-PAGE and western blot analyses. 
Samples were taken at 24 hpt, 48 hpt and 72 hpt (as indicated) and anaylzed for recombinant expression using a primary 
mouse α-His mAb and a secondary goat AP-conjugated α-mouse pAb. Colorimetric AP staining of the western blot was done 
with NBT and BCIP. The SDS gel was stained with InstantBlue. M: PageRuler Prestained, all samples were taken at 96 hpi. 1-
4 correspond to numbering of culture flasks.  
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Table 8-1: Buffer conditions of first H1 crystallization hits 
H1 Crystal Buffer compositions 
Fig. 3.17 A 20% (v/v) 2-Methyl-2,4-pentanediol + 0.1 M TRIS pH 8.5 
Fig. 3.17 B 0.2 M Trimethylamine N-oxide + 0.1 M TRIS pH 8.5 
Fig. 3.17 C 20% (w/v) Polyethylene glycol (PEG) 3350 + 0.15 M di-Sodium DL-malate 
Fig. 3.17 D 25% (v/v) PEG monomethyl ether (MME) 550 + 0.1 M HEPES pH 7.5 
 
Table 8-2: Buffer conditions of first H3 crystallization hits 
H3 Crystal Buffer compositions 
Fig. 3.18 A 30% (w/v) PEG MME 2000 + 0.1 M Potassium thiocyanate 
Fig. 3.18 B 30% (w/v) PEG MME 2000 + 0.1 M Potassium bromide 
Fig. 3.18 C 20% (w/v) PEG MME 2000 + 0.2 M Trimethylamine N-oxide 
Fig. 3.18 D 20% (w/v) PEG 3350 + 0.24 M di-Sodium malonate 
 
 
Figure 8.14: H1 crystals in optimization screen RI and commercial JCSG+ screen 
First hits of H1 crystals obtained from TGE in Hi5 cells. The harvested cell culture supernatant was directly subjected to 
HisTrap excel purification, followed by thrombin cleavage and SEC with a S200 Increase 10/300 GL column. The isolated 
trimer was concentrated to 10 mg/mL before crystallization was carried out at 19 °C with 1:1 protein to reservoir volume by 
using commercial available JCSG+ and self-prepared RI screen. First crystals in RI were observed as late as 33 days after 
crystallization setup due to a defect of the imager system. The buffer conditions in which the depicted crystals were grown 
are listed in Table 8-3.  
 
Table 8-3: Buffer conditions of H1 crystals grown in first optimization trail 
H1 Crystal Buffer compositions  
Fig. 8.14 A  0.2 M di-Sodium malonate + 27.8% (w/v)PEG 3350 + 0.133M Magnesium sulfate + 
0.1 M BIS-TRIS pH 7.022 
Fig. 8.14 B  0.1 M di-Sodium malonate + 23.3% (w/v) PEG 3350 + 0.1 M HEPES pH 7.889 
Fig. 8.14 C  0.15 M di-Sodium malonate + 25.6% (w/v) PEG 3350 + 0.1 M TRIS-BASE pH 7.667 
Fig. 8.14 D  0.2 M Lithium sulfate + 40% (w/v) PEG 400 + 0.1 M TRIS pH 8.5 
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Figure 8.15: H1 crystals of second optimization trail grown in commercial PEG Suite I screen 
H1 crystals obtained from baculoviral expression in Hi5 cells upon second optimization trail. The harvested cell culture 
supernatant was directly subjected to HisTrap excel purification, followed by thrombin cleavage and SEC with a S200 
Increase 10/300 GL column. The isolated trimer was concentrated to 10 mg/mL before crystallization was carried out at 
19 °C with 1:1 protein to reservoir volume by using commercial available PEGs screen. First crystals were observed 82 days 
after crystallization start. The buffer conditions in which the depicted crystals were grown are listed in Table 8-4.  
Table 8-4: Buffer compositions of H1 crystals grown in PEGs screen during second optimization trail 
H1 Crystal Buffer compositions  
Fig. 8.15 A  0.2 M Lithium chloride + 20% (w/v) PEG 3350  
Fig. 8.15 B  0.2 M Sodium chloride + 20% (w/v) PEG 3350 
Fig. 8.15 C  0.2 M Potassium chloride + 20% (w/v) PEG 3350 
Fig. 8.15 D  0.2 M Lithium nitrate + 20% (w/v) PEG 3350 
Fig. 8.15 E  0.2 M Potassium formate + 20% (w/v) PEG 3350 
Fig. 8.15 F  0.2 M Potassium acetate + 20% (w/v) PEG 3350 
Fig. 8.15 G  0.2 M K/Na tartrate + 20% (w/v) PEG 3350 
 
 
Figure 8.16: H1 crystals of second optimization trial in random screen RII 
Hits of H1 obtained from baculoviral expression in Hi5 cells in screen RII. The harvested cell culture supernatant was directly 
subjected to HisTrap excel purification, followed by thrombin cleavage and SEC with a S200 Increase 10/300 GL column. The 
isolated trimer was concentrated to 10 mg/mL before crystallization was carried out at 19 °C with 1:1 protein to reservoir 
volume by using commercial available JCSG+ and self-prepared RI screen. First crystals in RII were observed 3 days after 
crystallization setup, the following grew on day 18 or 82. The buffer conditions in which the depicted crystals were grown 
are listed in Table 8-5.  
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Table 8-5: Buffer compositions of H1 crystals grown in RII during second optimization trail 
H1 Crystal Buffer composition 
Fig. 8.16 A 0.17 M Magnesium sulfate + 45 % v/v PEG 300  
Fig. 8.16 B 0.1 M TRIS-BASE + 50 % v/v PEG 300  
 
 
 
Figure 8.17: H1 crystals of third optimization trial 
Hits obtained in the crystallization setup with H1 derived from both baculoviral expression and TGE in Hi5 insect cells. The 
cell culture supernatant was directly subjected to HisTrap excel purification, followed by thrombin cleavage and SEC with a 
S200 Increase 10/300 GL column for trimer isolation. Additional Strep-Tactin purification was performed before the 
samples were concentrated to 10 mg/mL and crystallization was carried out at 19 °C with 1:1 protein to reservoir volume. In 
this setup the commercial available PEG Suite I and self-prepared screens RI and H1-Grid were used. First crystals of H1 
obtained from baculoviral expression were observed on day 12 in PEG Suite I, whereas no crystals obtained in the other 
applied screens. The buffer conditions of depicted crystals are listed in Table 8-6.  
 
Table 8-6: Buffer compositions of H1 crystals grown in the last optimization trail 
H1 Crystal Buffer compositions 
Fig. 8.17 A 0.2 M Sodium chloride + PEG 3350 (20 % w/v)  
Fig. 8.17 B 0.2 M Magnesium formate + PEG 3350 (20 % w/v)  
 
Table 8-7: Buffer compositions of H3 crystals grown in optimization trail 
H3 crystal Buffer composition 
Fig. 3.18 A 0.35 M di-Sodium malonate + 16.7 % w/v PEG 3350 + 0.1 M HEPES pH 7.733 + 6.33 % 
w/v PEG 200 
Fig. 3.18 B 0.1 M di-Sodium malonate + 14.4 % w/v PEG 3350 + 0.272 M Lithium sulfate + 0.1 M 
TRIS-BASE pH 7.667 + 15 % w/v PEG 200 
Fig. 3.18 C 0.16 M Calcium acetate + 14.4 % w/v PEG 8000 + 20 % v/v Glycerol + 0.08 M Sodium 
cacodylate pH 6.5 
Fig. 3.18 D 30 % w/v PEG MME 2000 + 0.1 M Potassium thiocyanate 
Fig. 3.18 E 0.2 M Ammonium sulfate + 25.6 % w/v PEG 3350 + 16.7 % v/v Glycerol + 0.272 M 
Lithium acetate + 0.1 M TRIS-BASE pH 7 
Fig. 3.18 F 0.1 M di-Sodium malonate + 23.3 % w/v PEG 3350 + 0.1 M HEPES pH 7.889 
Fig. 3.18 G 20 % w/v PEG 8000 + 0.1 M CHES pH 9.5 
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Table 8-8: Data collection of H3 crystal 
X-ray Data-Processing Statistics 
Space group: H32 
Cell constants a; b; c (Å) 102.39 102.39 272.99 
Cell angles α; β; γ (°) 90.0 90.0 120.0 
Resolution range (Å) 84.333 - 1.446 
Highest resolution shell (Å) 1.471 - 1.446 
 overall Highest resolution shell          
Reflections, unique 98474 4841 
Rmerge (%) 8.1 6.4 
Rpim (%) 8.3 1.5 
Completeness overall (%) 8.5 100 
Multiplicity 8.6 19.8 
I/σ(I) 26.4 2.3 
CC1/2 (%) 8.9 100 
 
Table 8-9: Refinement statistics of H3 crystal 
Refinement Statistics 
Rwork (%) 17.7 
Rfree (%) 19.0 
Non hydrogen atoms 5172 
Non hydrogen protein atoms 4350 
Ligands/ions/others 158 
Solvent molecules 664 
R.m.s. deviations from ideal values 
Bond lengths (Å) 0.0093 
Bond angles (º) 1.052 
Average B values (Å2) 
All atoms 30.531 
Protein main chain atoms 25.699 
Protein all atoms 30.676 
Ligands/ions/others 65.620 
Solvent 36.069 
Φ, Ψ angle distribution for residues 
In most favoured regions (%) 95.3 
In additional allowed regions (%) 4.5 
In disallowed regions (%) 0.2 
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Appendix V 
Table 8-10: Thermofluor test conditions 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
50 mM 
NaAcetate 
50 mM 
NaAcetate 
50 mM 
NaCitrate 
50 mM 
NaCitrate 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM  
Bis-Tris 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
- - - - - - - - - - - - 
pH 4.0 pH 4.5 pH 5.0 pH 5.5 pH 6.0 pH 6.0 pH 6.5 pH 6.5 pH 7.0 pH 7.0 pH 7.0 pH 7.0 
B 
50 mM 
NaAcetate 
50 mM 
NaAcetate 
50 mM 
NaCitrate 
50 mM 
NaCitrate 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM  
Bis-Tris 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
pH 4.0 pH 4.5 pH 5.0 pH 5.5 pH 6.0 pH 6.0 pH 6.5 pH 6.5 pH 7.0 pH 7.0 pH 7.0 pH 7.0 
C 
50 mM 
NaAcetate 
50 mM 
NaAcetate 
50 mM 
NaCitrate 
50 mM 
NaCitrate 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM  
Bis-Tris 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
pH 4.0 pH 4.5 pH 5.0 pH 5.5 pH 6.0 pH 6.0 pH 6.5 pH 6.5 pH 7.0 pH 7.0 pH 7.0 pH 7.0 
D 
50 mM 
NaAcetate 
50 mM 
NaAcetate 
50 mM 
NaCitrate 
50 mM 
NaCitrate 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM 
MES 
50 mM  
Bis-Tris 
50 mM  
Bis-Tris 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
pH 4.0 pH 4.5 pH 5.0 pH 5.5 pH 6.0 pH 6.0 pH 6.5 pH 6.5 pH 7.0 pH 7.0 pH 7.0 pH 7.0 
E 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
50 mM  
Tris-HCl 
50 mM 
HEPES 
50 mM 
BICINE 
50 mM  
Tris-HCl 
50 mM 
BICINE 
50 mM 
CHES 
50 mM 
CHES 
50 mM 
CAPS 
50 mM 
CAPS 
- - - - - - - - - - - - 
pH 7.5 pH 7.5 pH 7.5 pH 8.0 pH 8.0 pH 8.0 pH 8.5 pH 8.5 pH 9.0 pH 9.5 pH 10.0 pH 10.5 
F 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
50 mM  
Tris-HCl 
50 mM 
HEPES 
50 mM 
BICINE 
50 mM  
Tris-HCl 
50 mM 
BICINE 
50 mM 
CHES 
50 mM 
CHES 
50 mM 
CAPS 
50 mM 
CAPS 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
100 mM 
NaCl 
pH 7.5 pH 7.5 pH 7.5 pH 8.0 pH 8.0 pH 8.0 pH 8.5 pH 8.5 pH 9.0 pH 9.5 pH 10.0 pH 10.5 
G 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
50 mM  
Tris-HCl 
50 mM 
HEPES 
50 mM 
BICINE 
50 mM  
Tris-HCl 
50 mM 
BICINE 
50 mM 
CHES 
50 mM 
CHES 
50 mM 
CAPS 
50 mM 
CAPS 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
200 mM 
NaCl 
pH 7.5 pH 7.5 pH 7.5 pH 8.0 pH 8.0 pH 8.0 pH 8.5 pH 8.5 pH 9.0 pH 9.5 pH 10.0 pH 10.5 
H 
50 mM  
Tris-HCl 
50 mM 
MOPS 
50 mM 
HEPES 
50 mM  
Tris-HCl 
50 mM 
HEPES 
50 mM 
BICINE 
50 mM  
Tris-HCl 
50 mM 
BICINE 
50 mM 
CHES 
50 mM 
CHES 
50 mM 
CAPS 
50 mM 
CAPS 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
500 mM 
NaCl 
pH 7.5 pH 7.5 pH 7.5 pH 8.0 pH 8.0 pH 8.0 pH 8.5 pH 8.5 pH 9.0 pH 9.5 pH 10.0 pH 10.5 
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